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Nanoparticles are the hallmark of nanomedicine, proving clinically relevant for the 
delivery of therapeutic and diagnostic drugs. Nanomaterials are highly versatile, with the ability 
for scientists to tailor composition and function to suit the desired application. Herein, two 
types of nanocarriers are investigated in the context of magnetic resonance imaging contrast 
agents: polymeric nanoparticles and protein carriers. 
A key research focus in applying nanoparticles for drug delivery is in understanding 
physicochemical properties affecting in vivo fate. Shape or morphology of a particle is a vastly 
underutilized property in the design of nanoparticles, and is difficult to predictably control in 
the context of polymeric nanoparticles. Investigations of block copolymer nanoassemblies 
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evaluate effects of the polymer structure and the self-assembly process to form interesting and 
diverse structures. 
In this work, ring-opening metathesis polymerization is employed to prepare and study 
block copolymer amphiphile self-assembly. First, a small library of amphiphiles are prepared 
in which the hydrophobic block functionality is varied. In varying the polymer structure and 
the solvent for assembly, different morphologies are produced, including small and large 
spheres, cylinders, y-junctions, and rods. In several cases, one polymer can take on different 
morphologies depending on the organic cosolvent used during micellization, highlighting the 
importance of assembly conditions and dynamics in forming kinetically trapped structures 
versus thermodynamically stable structures. These are important considerations when 
designing, synthesizing, and formulating polymeric nanoparticles for in vivo applications. 
Next, direct incorporation of a gadolinium based contrast agent for magnetic resonance 
imaging is studied. A novel monomer and chain transfer agent of a gadolinium-chelate are used 
to directly incorporate the contrast agent in to a polynorbornene polymer backbone. The 
resulting spherical and fibrillar nanoparticles exhibited enhanced relaxivity and are studied as 
MRI contrast agents using live imaging in murine models.  
Finally, a fatty acid ligand is conjugated to a gadolinium-based contrast agent is 
prepared and formulated with human serum albumin. In formulation with HSA, the agent 
exhibits high relaxivity and prolonged blood circulation. In addition, therapeutic conjugates 
formulated with HSA are evaluated for in vitro cytotoxicity and found to be effective in tumor 
growth suppression in vivo. 
 1 
Chapter 1   
Introduction to Polymeric Nanoparticles and 
Bioconjugates for Nanomedicine Applications 
1.1 Nanoparticle and Protein-Based Drug Delivery 
Nanoparticles are materials ranging in size from 1 to 1000 nm and used for a range of 
applications in the field of biotechnology. Nanoparticles (NPs) are the hallmark of 
nanomedicine, proving clinically relevant for the delivery of therapeutic and diagnostic drugs. 
These materials are highly versatile, with the ability for scientists to tailor composition and 
function to suit the desired application. The first examples of NP therapeutics involved polymer 
drug conjugates: polymeric materials enhance solubility, blood circulation time, stability and 
targeting of their small molecule counterparts, extending the therapeutic window, and thus 
efficacy, of therapeutics.1 The first clinical trial of polymeric anticancers was conducted in the 
1960s. The following decades of research were driven by the development of various polymer 
drug conjugates and micelle formulations.1 In 1995, Doxil, a liposomal formulation of 
doxorubicin, was approved for cancer treatment, leading the way for rapid development and 
approval of nanomedicines thereafter. Nanocarriers were thus identified as “an emerging 
platform for cancer therapy.”2,3 By the end of 2016, at least 50 unique NPs are approved for 
cancer treatments, as well as other diseases, with hundreds of other clinical trials ongoing.2,4  
In nanomedicine, NPs are used in therapeutic and imaging applications. The 
motivation in using nanoparticles is to find a more optimized strategy for delivering the existing 
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pharmaceutical drugs in humans.5  To achieve this aim requires collaborations between  many 
different scientific disciplines including chemistry, engineering, pharmacology and medicine. 
Advantages of nanoparticle formulations of existing therapeutics include strategies for 
delivering insoluble drugs, dosing at higher concentration, safer/less-toxic delivery and 
prolonged circulation time coupled with favorable biodistribution. The NP platform offers a 
highly modular and tailorable architecture that can incorporate targeting functional groups, 
multidrug loading at high doses and stimuli-responsive units, to name a few.  
 
Figure 1.1 Considerations of Nanoparticles for Nanomedicine. Many of these considerations 
are discussed throughout this dissertation, with focus on polymeric nanoparticle shape on in 
vivo circulation profiles and tumor targeting. 
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Successful use of NPs for cancer therapy stems from physicochemical properties 
specific to the nanoscaled material. These properties target nanoparticle delivery to tumor 
tissue, locally delivering cytotoxins or imaging agents. The Enhanced Permeability and 
Retention Effect (EPR) describes the apparent accumulation of macromolecular species in 
tumor tissue and nanoparticles are ideally situated as objects subject to this phenomenon. 
However, the translation of this effect in humans has limited the large-scale use of NPs in 
nanomedicine applications.  
The challenges to the clinical use of NPs prompts investigation of other modes of drug 
delivery. Using an endogenous drug delivery system that takes advantage of naturally evolved 
biological systems presents an intriguing and successful way to formulate small molecule and 
peptide medicines. Drug delivery involving human serum albumin, or HSA, has emerged as a 
promising platform for imparting favorable pharmacokinetic properties on drugs, and in some 
cases targeted delivery. Covalent or non-covalent tethering to HSA is a clever way to use a 
long-circulating blood protein to overcome barriers to drug delivery, including solubility, 
enhanced blood circulation times, and non-desired immune response. 
1.2   Considerations for Nanomedicines 
1.2.1 The EPR Effect 
The Enhanced Permeability and retention effect (EPR), coined by Matsuma in 1985, 
describes the preference of macromolecular or nanoscaled species like polymers and protein 
conjugates to accumulate in tumor tissue compared to normal tissue.6–8 The macromolecular 
targeting effect is attributed to the abnormal vasculature of the tumor and poor lymphatic 
drainage. The angiogenesis of new, leaky blood vessels in tumors is described thoroughly in 
the literature7,9; leaky tumor vessels in tumor tissue contributes to the enhanced permeability 
of the vasculature to macromolecular species. The compromised lymphatic drainage in tumor 
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contributes to the enhanced retention of large species, which are not subject to the diffusive 
properties that small molecules exhibit. Combined with the advantages that a high molecular 
weight (MW) species offers in terms of increased blood circulation times compared to small 
molecules, nanoparticles loaded with drugs offer many advantages in the drug delivery field.  
The advantages of nanoscaled accumulation in healthy versus tumor tissue is 
highlighted in Fig. 1.2 on the most simplistic level via the EPR effect. In healthy tissue (1.2a), 
small molecules and even small NPs may penetrate the extracellular space; through lymphatic 
drainage or diffusion, the materials are readily cleared from the tissue. Accumulation of small 
molecules or NPs in healthy tissue is an off-target effect, and is a negative aspect of small 
molecule therapeutics and nanoparticle delivery systems. In tumor tissue, the endothelial layer 
is leaky (1.2b), and small molecules and nanoscaled objects readily cross in to the extravascular 
space. Small molecules can diffuse out of the tissue, while NPs are retained and accumulate in 
the extracellular space. Further cell-specific targeting is described in Fig. 1.3. 
 
Figure 1.2 Small molecule and nanoparticle accumulation in healthy versus tumor tissue.  
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Though the EPR effect continues to be cited as the mechanism of accumulation of NPs 
and other macromolecular materials at tumor sites,10–14 critical reviews of nanoparticles for 
drug delivery argue that many claims of NP targeting are overstated and oversimplified. The 
attribution of targeting via the EPR effect does not translate as a targeting mechanism in 
humans.15–19 Further, the degree of leakiness in tumor endothelium and lymphatic structure is 
not uniform, and depends on the disease type, stage/progression, and site.7,9,18–20 In addition the 
tumor microenvironment is highly heterogeneous and varies from cancer type to cancer type 
affecting things like diffusivity of particle through the extravascular space (penetrating versus 
remaining on periphery21), and interactions of the NP with cellular targets.7,22,23 While genetic 
profiling of patients and tumors is paving the way for personalized medicine and tailoring of 
nanoparticle to a specific disease profile, tumor microenvironments can vary greatly across 
patient populations, even in the same disease state. It is not surprising, then, that NP 
therapeutics designed to accumulate based on the EPR effect have varying degrees of efficacy. 
A recent meta-review of nanoparticle targeted delivery reveals that a median of 0.7% of an 
injected NP dose reaches a solid tumor; this number accounts for particles of different sizes, 
shapes, charges, and compositions, employing active or passive targeting strategies.24 There 
remains a need for a better understanding of nanoparticle interactions in the highly complex in 
vivo environment in order to better engineer materials for efficient and effective therapeutic 
and diagnostic delivery.  
There is a tremendous interest in utilizing the capabilities researchers have for precise 
execution of NP design, and away from abstract, passive targeting effects (e.g. EPR) that seem 
to only be relevant in murine models.24,25 Further, it is argued that the EPR effect is not a 
targeting mechanism, but rather reflects the normal flow and diffusion of molecules throughout 
and out of the blood stream. The EPR effect should not be relied on for sufficient accumulation 
at tumor target sites. To reach the next generation of ubiquitous NP efficacy in targeted 
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delivery, a more robust understanding of the physicochemical properties of NPs leading to their 
accumulation in a target site must be realized.  
1.2.2 Nanoparticle Physicochemical Properties 
A key research focus in applying nanoparticles for drug delivery is in understanding 
physicochemical properties affecting in vivo fate and designing NPs within those constraints, 
tailored to the applicaiton.24 Many publications studying nanoparticle targeting convey that the 
physicochemical properties of NPs, including size, shape, charge, and surface 
functionalization, can dictate the materials’ pharmacokinetic (PK) and pharmacodynamic (PD) 
properties. Most studies of NPs for in vivo applications address at least one aspect of the 
physicochemical property that leads to its success.17,22–24,26–36 Though individual studies and 
reviews indicate trends in favorable physicochemical properties of nanoparticles,  no set design 
principles have been established in the preparation of NPs for all applications.31 There is no 
single property that overrides all other with regards to dictating in vivo PK/PD, highlighting 
the fact that nanoparticle systems are a multi-leveled, synergistic systems, with relatively 
unpredictable behavior in vivo. Furthermore, studies sometimes show contradictory 
conclusions with regards to the importance of physiochemical characteristics. Opposing 
conclusions may depend on the strategies used to evaluate nanoparticle efficacy, or the in vivo 
model employed. Overall it is difficult to make definitive trends or claims because of multiple 
changing factors per iteration of material, as well as variability in material, tumor 
microenvironment, and animal model tested. Herein, key examples highlighting the importance 
of physicochemical features are described, with an emphasis on nanoparticle shape. 
Size Effects 
Nanoparticle size affects extravasation, targeting in tumors, blood circulation time, and 
clearance mechanism.29,30,36 The size of a nanoparticle is important when considering 
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extravasation in leaky tumor vasculature, which has limits on fenestration size. In compromised 
endothelium of tumorigenic tissues, nanoparticles up to 200 nm, and even up to 2 µm may 
diffuse in to the interstitium.7,16 Smaller particles may accumulate and penetrate the tumor more 
effectively, whereas larger NPs may retain in the tumor longer, an artifact of the retention part 
of the EPR effect, attributed to poor lymphatic drainage of tumors.16 Studies have tracked the 
effects that small changes in size have on tumor accumulation: smaller NPs (2-3 nm) 
accumulate faster, penetrate the tumor better, but diffuse out of the tissue, compared to 25 nm 
NPs which demonstrated greater accumulation but were limited in distribution in the tumor.21 
In other cases, NPs of different sizes (30, 50 ,70 and 100 nm) circulate in the bloodstream on 
the same order, and diffuse at a similar extent through hyperpermeable tumors such as murine 
colon adenocarcinoma. In models like human pancreatic adenocarcinoma that are less 
permeable, only NPs less than 70 nm penetrate and accumulate tumor tissue.37 These select 
examples demonstrate that a range of NPs may be appropriate for in vivo applications, but the 
effects may be countered by other physicochemical parameters and the heterogenous tumor 
microenvironment. 
Another artifact of a NP’s size is the effect on the cell uptake pathway: specifically, 
larger NPs greater than ~500 nm to micron-scaled nanoparticles will be phagocytosed, while 
subtle changes in NP size can affect endocytotic uptake mechanism.38,39 These are important 
considerations when therapeutic targets are inside the cell, and when aiming to avoid 
macrophage uptake. 
Perhaps the most important aspect of size is the inherent increased molecular weight, 
resulting in NPs with extended circulation time, and a shift towards clearance via the 
reticuloendothelial system (RES). Low molecular weight small molecules and small NPs < 5-
10 nm are rapidly cleared from the blood stream via the kidney (renal clearance).30,36 Very large 
NPs (> 1 µM) are opsonized and readily taken up in the RES system (liver, spleen). NPs on the 
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order of 20-200 nm represent a good range of target size as these will circulate in the 
bloodstream for a while, and have favorable sizes for extravasating in tumor tissue.  
Shape Effects 
A drastically under-utilized property of nanoparticles for in vivo applications is the 
shape, geometry or morphology. It is generally accepted that cylindrical NPs, or those with 
higher aspect ratios than spheres, exhibit good tumor targeting while evading premature 
clearance. Other less common morphologies, such as rods and bicompartmental micelles, are 
less studied in vivo. Admittedly, studying shape effects of polymeric NPs is challenging due to 
the difficulty of predictably preparing these materials via self-assembly processes, and 
compounded by the fact that changing one variable (e.g. shape) also changes other variables 
(size, overall charge). This offers an aim for future studies, and a motivation for the research 
in this thesis.  
A number of studies highlight the importance of particle shape/geometry, either on its 
own or in conjunction with other physicochemical parameters (size, charge), with regards to in 
vivo or in vitro effects (e.g. cell uptake).28,33,34,40–44 Some key studies highlight the advantages 
of high aspect ratio nanoparticles over spherical counterparts with regards to tissue targeting 
and cell uptake. A prominent example from the Discher group evaluates the prolonged 
circulation time of biodegradable filomicelles compared to stealth-like spherical nanoparticles; 
the filomicelles circulate up to a week post injection, accumulate in a tumor, and evade RES 
uptake.45,46 Colleagues in the Sailor Lab at UCSD have systematically evaluated advantages of 
dextran-coated iron oxide nanoworms for tumor targeting. The nanoworms target tumors better 
than spheres, with neutral peptide targeting moieties and poly(ethyleneglycol)-linkers aiding 
in favorable circulation times and multivalent interactions with the tumor target.40,47   
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With regards to cell uptake effects, many studies have found a positive correlation 
between high aspect ratio particles and greater uptake via endocytosis, with some dependence 
on material composition. For example, mesoporous nanoscaled particles with an aspect ratio 
of two are internalized faster and to a greater extent than longer or shorter rods.48,49 Templated, 
rod-like NPs were taken in to HeLa cells faster and to greater values compared to micron-scaled 
particles, or their spherical counterparts.27 The Mitragotri group showed that macrophage 
phagocytosis of large nano- or microparticles depends on both the shape of the particle and the 
contact angle; rod-like particles approaching on the short axis are more readily phagocytosed 
compared to approach on the long-axis.39,50 
Overall, cylindrical, worm-like, or NPs with aspect ratios greater than one hold 
promise for more efficient NP drug delivery carriers based on their prolonged circulation times, 
ability to evade RES uptake, and flexibility. The multivalency of less-curved surfaces allows 
for more favorable interactions with the NP surface, an especially important point when 
incorporating targeting moieties.  
Surface Functionalization and Charge 
As alluded to above, charge and surface chemistry are important when it comes to how 
an organism interacts with the NP. Surface functionality may include PEGylation, a strategy 
often employed for both solubility and stealth-like properties to evade protein opsonization and 
RES uptake.  
Though incorporating positively charged moieties is a useful tool for internalizing 
materials in to cells,49,51 cationic charges can have detrimental effects on systemically 
introduced NP solutions. Positively charged NPs are more likely to induce an inflammatory 
response than negative or neutral particles,38 and can have hemolytic/cytotoxic properties, in 
addition to high RES-uptake.52 Interestingly, highly negatively charged NPs also demonstrate 
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high levels of accumulation in the liver, though not as high cytotoxic properties.52  These 
observations indicate that charged species encourage unfavorable interactions with in vivo 
components like blood proteins and macrophages.  
Examples demonstrating the importance of charge is highlighted by studies 
investigating the charge effects on dendrimer NP in biodistribution patterns. Small dendritic 
NPs (G4 and G7-PAMAM) around 8-10 nm with cationic charge show greater accumulation 
in the liver compared to the kidney, and compared to neutral or negatively charger counterpart, 
despite their small size.53 In another example, cationic, PEGylated particles displayed 
hemolytic activity and toxicity in cultured macrophage cells.52 In vivo, the PEGylated NPs with 
either highly positive or highly negative charges demonstrate a high degree of liver uptake, 
whereas particles with a slightly negative charge evaded RES uptake and instead accumulated 
at the tumor.  
1.2.3 Active Targeting 
Strategies to incorporate targeting moieties such as antibodies or cell penetrating 
peptides are meant to target NPs to specific cell receptors or extracellular markers at the site of 
interest (Fig. 1.2). This in turn leads to greater accumulation than effects from macromolecular 
accumulation due to poor lymphatic drainage. However, clinical translation of active targeted 
NPs has been minimal.7,30–32 Another approach to actively targeting NPs is to incorporate 
stimuli-responsive units, where stimuli can be light, a change in pH or specific enzymes.31 The 
Gianneschi lab has an interest in using enzymatic stimuli, specifically enzymes that are 
associated with cancer, in a platform coined enzyme-directed assembly of nanoparticles at 
tumor (EDAPT). Matrix metallopreinases (MMPs) are extracellular matrix proteins involved 
in matrix remodeling, and have long been studied as target biomarkers for drug delivery 
materials.54–62 In the Gianneschi Lab, peptides designed to be recognized by MMP-2/9 
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enzymes, which are known to be upregulated in cancers and heart tissue post-myocardial 
infarction (MI), are incorporated in to a polymer backbone. Upon self-assembly in buffer, the 
peptides are displayed upon the corona of the NP, accessible to enzymatic processing. 
Fluorescence-resonance imaging transfer (FRET) dye-pairs rhodamine and fluorescein are 
incorporated to track NP circulation in vivo. When recognized by the enzyme, the sequence is 
cleaved, disrupting the hydrophobic-hydrophilic interactions of the assembly, resulting in a 
microscaled aggregate which retains in the tissue and exhibits a unique FRET signal. 
Accumulation of material in the tissue confirmed via in vivo imaging63; further, super-
resolution fluorescence microscopy (stochastic optical reconstruction microscopy, STORM) 
confirmed that the aggregates of NPs accumulate in tissue, and not an accumulation of spherical 
particles.64 EDAPT’s effectiveness has been demonstrated in the delivery of enzyme-
responsive therapeutic compound-carrying NPs in cancer or MI animal models.65,66  
 
Figure 1.3 Active targeting of Nanoparticles to tumor tissue. 
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1.2.4 Challenges to Studying Nanoparticles in the Lab 
Another aspect of clinical translation involves the process by which novel NPs are 
developed and tested in the lab. In the lab, toxicity and cellular targeting are evaluated in vitro 
using high through-put assays. Pharmacological parameters of absorption, deposition, 
metabolism and elimination are performed in vivo to determine toxicity and efficacy. 
Identifying in vitro and in vivo preclinical models that indicate potential for success of a 
nanotherapeutic is crucial.5 Cultured cells for in vitro screens is a reasonable and telling way 
to identify intracellular targets and efficacy, and is the standard used by the National Cancer 
Institute to evaluate toxicity of new compounds.5 However, these cells are typically grown in 
monolayers, in isolation, with optimized media and growth conditions and is thus not 
representative of the highly heterogeneous tumor microenvironment. In vivo xenograft models 
of human cancers are established and ubiquitous methods to evaluate efficacy across the 
spectrum of cancer cells, either cultured or from patient biopsies. For the most part, preclinical 
translation to humans reflects efficacy in xenograft models when the same cancer type is 
evaluated, while the response is not as strong when different cancers are evaluated.5  
Nonetheless, cancer is a heterogenous disease,  and cells and mice grown in controlled 
environments are simply experimental vessels.  
1.3 Polymer Amphiphile Self-Assembled Nanoparticles 
Controlling a self-assembled nanoparticles’ physicochemical properties offers a good 
starting platform for tailoring NPs to the intended target. However, as alluded to above, control 
over the self-assembly process in terms of predictability of a nanostructure “product” is not 
ubiquitous. The ability to have predictive control over NPs structure, particularly shape, 
motivates the next section of this introduction.  
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Two strategies towards preparing discrete NPs with specific physicochemical 
properties and functions employ either a bottom-up approach or top-down methodology. 
Bottom-up approaches include self-assembly of molecules, synthesis of macromolecules, or 
preparation of inorganic nanoparticles. The self-assembly approach is favorable in the number 
of parameters tailorable towards the scientist’s application, encompassing atomic- and 
molecular-level control.42 Self-assembly approaches are inspired by nature, where molecular 
self-assembly is responsible for creating hierarchically ordered composite structures with 
exquisite control and function.43,67 In contrast, templated NP preparations or top-down 
approaches are also widely used in nanoparticle applications due to their ability to prepare well-
defined and complex structures with excellent control.  Common top-down approaches include 
particle replication in non-wetting template (PRINT®),27,68 elastic stretching of spherical 
particles,39,50 step-flash imprint lithography (S-FIL, Molecular Imprint®)69 and template-
induced printing (TIP).42 
The strategy of choice in this work is to use amphiphilic block copolymers in a bottom-
up approach to self-assembled NPs. This approach allows for many opportunities to control the 
outcome of self-assembled polymeric NP, which fall in to two inherently interrelated 
categories: control in polymer synthesis and architecture, and control in the self-assembly 
process.  
1.3.1 Theories on Self-Assembly 
Theories of self-assembly establish that assembled nanoparticle structures are 
dependent on the volume ratio of the blocks and the packing parameter of unimers. The 
spontaneous formation of ordered macromolecular surfactants relies on favorable hydrophobic 
interactions in the core, interplay between corona and core, and corona solvation of core and 
repulsion of strands.70,71 The morphology a nanoparticle adopts depends on these interactions, 
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and can be affected by parameters such as polymer chemical structure (e.g. change in molecular 
weight and block ratios of polymer) and environmental factors like solvent conditions during 
assembly.13 Nanoparticle geometry is dictated by the packing parameter (p) of the polymer 
components, which is in turn determined by volume (v) and length (l) of hydrophobic block, 
and interfacial area per molecule (a) according to the equation p = v/(al).43,70,72 For p < 1/3, 
spherical micelles are the predicted nanoassembly, 1/3 < p < ½ for cylindrical micelles, and 
1/2 <p <1 for bilayers. For the surface area a, the optimal interfacial area is not a geometric 
area, but a thermodynamic value determined from equilibrium.72 Therefor, the polymer 
chemical structure dictates the constraints of possible, thermodynamically stable geometries 
(parameters volume and length above), while the process of self-assembly can be used to 
modulate polymer interactions and block solubility affecting interfacial surface area. Taking 
advantage of the self-assembly process can lead to kinetically “trapped” structures that are 
locally stable, perhaps even for months, unless perturbed by outside parameters. Some block 
copolymers (BCPs) are thus nonergodic: the self-assembly pathway selected results in many 
kinetically trapped structures from one polymer, and these structures may or may not be the 
most thermodynamically stable species.73,74 Nonetheless, it is clear that polymer structure and 
pathway of assembly may be optimized to prepare nanoparticles of tailored morphologies for 
optimal performance in the desired application. Over the years, many groups have studied the 
assembly processes of BCP towards understanding these parameters. 
1.3.2 Experimental Investigations of Polymer Self-Assembly 
Understanding, predicting, and controlling the self-assembly process of organic 
polymers in aqueous environments is of utmost importance as polymeric NPs become more 
prevalent for applications in areas like drug delivery. Polymer self-assembly has been studied 
by many research groups of different disciplines over the last few decades.43,73–95 From these 
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studies, trends and key observations on controlling the assembly of polymers in to discrete and 
interesting NP architectures has been observed. Eisenberg and coworkers, for example, have 
studied crew-cut BCPs (in which the core block is greater than the corona block) and the many 
morphologies of NPs they can take, including spheres, rods, vesicular, lamellar, large 
compound-micelles, bicontinuous micelles, and other inter-connected or network like bilayer 
structures.78,81 These studies investigate both polymer structure effects on NP self-assembly, 
and modulators of the self-assembly process.82 A general trend is seen with varying ratios of 
hydrophilic-to-hydrophobic block: as the weight percent of hydrophilic portion increases, NPs 
trend towards higher curvature assemblies, e.g. spheres. Specifically, study of the assembly of 
polystyrene-b- poly(acrylic acid) polymers shows that as acrylic acid (hydrophilic) content is 
decreased, aggregate morphology goes from spheres to cylinders, bilayer morphologies 
(lamellar and vesicular) and compound micelles.78 In a set of comprehensive studies by the 
Bates group, a phase diagram for a set of PS-b-PEO BCPs was established.84,85 By 
systematically varying the ratio of hydrophilic to hydrophobic blocks, and overall polymer 
MW, self-assembled nanostructures were surveyed. Again, the trend of higher weight ratios of 
hydrophilic blocks favoring formation of high curvature spheres was observed. The exact 
weight ratio required to form spheres versus cylindrical versus bilayer structures was dependent 
on the polymer chemical identiy.84,85  
Complicating effects of polymer architecture on self-assembly structure, parameters 
such as solvent selection, electrolyte additives and temperature can affect the morphology of 
an identical polymer chain.74,83 For example, a polystyrene-b-poly(ethyleneoxide) (PS-b-PEO) 
BCPs assembles in to lamellar structures under one solvent condition, but upon adding salts, 
the assemblies are large compound vesicles. Assembling the polymer at sub-ambient 
temperatures also favors bilayer aggregates like large compound vesicle (LCV), compared to 
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rod-like or lamellar structures when assembly occurs at room temperatures.74 These studies 
show both how polymer structure and solvent conditions can lead to various NP structures. 
1.3.3 Kinetic and Thermodynamic Equilibria in Polymer Self-Assembly 
Many self-assemblies of soft materials are often found as mixed-phases, evidence of 
the delicate balance of kinetic and thermodynamic properties in forming stable nanoscaled 
aggregates. For example, in the Bates study, uniformed phases consisting of cylinders only 
existed in a narrow window, and were often found as mixed phases with spherical structures.85 
The importance of thermodynamic or kinetic control in NP self-assembly are investigated 
alongside the above described studies looking at final nanostructure morphology. Eisenberg 
studied the thermodynamics of micelles in mixed solvent systems for various polymer 
architectures.82 In aqueous conditions, BCP assembly is a balance of entropic penalties and 
enthalpic- favored interactions: under experimentally investigated conditions, low weight % 
water solvent mixtures had negative enthalpies, overcoming negative entropically unfavorable 
events to form defined assemblies. Here, hydrophobic block solubility drives the micellization, 
whereas the hydrophilic block is not as important. As water content increases, solubilizing of 
the hydrophilic portion and entropy is more important for micellization. There is a critical water 
content value necessary for BCPs to assemble; exact values will depend on the polymer system 
and solubility in the solvent mixture.  
Detailed studies highlight the importance of kinetic and thermodynamic equilibria in 
polymer self-assemblies. An advantage of using large MW amphiphiles as opposed to small 
molecule surfactants is the ability to kinetically trap structures that are not at the globally most 
stable conformation. Two kinetic processes contribute to stable macromolecular assemblies: 
the fast, intramicellar chain rearrangement as a solution reaches a critic water concentration for 
aggregation, followed by slow chain exchange kinetics of individual polymer strands towards 
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reaching a thermodynamically stable assembly.76 The hydrophobic effect drives the former, 
fast process, wherein the insoluble block immediately aggregates to a conformation that 
minimizes interactions with the poor solvent. The second step, wherein unimer (polymer) 
exchange occurs, is very slow due to the relative stability of the already existing nanoassembly, 
and the high energetic penalty for exchange or global rearrangement, leading to mostly frozen 
structures. Though these initial assemblies may not be the most thermodynamically stable 
nanostructure possible based on packing parameter considerations, they can be stable up to 
months after formation,86,87 and are thus referred to as kinetically trapped structures. 
Researchers highlight the value of trapping complex structures by using the process of 
assembly to exhibit kinetic control over micelle assembly.73 In a detailed study by Epps and 
coworkers,92 the kinetic formation and stability of a polymeric NP in mixed solvent 
environment (0-50% tetrahydrofuran in water) was evaluated. After formulating spherical NPs, 
the structure was allowed to equilibrate to its thermodynamically favorable state. Over several 
weeks the authors observed a change in morphology to larger spheres as the amphiphilic 
polymer unimers rearranged to a more thermodynamically stable structure. In other studies, 
solvent selection was used to kinetically trap non-thermodynamically equilibrated structures 
like complex dislike micelle, demonstrating the idea of BCP nonergodicity.73,87 These studies, 
among many others in the literature, indicate that solvent selection and processing of polymer 
amphiphiles, including dynamics of assembly, are important considerations towards reaching 
kinetically or thermodynamically stable nanoparticles.   
1.3.4 Polymer Architecture for Self-Assembly 
It is apparent that the polymer architecture, can play a role in polymeric self-assembly 
towards distinct NPs. There are numerous polymerization methods that can yield desired 
polymer architectures with good control. These methods including reversible addition-
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fragmentation chain transfer (RAFT), ring-opening polymerization (ROP), atom transfer 
radical polymerization (ATRP), anionic polymerization and ring-opening metathesis 
polymerization (ROMP), among others.89,96 Studies of polymer amphiphiles obtained from 
ROMP are of particular interest because of the range of functional groups amenable to the 
technique and low dispersity of resulting polymer, stemming from living polymer growth 
mechanism.97 
ROMP enables preparation of functional block copolymers BCPs via graft-to, graft-
through or graft-from approach. The Gianneschi lab primarily uses ROMP towards polymeric 
NPs in graft-to and graft-through approaches. In a graft-to approach, a conjugatable monomer 
unit is polymerized in to the polynorborne BCP scaffold, followed by post-polymerization 
reaction with a functional unit to achieve the desired BCP. In the graft-through approach, 
functional monomers are first prepared, then polymerized, with the resulting BCP amphiphile 
ready for micellization. The functional group tolerance of ROMP extends to various 
hydrophobic and hydrophilic moieties, conjugatable units, a range of fluorescent and quencher 
dye molecules, magnetic resonance imaging agents (MRI) and biomolecules, facilitating 
preparation of highly functional and useful polymeric materials.98–100 An overview of 
polymeric NPs from polynorbornene polymers is described elsewhere,89 with some key 
examples highlighted here. Carrillo and Kane tuned NP size by controlling the composition of 
the BCP: as overall polymer MW increased, NP size similarly increased.90 Another study 
looked at the effect of polymer architecture on self-assembly, finding that BCPs more readily 
formed spherical micelles in an organic solvent mixture compared to blended copolymers.91 In 
a systematic study of ROMP a hydrophilic-to-hydrophobic block ratio and overall polymer 
MW were varied to investigate micelle formations effects.93 When the block ratios were fixed 
at an equal-block ratio and the overall MW varied, micelle size increased with polymer size. 
When the overall block length was kept constant, and the block ratio was varied, micelle size 
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was constant, while the core size decreased correlating with decrease in hydrophobic block 
length. A comprehensive and systematic study of polymer effects on micelle assembly was 
carried out in the Gianneschi lab to establish phase diagrams for polynorbornene structures of 
interest.71 In a similar method to Bates,85 hydrophilic-to-hydrophobic block ratios were varied, 
along with polymer MW (low and high degrees polymerizations) and identity of chemical 
functionality used as the hydrophilic molecule. As higher weight fractions of hydrophilic 
portion were prepared, spherical nanoassemblies were observed. However, the phase diagram 
and regime of morphological distribution was highly dependent on the hydrophilic functional 
group, indicating that solvation of the corona and repulsive forces of charged functional groups 
are critical. Larger MW polymers did not see the diversity in morphologies as the lower MW 
polymers did. Similar to other studies investigating kinetically trapped nature of some polymer 
self-assemblies, some polymers assemble in to different structures depending on the process, 
or solvent, used during micellization. In all examples in this study, the hydrophobic group is 
kept constant (norbornyl-phenyl). In some cases, however, the core group may need to be 
changed, for example to include a hydrophobic drug moiety.65 For example, stimuli-responsive 
polymeric NPs incorporating peptides or nucleic acids are restricted to architectures where the 
biomolecule is incorporated as the hydrophilic portion, displayed on the corona of the NP so 
as to promote interactions with its environment.63,101–105 
 In this work, there is an interest in using chemical control of polymer synthesis to 
prepare nanoparticles of discrete and diverse morphologies. By introducing a variety of 
hydrophobic functionalities, and changing solvent conditions during self-assembly, control 
over nanoparticle structure was achieved. Building off previous work in the lab, we present 
new strategies for preparing polynorbornene polymers towards nanoassemblies of diverse 
morphologies.  
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1.4 Nanoparticles for In Vivo Imaging Using MRI 
Nanoparticle (NP) based drugs have reached the clinical mainstream, with established 
efficacy predominantly in oncology and infectious diseases.106–108 There is a growing interest 
in NPs as carriers of diagnostic agents capable of unique behavior and biodistribution patterns 
not observed for small molecule analogues.109 To this end, several strategies for the 
incorporation of imaging reporters within NPs have been introduced, allowing for NP 
visualization using, fluorescence,110 ultrasound,111 CT,112 MRI,113 and nuclear imaging.113,114 Of 
these modalities, MRI offers several advantages including exquisite anatomic co-registration 
with excellent tissue characterization, lack of ionizing radiation, and in general, provides high 
quality images at clinically relevant imaging depths. In turn, many NP-based MR imaging 
strategies have been explored using either inorganic111,112,115–119 or soft polymeric organic 
materials as contrast agents.120–123 
1.4.1 Molecular Basis for Gadolinium-based T1 contrast agents 
MRI images and signals are generated using similar basic principles to that of Nuclear 
Magnetic Resonance. A patient is placed in a low-field magnet to align the spin of protons, and 
radiofrequency (RF) pulses at the resonance frequency of water protons are introduced, tipping 
the magnetization of protons. As the protons relax back to equilibrium, the longitudinal (1/T1) 
or transverse (1/T2) relaxation rates are detected, and relative changes in these rates are 
processed to give a signal strength per voxel to generate an image with precise 3D 
information.124 Contrast in an MRI image reflects differences in relaxation rates of water in 
different chemical environments. Contrast agents may be introduced to enhance the contrast in 
areas where the agent is present. Gadolinium-based contrast agents (GBCAs) are T1-weighted 
contrast agents in MRI that provide enhancement by shortening the longitudinal relaxation time 
of metal-bound water molecule protons resulting in brighter image intensity. GBCAs can affect 
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T2 relaxation times as well, but the effect is not as great as that on T1 relaxation rates. T2 contrast 
agents include manganese or iron-based materials, and provide an alternative gadolinium-free 
drug for patients not eligible to receive GBCA, such as those with impaired renal function.  
The effectiveness of a contrast agent is described as relaxivity, with the equation r1 = 
1/ T1, where n = 1 for longitudinal relaxation times or n = 2 for transverse relaxation. Relaxivity 
is normalized to concentration of contrast agent with units in mM-1sec-1. The gadolinium (III) 
ion on itself is toxic, and therefore must be sequestered with an organic chelate. Typical 
gadolinium chelating agents are octadendate ligands consisting of amine and oxygen binding 
moieties to the metal center, leaving 1 open site for a water molecule to bind to gadolinium, 
and can by macrocycles or linear.125 The metal-ligand complexes exhibit very high 
thermodynamic equilibria (stability), as well as low kinetics of ligand exchange.126 Despite the 
relative chemical inertness at neutral pH, in acidic conditions, ligands can be labile due to 
proton-associated dissociation, leading to instability of the metal complexes; linear chelates are 
more susceptible to this dissociation compared to macrocyclic ligands.126 The gadolinium-
chelate circulates in the blood stream as the Gd-L complex, thus obviating any negative 
interactions of the gadolinium ion in physiological processes or deposition in vivo.125 Select 
examples of clinically approved GBCA are depicted in Fig. 1.4.125 
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Figure 1.4 Clinically approved small molecule gadolinium based contrast agents. 
The molecular basis driving relaxivity enhancements with GBCA stem from the 
paramagnetic contributions of the gadolinium-based molecule. Water molecules can interact 
with the Gd-chelate either through an inner sphere mechanism (the water molecules interacting 
directly with the metal) or second-sphere mechanism (bulk water exchange) (Fig. 1.5). The 
inner sphere contributions to relaxivity are predominant, and are described in equation 1 as127: 
Equation 1: r1(IS) = q/[H2O] / (T1m + τm) 
where the q value is the hydration number, or number of water molecules bound to Gd; T1m is 
the relaxation time of the water and τm is the water residency time (time spent bound to Gd). 
To increase relaxivity, then, one would aim to increase the q value, or decrease T1m and τm. For 
examples highlighted in Fig. 1.4, q is 1. To increase q, a different type of ligand is required, 
with less than eight ligand sites, while maintaining appropriate thermodynamic stability and 
kinetic inertness. One such example is the hydroxypyridinonate (HOPO)-ligands developed by 
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the Raymond group.128 To decrease the water relaxivity and residency times, there are many 
factors to consider. The derivation of these factors are discussed elsewhere127 and depend on 
the field strength and the nature of the chelate (which can promote water exchange or alter the 
radius of Gd-water interaction). 
 
Figure 1.5 Molecular parameters of GBCA interreacting with water to enhance relaxation time 
and contrast. Adopted with permission from Ref. 129, Copyright 2012 American Chemical 
Society.  
Another approach to increasing relaxation rate is in altering the rotational correlation 
time (Fig. 1.5). The relaxation time of water is dependent on field strength, radius of the Gd-
H(water) bond, and rotational correlation times τc. Rotational correlation time τc is dependent 
on the water residency time τm (the inverse of which is the water exchange rate, kex), the 
rotational correlation time τR and the electronic relaxation time T1e. Conceptually, this means 
that coupling the Gd-L to a slow-tumbling macromolecule could significantly increase the 
relaxation time. Or, in another strategy, the ligand could be modified to shorten the radius of 
interaction between Gd-water or promote faster chemical exchange of water molecules in the 
inner sphere. Nuclear magnetic resonance dispersion (NMRD) profiles of clinical GBCA 
demonstrate that at clinically relevant field strengths, 1.5 T, rotational correlation time is most 
important for increasing relaxivity; Gd species whose diffusion rates are coupled to 
macromolecules demonstrate increases in relaxivity experimentally.127 Further, simulations of 
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relaxivity for slow tumbling (10 ns), intermediate (1 ns) and fast (0.01 ns) rotation illustrate the 
field-strength dependence of relaxivity for different categories of contrast agents (Fig. 1.6). 
Although slow tumbling species (10 ns) model as very high-relaxivity species at low field 
strength, at higher field strengths there is no advantage of the macromolecule over a small 
molecule. The intermediate and small molecule species show stable relaxivity across field 
strength, with a small molecule having a lower relaxivity. This is important when thinking 
about designing the next generation of contrast agents for clinical translation: as technology 
has improved, clinics are moving towards higher field strength magnets. At the higher fields, 
GBCA appended to macromolecules may not provide the best results. Designing contrast 
agents for the future should address the variable relaxivities of these agents, and be tailored for 
specific applications.  
 
Figure 1.6 Effect of rotational correlation time on relaxivity at different field strengths. 
Reproduced from Ref. 127 with permission from The Royal Society of Chemistry. 
Because of the vast improvements that slowing the rotational correlation time of a 
GBCA can have on the relaxivity, macromolecular, or NP-based contrast agents have been 
postulated as superior contrast agents for MRI based on the underlying physical parameters 
dictating MRI and high-relaxivity species.127 Contrast agents are administered in 30% of scans, 
and are designed to provide contrast systemically, or at areas of interest. In our research, we 
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are interested in using MRI as a non-invasive imaging tool with clinical relevance. As such, in 
Chapter 3, strategies towards directly incorporating a gadolinium-chelate derivative in to a 
polynorbornene scaffold are described. The relaxivities are described, and in vivo imaging 
performed, demonstrated enhanced circulation times in vivo compared to a small molecule 
counterpart.  
1.5 Albumin as a Drug Carrier 
In the previous sections, the use of nanoparticles as drug carriers are discussed with 
regards to the potential use in nanomedicine and targeted drug delivery to tumor targets. While 
exploration of nanoparticles holds promise, there are still challenges to implementation in the 
clinic.2,4,129 Moving forward with a clinical translation of research in nanomedicines is difficult 
due to discussed problems associated with efficient nanodelivery, results in animal models, and 
subsequent translation to humans.24 An alternative approach for drug delivery has emerged and 
uses an endogenous protein as a drug carrier and delivery vehicle as a simple yet elegant means 
towards more effective therapies. Specifically, human serum albumin, the most abundant blood 
protein in human plasma, has been shown to be an effective drug carrier, providing a platform 
that prolongs circulation of molecules bound to the protein, and offering favorable 
physiological interactions in vivo.130–132 This strategy has reached the clinical mainstream with 
several examples of therapeutic- or diagnostic- agents based on interactions with HSA on the 
market.130,133,134 
Human serum albumin (albumin, HSA), a 66.5 kDa protein, exists in vivo at very high 
concentrations (42-54 g/L), with a half-life of about 19 days.135 Albumin has robust stability, 
is biodegradable and is amenable to covalent or non-covalent modifications for appending 
bioconjugates or drugs of interest.8 Native albumin acts as a carrier of various small molecules 
in the blood stream, especially hydrophobic molecules (e.g. hormones, fatty acids, and amino 
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acids) and because it is an endogenous protein, conjugates designed to interact with HSA are 
non-immunogenic. Successful examples of HSA drug carriers rely on two main features: (1) 
improved pharmacokinetics due to the extended blood half-lives achieved by hitchhiking on 
the long-circulating HSA thus allowing the potential for more efficacious drug delivery, and 
(2) improved targeting to disease targets.   
The improvement of blood half-life for small molecules that have fast clearance 
profiles has been demonstrated for a range of molecules, especially with regards to diagnostic 
imaging applications.134,136,137 The extended circulation of specially designed diagnostic agents 
in the body can be visualized using a multitude of imaging techniques and offers the advantage 
of steady state imaging, and visualization of normal or abnormal vasculature. Blood half-life 
extension in the context of MRI is of interest for a wider window for in vivo imaging and 
clinical translatability.  Several examples of gadolinium-based agents designed to interact with 
albumin have been clinically approved.127,134,138 For example, MS-325, gadofosveset trisodium, 
tradename Ablavar or Vasovist, was approved as a blood pool contrast agent for angiograms 
in the 2008.138–141 The Gd-agent is a diethylenetriaminepentaacetic acid (DTPA)-derivative 
with a phosphodiester linked bis-phenyl, where the hydrophobic moiety is designed to interact 
with hydrophobic pockets of HSA (Fig. 1.4).134 In addition to enhanced blood circulation times, 
upon binding to albumin, the rotational correlation time of the Gd-based center is coupled to 
that of the slower tumbling protein, resulting in an enhancement of relaxivity in vitro. 
Gadobenate dimeglumine (tradename MultiHance),142,143 is another clinically approved blood 
pool imaging agent (Fig. 1.4). The DTPA ligand is modified with a phenyl ring, creating a 
hydrophobic moiety for interacting with HSA. Upon binding with HSA, relaxivity 
enhancements are observed, and the blood circulation time is prolonged compared to that of 
other Gd-based small molecule imaging agents (such as Dotarem). In these two examples, a 
hydrophobic moiety is installed on a linear Gd-chelate to promote hydrophobic interactions 
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with an endogenous protein for the purposes of improved blood circulation times, allowing for 
blood pool imaging applications. Of note is that neither Vasovist or MultiHance have been 
approved for tumor imaging applications. 
Albumin has also been demonstrated to accumulate in tissues with abnormal 
vasculature or inflammation.12,144 In fact, albumin-Evans Blue “nanoparticles” were used by 
Matsumura and Maeda to describe the EPR effect in the 1980s.6 Since establishing that albumin 
proteins may experience an EPR effect at tumor sites, the protein has also been implicated as 
catabolites in tumors, an idea that hinges on the fast-growing cancer cells needing a nitrogen 
source for cell proliferation.14–16,131 Additionally, a subset of albumin-binding proteins is 
attributed to the mechanistic underpinnings for accumulation and efficacy of albumin-based 
drug carriers. Several albumin-binding proteins have been identified; the discussion here will 
focus on glycoprotein 60 (gp60), or albondin, and cell membrane receptor and extracellular, 
secreted protein, acidic and rich in cysteine, or SPARC. 
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Figure 1.7 Depiction of albumin and albumin-bound molecules accumulating in tumor tissue. 
It is understood that gp60, a 60 kDa glycoprotein, localized to the continuous 
endothelium cell surface, is selective for native albumin and facilities the transcytosis of 
albumin from the capillaries to interstitial space.131 A host of detailed mechanistic studies 
reveals this receptor-mediated internalization occurs via a caveolin-dependent pathway 
trafficking proteins into the tissue without degradation.145–147 Receptor-mediated transcytosis 
is responsible for 50% of the albumin leaving the vasculature; fluid-phase transcytosis and 
passage through leaky vasculature (e.g. EPR effect) contributes to the remainder of albumin 
movement.131,145,147 Albumins that are modified or conformationally different are endocytosed 
by gp18 and gp30 receptors; these protein receptors are not localized to endothelial cells, but 
found throughout organ tissues, and are specific enough such that they do not recognize 
competent albumin. Gp18 and gp30 are considered scavenger proteins, and upon endocytosis, 
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degrade the protein. SPARC proteins are extracellular proteins, and like gp60, selectively bind 
albumin. It is suggested that SPARC-recognition of the albumin leads to the increased 
accumulation of albumin in tumor tissue, though there is no direct evidence of SPARC-
mediated uptake of albumin in cancer cells. Nonetheless, SPARC shares a similar selectivity 
for albumin, hinting that the two protein receptors share a similar binding domain, despite 
extracellular location (SPARC) versus location on endothelial cells (gp60).148  
In addition to endothelial cell receptor gp60 and extracellular SPARC proteins specific 
for albumin, and gp18 and gp30 receptors for non-native albumin, several other membrane-
bound albumin binding proteins have been identified: neonatal FC receptor (FcRn), 
heterogenous nuclear ribonuceloproteins (hnRNPs), calreticulin, cubulin and megalin.131 Of 
these, hnRNP and calreticulin have been identified from human cancer cell membranes, yet 
their role in albumin-mediated uptake in tumor cells remains elusive.149 Countless studies 
tracking HSA in tumor tissue confirms uptake of the protein in cells, yet the exact mechanism 
responsible for cancerous cell targeting remains vague; understanding this process is critical 
for improving cellular targeting of HSA drug carriers. 
An illustrative example of therapeutic delivery based on HSA binding is the 
blockbuster drug Abraxane (ABX). Abraxane is described as a nanoparticle formulation of 
paclitaxel with HSA, wherein the hydrophobic taxane drug is formulated solvent-free with an 
endogenous protein. ABX is safer than a clinically comparable formulation of paclitaxel with 
Cremophor EL allowing for higher, safer dosings, with less side-effects than the formulation 
compound.150 Developed by Abraxis and Desai in the early 2000s, ABX was approved for 
clinical use in 2005, and is now used for a host of indications.2,150–154  The mechanism of ABX 
targeting to tumors is attributed to selective transcytosis of the albumin-bound taxane across 
the endothelium to tumor tissue, where SPARC recognizes it, facilitating accumulation in the 
tumor site.153,155,156 The role of SPARC in ABX efficacy is highlighted by a clinical study that 
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showed enhanced efficacy of ABX in tumors with elevated SPARC levels.157 It is important to 
note that the interactions between paclitaxel and albumin are non-selective, weak, hydrophobic 
and non-covalent interactions; nonetheless, the drug experiences advantageous effects from 
HSA as a carrier in the blood stream with selective accumulation in tumor sites, leading to 
greater therapeutic efficacy. The targeting effect to tumors of the HSA-drug conjugate is 
applicable to other therapeutics as well: docetaxel, doxirubicin and methotrexate approved 
formulations with HSA have demonstrated clinical efficacy.2 
While the success of many albumin-carried drugs relies on non-covalent or covalent 
(not described here) interaction of warheads with albumin, few examples exist where a warhead 
is modified with a selective-binding moiety. Of the examples described above, imaging agents 
or therapeutic payloads in MS-325, MultiHance or ABX do not have highly specific binding 
regions, yet still display efficacy stemming from improved circulation times, and in the case of 
ABX, enhanced targeting to tumors by HSA. One of albumin’s native functions in the body 
include transport of fatty acids. Detailed protein crystallographic studies demonstrate the 
specific binding of fatty acids of various carbon lengths in specific binding sites of the 
protein.158–163 This selective interaction of a long chain fatty acid with albumin was harnessed 
for the clinically approved drug Levemir, developed by Novo Nordisk and approved in 2004.133 
Levemir is the albumin formulation of an insulin polypeptide modified with myristic acid (C14). 
Compared to free insulin, Levemir has increased blood circulation time and is more efficacious.  
We were interested evaluating a long-chain fatty diacid, octadecanedioic acid (ODDA, 
C18) for use in site-specific binding with HSA, and synthetic modifications to append 
interesting warhead molecules. Stearic acid (C18) was shown to have a binding equilibrium with 
values ranging from ~ 9. x 108 to ~ 3.5 x 107 M for the first 5 binding molecules to the protein, 
with up to 7 molecules binding with the protein.160,162,163 Studies specifically investigating 
diacids, and ODDA, reveal that the diacids bind with albumin on the μM range, at a lower 
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molar ratio of about 4 molecules fatty acid to albumin.161,164 The binding of long chain lipids is 
facilitated by a combination of non-polar interactions with hydrophobic binding pockets and 
cationic residues deep in the binding pocket, leading to electrostatic interactions. In our work, 
a novel platform technology has been developed, in which an octadecanedioic molecule is 
modified unilaterally to covalently link a warhead, either a therapeutic molecule, imaging 
agent, or some other compound of interest. The unmodified free acid remains to bind 
specifically and strongly with HSA in a reversible manner. Preliminary modeling of a novel 
ODDA-PTX molecule confirms a strong and specific interaction of the hydrophobic tail, 
anchored in the binding pockets with electrostatic interactions between cationic amino acid 
residues and the free acid (data not shown). The long chain FA acts as a means to “piggy-back” 
on to the endogenous protein, lending favorable blood circulation times and biodistribution. 
We sought to investigate the platform technology in regards to therapeutic small molecules, 
therapeutic peptides, and diagnostic/imaging agents.  
1.6 Conclusions for Introduction and Dissertation Overview. 
As overviewed in Fig. 1.1, there are many variables to consider when preparing 
nanoparticles for optimal in vivo function. This work will highlight characteristics of NPs that 
are vastly underutilized. Methods towards preparing polymeric NPs in a bottom-up approach 
to achieve interesting NP morphologies are presented in Chapter 2. Nanoparticles for in vivo 
imaging using MRI are described in Chapter 3. An alternative approach to NP drug delivery 
using a platform technology for hitchhiking on HSA is presented in Chapter 4. In using two 
fundamentally different approaches towards nanoparticle delivery to tumor tissue, polymeric 
and bioconjugate materials are designed and prepared, with evaluation in biological systems. 
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Chapter 2   
Accessing Diverse Nanoparticle Morphologies 
via Ring Opening Metathesis Polymerization 
2.1 Introduction 
As we strive to create NPs for optimal performance in vivo, engineering the polymeric 
NP for favorable blood circulation profiles and accumulation at the target is crucial. NPs of 
non-spherical morphology are vastly underutilized in clinical applications, and combined with 
the unpredictability in assembled polymeric morphology, there is a motivation for 
experimentally exploring the role of polymer structure and self-assembly conditions in forming 
interestingly-shaped NPs.  
As described in Chapter 1, vast numbers of research groups have explored polymeric 
self-assemblies with respect to their utility in a variety of medical applications and on a more 
fundamental level, design rules for controlling NPs with specific physicochemical properties. 
The two main strategies employed for imparting control on the NP morphology include 
dictating polymer chemical structure and architecture, that is the packing parameter 
considerations, and control over the self-assembly process, that is the thermodynamic and 
kinetic consideration. The approaches towards these two strategies involve chemical synthesis 
of the polymer (e.g. monomer selection, block length, dispersity) and control of the self-
assembly process. This second strategy includes utilizing specific routes of assembly such as a 
solvent switch where solvent selection and mixing can alter the dynamics of assembly to 
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kinetically trap structures in a non-thermodynamic state. Towards this end, ionic 
polymerization techniques are commonly used to prepare polymers for study of self-assembly 
properties (there are many studies, discussed in Chapter 1, with exceptional work from Bates 
and Eisenberg). The work in this chapter relies on the ring-opening metathesis polymerization 
(ROMP) strategy to synthesize block copolymers to navigate biologically complex systems. 
As such, there is a need to understand how to best design and prepare polymers for specific 
nanoscale properties. We elect to use ROMP because of the synthetic control the living 
polymerization allows in preparing monodispersed blocks with specific molecular weights; this 
is crucial given that molecular architecture can alter the nanoassembly. 
Previous work from the Gianneschi Lab and many others investigate polymer structure 
effects in the self-assembly process.  In  various studies, hydrophilic block of a block copolymer 
(BCP) was varied, along with ratio of hydrophilic-to-hydrophobic, and the overall polymer 
molecular weight (MW).1–3 Phase diagrams were developed to characterize the range of 
morphologies that were accessed upon assembly in aqueous solution. Interestingly, identical 
polymers could access different morphologies based on the pathway for self-assembly, 
highlighting the nonergodic nature of polymer self-assemblies, and ability to kinetically trap 
locally stabile structures using different solvent preparation procedures. 
This chapter is primarily interested in strategies to modulate the hydrophobic block of 
an amphiphilic BCP. In some applications, the hydrophilic block of a polymer may be 
constrained, for example when incorporating peptides as targeting moieties, or incorporating a 
hydrophilic imaging agent. Therefore, it is imperative that we investigate the feasibility of 
using the hydrophobic block to affect polymer self-assembly structure. A library of polymers 
with different architectures is prepared in which a range of hydrophobic blocks, in both length 
and functionality, are chain extended with a hydrophilic poly(ethyleneglycol) monomer (PEG), 
followed by assembly using varied conditions. The resulting assemblies, while not predictive 
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or adhering to a defined phase diagram, did substantiate the hypothesis that nanoparticle 
morphology depends on both polymer architecture and self-assembly route.  
A fluorinated hydrocarbon norbornene monomer was investigated as to feasibility in 
acting as a hydrophobic moiety in an amphiphile BCP. Perfluorohydrocarbons are interesting 
for their use in ultrasound contrast agents, in addition to the growing interest in 19F-MRI. 19F, 
not to be confused with the radioisotope 18F used for positron emission tomography (PET), 
shares similar magnetic properties to a proton, and gives a distinct signal in NMR. The 19F 
nucleus is in 100% natural abundance with a gyromagnetic ratio comparable to that of 
hydrogen, with 83% the sensitivity of the proton.4 Since only very small amounts of fluorine 
are present in the body, a contrast agent containing 19F must be administered to generate a 
detectable signal. Fluorine MRI has been discussed as a new generation imaging technique, 
though clinical translatability is limited by the sensitivity to administered 19F-containing agents, 
with some reports finding a detection limit of 126 mM 19F atom for detection in phantoms at 
3T.4  
In addition to utility in imaging applications, the perfluorohydrocarbon monomer is 
investigated with interest in properties pertaining to the fluorous effect.5 This effect relies on 
the observation that fluorine is neither hydrophilic or hydrophobic, and prefers to interact with 
itself. In an amphiphilic polymer self-assembly process, this could prove advantageous as a 
strategy to drive aggregation in an aqueous environment: the fluorine-containing molecules 
aggregate together to minimize any contact with water. Results here articulate the utility of 
using fluorine to formulate polymeric NPs in water. Applications in ultrasound contrast agents 
were explored elsewhere.6 This work provides strategies towards using ROMP to make 
fluorine-containing NPs of various morphologies towards NP imaging agents. 
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2.2 Selection of Monomers and Preparation of Polymers 
In many studies of polynorbornene amphiphiles, a norbornyl-phenyl is the 
hydrophobic block of the polymer. This monomer offers advantages such as ease of synthesis 
and fast polymerization kinetics. However, phenyl-based blocks are known to form relatively 
crystalline cores upon assembly. Due to strong hydrophobic interactions, the block readily 
packs together to minimize unfavorable interactions with water. The result is high Tg species 
(> 100˚C) 1 that requires high energy input to transition the core to a more mobile phase capable 
of undergoing chain rearrangement towards other equilibrium structures. In some cases, the 
resulting assembly structure is referred to as kinetically trapped, that is a structure that cannot 
reach thermodynamic equilibrium. Obtaining a kinetically trapped structure versus the 
thermodynamic structure can happen by modulating the assembly process. Utilizing different 
solvents and/or solvent mixtures for either blocks, one can access and subsequently trap the 
polymer structures along the path towards the most energetically stable structure before the 
kinetic structure can relax to the thermodynamic state.  
This study investigates hydrophobic blocks of various functionalities, and the utility in 
using polymer structure to access kinetically trapped structures. Due to the less hydrophobic 
nature of the monomers selected for this study (Fig. 2.1), it was predicted that the BCPs 
prepared would lead to more diverse and exotic structures as the dynamics of polymer 
reorganization will be more favorable. All BCPs prepared here contained a 
(poly)ethyleneglycol (PEG, monomer 1) hydrophilic block, which in all cases, was 
polymerized first, followed by the hydrophobic block, to ensure adequate solubility of the 
propagating block copolymer. Novel saturated hydrocarbons were prepared for investigation 
(norbornene- decylamine [Dec, monomer 2], -hexylamine [Hex, monomer 3] and -
cyclohexanemethylamine [Cy, monomer 4]) (Figs. 2.1 and 2.6). Monomers containing 
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naphthalene (Nap, monomer 5), phenol (Phen, monomer 6) and pyridine (Pyr, monomer 7) 
moieties were utilized to further explore the scope of hydrophobic block. A control polymer 
containing -phenyl (-Ph, monomer 8) was also synthesized.  
 
Figure 2.1 Ring opening metathesis polymerization (ROMP) scheme used to prepare all 
polymers. Monomers used for this study are described in the right panel. 
Polymers 1-17 were synthesized via ROMP and characterized by SEC-MALS (Tables 
2.1 and 2.3 and Figs. 2.7 and 2.8). All polymers demonstrated fidelity for living chain extension 
as evidenced by achieving desired target degrees of polymerization (based on equivalents n of 
monomer added to the living polymer chain) except for monomers 6 and 7. Good 
polymerization control is shown by the lower polymer dispersities. The phenol and pyridine 
moieties are known to coordinate to the ruthenium catalyst, thus negatively impacting the 
polymerization.7 SEC traces for Polymers P5, P6 and P7 display broad peaks and shoulders 
indicative of lack of control during the polymerization. Once polymerized, the polymers were 
used as is for micellization procedures. 
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Table 2.1 Molecular Characterizations of P1-P8. 
Polymer Composition Material Name DP (m) 
a DP (n) a Mn b Ð c 
P1 118-b-224 PEG18-b-Dec24 18 (75) 24 (25)[37] 13,690 1.012 
P2 118-b-318 PEG18-b-Hex18 18 (75) 18 (25) [27] 10,950 1.020 
P3 118-b-422 PEG18-b-Cy22 18 (75) 22 (25) [26] 11,970 1.019 
P4 121-b-520 PEG21-b-Nap20 21 (30) 20 (15) 13,880 1.167 
P5 121-b-689 PEG21-b-Phen89 21 (30) 89 (30) 31,870 1.039 
P6 121-b-671 PEG21-b-Phen71 21 (30) 71 (15) 27,150 1.020 
P7 121-b-759 PEG21-b-Pyr59 21 (30) 59 (30) 23,080 1.065 
P8 114-b-820 PEG14-b-Ph20 14 (20) 20(20) 10,060 1.015 
a 
 The degree of polymerization (DP) m and n, are determined using SEC-MALS. Target DPs are in parentheses. 
For n, the reported DP was determined by SEC-MALS in DMF, while the number in brackets is the 1H-NMR 
integration.  b  The number average molecular weight.   The dispersity of copolymer (Mw/Mn). 
2.3 Nanoparticle Formulation 
A solvent switch method, was employed for all micellization procedures. In this 
method, a water miscible organic solvent is used to dissolve the polymer. After solubilizing the 
polymer in either acetonitrile (ACN), dimethylformamide (DMF), or dimethylsulfoxide 
(DMSO) solvent, MilliQ water was added dropwise to the polymer solution. Unless otherwise 
indicated, an equal volume of water was added, followed by transfer of solution to snakeskin 
dialysis tubing, with MW cutoff of 3500, and dialysis against water over two days to remove 
organic solvent. The resulting nanoparticles were used as is for further analysis. The 
nanoparticles were numbered according to the polymer used to formulate the particle, for 
example NP1, NP2 and NP3 were prepared from P1, P2, and P3, respectively. 
Polymers P1-3 contained identical hydrophilic block, and comparable hydrophobic 
degree of polymerization, with similar resulting polymer MWs. The resulting nanoparticles 
had several morphologies, depending on the polymer and the cosolvent used in the 
micellization procedure. NP1 resulted in spherical NPs, regardless of the solvent selected (Fig. 
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2.2). NPs formulated from DMF and DMSO were approximately 20 nm in diameter by 
transmission electron microscopy (TEM), whereas NPs from ACN were slightly larger in 
diameter, and less uniform by TEM analysis. The observation of similar morphologies for NP1 
indicates that the polymer architecture is most important factor in forming NPs with distinct 
structures, and that there are multiple pathways (e.g. solvents) to access that structure. NP2 
prepared from ACN or DMSO resulted in non-discrete aggregates, while the micelles prepared 
from DMF solvent had an interesting diversity of high-aspect ratio nanoparticles, including 
branched micelles, rod-like micelles, and short worm-like structures. By using varied polymer 
structure and varied micellization conditions, NPs of various morphologies were prepared. 
Finally, NP3 were predominantly spherical, with a few high-aspect ratio cylinders observed 
for the DMF micelle solution, compared to mostly large aggregates when prepared from 
DMSO. Here, solvent selection and polymer architecture are important in accessing 
equilibrium nanoassemblies. 
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Figure 2.2 NPs 1-3, formed from P1-3, respectively. The solvent ACN, DMF or DMSO, is the 
solubilizing solvent, and was dialyzed away to leave fully aqueous solutions of the resulting 
NP, with representative TEM images here. 
Next, the self-assembly conditions were further probed to investigate the effect on NP 
morphology. Interestingly, when P2 was micellized with DMF solvent, different morphologies 
were accessed from those previously achieved (Fig 2.10). This is attributed to the strategy of 
using dynamics of self-assembly to achieve equilibrium structures. If undergoing a slow 
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addition of water, worm-like structures dominated the solution (Fig. 2.10a). When allowing for 
equilibration at low weight% water by stirring the solution overnight in 13% water in DMF, 
spherical nanoparticles of about 30-50 nm diameter were observed, indicating that the 
dynamics of assembly and rearrangement are important in reaching a stable structure (Fig. 
2.10b). Upon removing DMF from the 13% water solution via dialysis, slightly smaller spheres 
around 25-30 nm were observed (2.10c). The dynamics of reorganization of polymer chains in 
this system is slow, and overnight equilibration at low weight percent water allows for 
reorganization to a lower energy state. The dynamics of assembly will depend on the polymer 
and solvent conditions; for all polymers herein, the hydrophobic block is relatively large, and 
upon water addition, the polymer solutions readily self-assemble in to trapped structures. 
NPs 9-11 (Fig. 2.11) were prepared from P9-11. These polymers share the same 
monomer functionality as P1-3, but overall DP and molecular weights were much greater. In 
this small subset of the polymer library, the polymers were not as soluble in the solvents 
selected, but nevertheless some particles were observed. No particles were observed for NP9 
and NP10 in DMSO, or NP11 from both ACN and DMF. P9 and P10 formed spherical NPs 
around 25 nm, with NP9-DMF resulting in a distribution of smaller (25 nm) and larger (100 
nm) NPs. NP11 resulted in larger spherical particles with greater size distribution. P9 had a 
bimodal distribution by SEC; two polymer populations can lead to greater particle dispersity if 
the polymers are trapped in different assemblies or the mixing of the polymers in solution is 
not good.   
The NP8, (Fig. 2.12) was prepared from the control polymer P8, using a variety of 
solvents. NP8 was formulated from ACN, DMF, tetrahydrofuran (THF) or trifluoroethanol 
(TFE, not used in previous formulations). THF and TFE were selected as less hydrophilic 
solvents, compared to ACN or DMF; the fluorinated solvent is particularly of interest for the 
fluoropolymers discussed in the next section. All processes resulted in spherical nanostructures, 
50 
 
though each of a different size (20 nm, 100nm, 15nm, and 20nm, respectively). The increase 
in size seems to correlate with decreasing polarity, with THF, the least polar solvent employed 
in this series, giving the smallest NPs. This might occur do to the favorable interaction between 
a very solvophobic hydrophobic block and less polar solvent. We were interested in whether 
NP formulation solutions in a mixed solvent system were kinetically trapped or able to 
equilibrate to a more energetically stable structure. To test this, the micelle solution for P8 in 
DMF to water transition was imaged before dialyzing the organic solvent away: TEM of the 
50% water solution reveals interesting flower-shaped morphologies, and appear to be 
comprised of an aggregated worm-like structure flanked by spherical structures. When the 
DMF was removed, the NPs relaxed to spherical morphology of ~100 nm diameter. Upon close 
inspection, the particles are bicontinuous structures, though without further probing with cryo-
EM, for example, the internal structure cannot be ascertained.  
NP5, 6, 7 and 17 were prepared from P5, P6, P7 and P17, respectively, and are shown 
in Fig. 2.13. These polymers demonstrated difficult solubility in organic solvent and upon 
addition of water during micellization and a very limited sampling of NPs were obtained under 
the conditions probed. Solubility problems perhaps stem from the hydrophobic nature of the 
aromatic functional moieties.  
These studies highlight that diverse and stable morphologies may be formed through 
manipulation of the self-assembly process or by changing the polymer architecture. The 
dynamics of assembly was another strategy to formulate stable NPs. While not exhaustive or 
predictive, these strategies are feasible for manipulating the self-assembly of polymeric 
nanoparticles. 
2.4 Fluorinated Monomer, Polymers, and Nanoparticles 
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Next, polymers were prepared in which the hydrophobic block consisted of a 
perfluorinated carbon chain (PFC, monomer 9, Fig 2.1). This monomer has been used 
previously for applications in ultrasound contrast agents.6 In this series of polymers, PEG was 
polymerized first followed by the PFC to promote solubility and allow for easier 
characterization. It was anticipated that a poly(perfluorohydrocarbon) block would have 
differing solubility from the monomer; the strategy of polymerizing a solubilizing group first 
has been utilized in our group.8 The resulting polymers, fluorinated polymers 1-3 (FP1-3) were 
analyzed by SEC in chloroform (Table 2.2, Fig. 2.9). 1H NMR was used in attempt to determine 
the degree of polymerization of the second (PFC) block,1,9 but in all cases, the  integration 
values were extremely low (proton integration of polynorbornene backbone olefin peaks 
compared to terminal PEG -OCH3 peak gave a degree of polymerization of the PFC block 
between 1 and 4). Even though deuterated chloroform, a non-polar solvent, was used for NMR, 
the polymer may still have aggregated in solution, shielding the protons of the polynorborne 
olefin backbone, and misrepresenting the actual integration value of protons of interest. Thus, 
the results from SEC in chloroform were used for reporting the molecular weights and degree 
of polymerization for FP1-3.  
Table 2.2 Fluorinated polymer characterizations. 
Polymer Composition Material Name DP (m) a DP (n) a 
Mn 
b 
 CHCl3         DMF   
Ð c 
CHCl3   DMF    
FP1 120-b-937 PEG20-b-PFC37 20 (25) 37 (50) 32,540 525,900 1.278 1.093 
FP2 116-b-940 PEG16-b-PFC40 16 (20) 40 (20) 32,740 243,500 1.262 1.226 
FP3 120-b-9112 PEG20-b-PFC112 20 (40) 112 (25) 83,690 490,400 1.013 0.1498 
a 
 The degree of polymerization (DP) m and n, are determined using SEC-MALS. Target DPs are in parentheses. 
For n, the fluoro-block, the reported DP was determined by SEC-MALS in CHCl3. b  The number average 
molecular weight from SEC in CHCl3 or DMF.   c The dispersity of copolymer (Mw/Mn). 
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 The polymers were solubilized in various organic solvents before slow transition in to 
water, and subsequent imaging of micelle solutions to asses morphology. Due to the fluorinated 
“hydrophobic” group, we probed the utility of a fluorinated solvent for polymer self-assembly 
in water, and the effects of solvents with varying polarity. The polymers were not soluble in 
highly polar solvents like DMF and DMSO, and these were subsequently omitted from the 
screen. Self-assembly from acetonitrile solution was attempted, but only FP3 was soluble in 
the solvent.  
 All 3 FPs, when using the fluorinated solvent TFE for the solvent-switch formulation, 
resulted in similarly sized and relatively monodispersed spherical nanoparticles (FNPs 1-3, 
Fig. 2.3). Because of the nature of the fluorous effect, and the preference for fluorine to 
solubilize fluorine, using a fluorinated solvent with a perflorinated polymer block is thought to 
provide excellent solubility of the core group. This solubility may provide the environment for 
the fluoro-block to arrange into similar and favorable architectures, leading to a similar 
morphology. Upon further experimentation with FP2 and FP3, different morphologies were 
accessed depending on the cosolvent used (Figs. 2.4 and 2.5, respectively) which again 
supports the idea that nanoparticle morphology can be controlled during the self-assembly 
process by altering solvent conditions. For example, FNP2- THF yielded a [mostly] spherical 
morphology with some rod-like structures distributed on the grid. Micellization from a dioxane 
solution gave small branched-like structures. When the same polymer (FP2) was used to repeat 
the micellization procedure, the same phases were accessed (FNP2’): formulation form TFE 
gave spherical NPs, formulation from THF gave a mixture of rod-like structures and spheres, 
and micellization from a solution in dioxane resulted in a solution of branched-micelles and y-
junction mixed phase. For FP2 and FNP2, differential solubility of the fluro-block by the less 
polar solvents (TFE, THF and dioxane) was critical for the polymers to arrange in to different 
structures. FNP3 took the form of spherical NP when micellized from a TFE, THF or dioxane 
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solution, but when prepared from more polar acetonitrile, the NPS were rod-like in 
morphology. These results demonstrate (a) utility of using a perfluorinated monomer as a 
hydrophobic block, and (b) that solvent selection can affect the self-assembly of fluorinated 
polymers. 
 
Figure 2.3 TEMs of FNP1-3, dialyzed from trifluoroethanol to water. All polymers gave 
spherical NPs with similar diameter. 
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Figure 2.4 TEMs of FNP2 prepared from different organic solvent conditions. The bottom 
panel is the repeat preparation of micelles under the same conditions (FNP2’) and demonstrates 
the reproducibility of micelle formation for this system. 
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Figure 2.5 TEM of FNP3 prepared from different organic solvent conditions. 
With the FNPs in hand, the solutions were investigated for a 19F signal in NMR, but 
no signal from the micelle was observed for the nanoparticles. In a control experiment, polymer 
dissolved in organic solvent was subjected to NMR: a proton and fluorine NMR spectra were 
acquired, both nuclei showing the expected spectra. The observation of the micelle not giving 
a signal was similar to previously studied perfluorinated cores in polymeric nanoassemblies.10 
The perfluorocarbon group is restricted in movement in the core, and does not give a signal in 
solution-phase NMR. Future work needs to be done to optimize these systems for utility in 19F 
MRI applications. 
2.5 Conclusions and Outlook 
The design, synthesis, and formulation of organic polymers for self-assembled 
nanoparticles is an intriguing and rich area of research. The work described here complements 
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other published studies to show how polymer architecture, chemical functionality and 
manipulation of the self-assembly process can be utilized to prepare discrete nanoparticles 
towards biomedical applications. We are particularly interested in strategies to formulate 
nanoparticles of non-spherical morphologies. Towards this goal, we investigated a variety of 
hydrophobic functionalities in polynorbornene amphiphiles for probing trends in polymer self-
assemblies, and demonstrated the ability to kinetically trap equilibrium structures of different 
phases. 
This works demonstrates that varying the chemical identity of the hydrophobic block 
of an amphiphilic polymer, especially when selection of the hydrophilic block is restricted, 
serves as a tool in designing NPs with interesting morphologies. Omitting a low Tg hydrophobic 
block (-Ph), and instead using hydrocarbon groups like -decyl, -hexyl, and -cyclohexyl, non-
spherical micelles were obtained. Additionally, by varying the organic cosolvent used in the 
micelle preparation procedure, it is possible to obtain many NP morphologies from one 
polymer. When using hydrophobic blocks with aromatic-type moieties (naphthalene, phenol 
and pyridine), the polymers in this study gave spherical NPs exclusively, if the polymers could 
be solubilized.  
The most interesting results from this study demonstrated the robustness of a 
perfluorohydrocarbon monomer in synthesizing amphiphilic polynorbornene monomers, and 
their subsequent utility in preparing differently shaped NPs. Using a fluorinated cosolvent 
during micellization resulted in monodispersed spherical NPs, while using other less-polar 
solvents like dioxane and THF resulted in a diversity of morphologies.  
Overall, these results indicate that tuning the hydrophobic moiety and self-assembly 
conditions can result in desired NP morphologies. Several research groups have employed this 
strategy in studies where NP structure was probed as a function of various parameters of overall 
molecular weight and ratio of hydrophilic to hydrophobic blocks to optimize polymer self-
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assemblies. For example, in a study of polycatechol NPs as gadolinium-free MRI contrast 
agents, Li and coworkers employed the -hexyl hydrophobic moiety in the preparation of 
cylindrical micelles.11 Future studies of nanoparticle self-assemblies should capitalize on using 
non-aromatic moieties and solvent conditions, especially where biomolecules like peptides 
must be incorporated in to the hydrophilic block.  
Towards applying fluorinated polymer micelles in 19F-MR imaging, NP systems will 
need to be optimized. The perfluorohydrocarbon monomer used here is just one of many 
possible monomers, and the polymers structure can be further tuned. Contrast agents for 19F-
MRI hold great promise for a new generation of in vivo imaging tools, especially useful since 
the nucleus probed is non-endogenous. 
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2.7 Methods 
All reagents were purchased from Sigma-Aldrich and used without further purification. 
1H (300 and 400 MHz) and 13C (100 MHz) NMR spectra were recorded on a Varian Mercury 
Plus spectrometer. Mass spectra were obtained at the UCSD Chemistry and Biochemistry 
Molecular Mass Spectrometry Facility. Polymer dispersities and molecular weights were 
determined by size-exclusion chromatography (SEC, Phenomenex Phenogel 5μ 10E3A, 1K-
75K, 300 x 7.80 mm in series with a Phenomex Phenogel 5μ 10E3A, 10K-1000K, 300 x 7.80 
mm (0.05 M LiBr in DMF or HPLC grade CHCl3) using a Shimatzu pump equipped with a 
multi-angle light scattering detector (MALS, DAWN-HELIOS: Wyatt Technology) and a 
refractive index detector (Hitachi L-2490) normalized to a 30,000 MW polystyrene standard 
using dn/dc of 0.179. TEM was performed on a FEI Sphera microscope operating at 200 keV. 
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TEM grids were prepared by depositing small (3.5 μl) aliquots of sample onto grids (formvar 
stabilized with carbon [5-10 nm] on 400 copper mesh, Ted Pella Inc.) that had previously been 
glow discharged using an Emitech K350 glow discharge unit and plasma-cleaned for 90 s in 
an E.A. Fischione 1020 unit. The sample grid was then stained with 1% uranyl acetate solution, 
rinsed with water (~5 µL), and excess liquid was removed. Micrographs were recorded on a 
2K X 2K Gatan CCD camera 
2.7.1 Monomer Synthesis 
 
Figure 2.6 Synthetic scheme to prepare monomers 2, 3 and 4. 
Synthesis of monomer 2, 3 and 4. The same reaction conditions were used for the 
synthesis of all monomers, in a similar manner previously published protocols.9 Briefly, cis-5-
norbornene-exo-2,3-dicarboxylic anhydride (250 mg, 1.5 mmol), was dissolved in dry toluene, 
followed by the addition of  a solution of decylamine, hexylamine or cyclohexanemethylamine 
(1.6 mmol, slight excess), (towards monomers 2, 3, or 4, respectively). The reaction was heated 
to reflux over night with a Dean Stark trap in place. After the reaction was complete, the 
solution was cooled, then washed with 3x with 1M HCl, then NaHCO3(sat). The organic phase 
was then dried over sodium sulfate, filtered and concentrated to give a yellow tinted viscous 
solution (monomer 2, 3) or white solid (monomer 4).  
Monomer 2-1H-NMR (CDCl3)- (δ ppm): 0.85 (t, 3H, -CH3), 1.19-1.33 (m, 15H, 6xCH2 and H 
of CH2), 1.45-1.55 (m, 3H total, -CH2  and H of CH2), 2.64 (s, 2H, 2xCH), 3.25 (s, 2H, 2x CH), 
3.42 (t, 2H, -CH2), 6.26 (s, 2H, CH=CH).  
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Monomer 3-1H-NMR (CDCl3)- (δ ppm): 0.78 (t, 3H, CH3), 1.11-1.28 (m, 7H total, 3xCH2, H 
of CH2), 1.39-1.52 (3H total, -CH2  and H of CH2), 2.58 (2H, 2x CH), 3.17 (2H, 2x CH), 3.36 
(t, 2H, CH2), 6.20 (s, 2H, CH=CH).  
Monomer 4-1H-NMR (CDCl3)- (δ ppm): 1.10-1.32 (3H, 1xCH2 and H of CH2), 1.49-1.77 (m, 
10H, 4xCH2 and H of CH2, H of CH2), 2.69 (s, 2H, 2xCH), 3.31 (m, 4H, -CH2 and 2xCH), 6.29 
(s, 2H, CH=CH).  
PEG monomer (1) and perfluorohydrocarbon monomer 9 were prepared as previously 
described.6,12,13 
2.7.2 Polymer Synthesis and Characterization 
Third generation Grubbs catalyst was prepared as described previously.14,15 Briefly, the 
second generation catalyst ([(H2IMes)(PCy3)(Cl)2Ru=CHPh]) was dissolved in dry toluene, 
and an excess of pyridine dropped in to a stirring solution. Then that solution was added 
dropwise to cold hexanes to precipitate the catalyst: [(H2IMes)(py)2(Cl)2Ru=CHPh]. 
Polymerizations were performed under a dry dinitrogen atmosphere with anhydrous, degassed 
solvents in a glove box. For all monomers in this study, polymerization kinetics were fast 
(detailed studies not determined here, but similar kinetics as described in Ref. 9) and after ~30 
minutes, a small aliquot of the living polymer solution was removed, quenched and analyzed 
for block length and dispersity. Then the second monomer was dissolved and added to the 
solution and allowed to react another ~30 minutes. The reaction was quenched with ethyl vinyl 
ether, and analyzed for coblock molecular weight and dispersity using SEC-MALS in DMF 
(except where indicated). The polymer solution was concentrated then precipitated three time 
with cold ether to remove quenched “Ru” catalyst. The polymers were used as is for 
micellization procedures. Characterization for P1-P8 is in Table 2.1, and for P9-P17 is in Table 
2.3. Fluorinated polymers (FP) 1-3 are described in Table 2.2. The SEC chromatograms are in 
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Figs. 2.6-2.8. In many cases, a PEG homopolymer was prepared, characterized, and split in to 
batches before addition of second monomer, hence these polymers have identical hydrophilic 
block. 
Table 2.3 Molecular Characterizations of P9-P17. 
Polymer Composition Material Name DP (m) 
a DP (n) a Mn b Ð c 
P9 150-b-2107 PEG50-b-Dec107 50(50) 107(50) 50,660 1.2 
P10 150-b-397 PEG50-b-Hex97 50(50) 97(50) 42,680 1.028 
P11 150-b-456 PEG50-b-Cy56 50(50) 56(50) 32,080 1.055 
P12 124-b-343 PEG24-b-Hex43 24(30) 43(30) 19,160 1.010 
P13 124-b-314 PEG24-b-Hex14 24(30) 14(15) 11,900 1.013 
P14 142-b-228 PEG42-b-Dec28 42 (30) 28(30) 23,400 1.096 
P15 142-b-24 PEG42-b-Dec14 42 (30) 14(15) 19,370 1.132 
P16 121-b-537 PEG21-b-Nap37 21(30) 37(30) 19,270 1.039 
P17 114-b-714 PEG21-b-Pyr72 21(30) 72(15) 26,200 1.049 
a 
 The degree of polymerization (DP) m and n, are determined using SEC-MALS. Target DPs are in parentheses. 
For n, the reported DP was determined by SEC-MALS in DMF.  b  The number average molecular weight. c  The 
dispersity of copolymer (Mw/Mn). 
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Figure 2.7 SEC-MALS traces for polymers P1-P8. 
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Figure 2.8 SEC-MALS traces for P9-P17. 
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Figure 2.9 SEC-MALS traces for FP1-3. The first two chromatograms in each row are the 
PEG block followed by the coblock, run in DMF. In all cases, the polymers seemed to aggregate 
on the column and gave unrealistically high polymer MWs. Thus, these polymers were run 
with chloroform as a mobile phase, resulting in much cleaner analyses. The results of the 
coblock polymer run in chloroform was used to identify the polymer block lengths. 
2.7.3 Formulation of Nanoparticles 
General procedure: Polymers were solubilized in organic solvent (1-2 mg/mL). Water 
was added dropwise with gentle mixing until reaching a 1:1 v/v solution. The solution was then 
placed in snakeskin dialysis tubing with 3500 MWCO, and dialyzed against water, changing 
the dialysate two times. Nanoparticles were imaged using dry-state TEM. Samples were 
prepared as described in general methods section; all were negatively stained with uranyl 
acetate.  
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Figure 2.10 TEMs of NP2. Polymer 2 dialyzed from DMF to water, under the following 
conditions: a. slow addition of water, b. DMF + 13% v/v water, c: sample from previous panel 
dialyzed to remove solvent. 
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Figure 2.11 TEMs of NP9, NP10 and NP11, from polymers P9, P10 and P11, respectively. P9 
and P10 first dissolved in DMSO did not result in any discrete structures when observed by 
TEM. P11 first dissolved in DMF did not yield discrete NPs either, and formulation using 
acetonitrile as a solvent was not done. 
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Figure 2.12 TEMs of NP8. Polymer 8 micellized under various solvent conditions. The solvent 
descriptions represent the initial solvent used, except for “NP8-50%DMF,” which is an image 
of the solution at 50% v/v water in DMF. That solution was then dialyzed in to 100% water to 
give the structures in “NP8-DMF.” 
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Figure 2.13 TEMs of NP4, NP5, NP6, NP7 and NP17. Discrete NPs were not observed for 
P9-P11 or P16-17. P12-P15 were not used in any NP formulation screens. The solvent 
description is the initial dissolution organic solvent and the solutions imaged are the dialyzed, 
100% water micelle solutions. “DMF/DMSO” represents dissolution in a 1:1 v/v solvent 
mixture of DMF/DMSO. 
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Chapter 3   
MRI Contrast Agent Labeled Polymeric 
Nanomaterials for In Vivo Imaging 
3.9 Introduction 
The utility of macromolecular platforms, specifically polymeric and nanoparticle 
systems, in nanomedicine applications was discussed in detail in Chapter 1. It is highly 
desirable to develop nanoparticle platforms with their clinical translatability in mind, with 
regards to both therapeutic and diagnostic applications. This chapter focuses on diagnostic 
applications in nanomedicine, and specifically in vivo imaging using the magnetic resonance 
imaging (MRI) modality.  
The Molecular Imaging and Contrast Agent Database, maintained by the National 
Center for Biotechnology Information at the National Institutes of Health, documents 
thousands of molecular imaging probes and contrast agents.1 As of 2013, there are over one 
hundred FDA-approved contrast agents on the market for optical, X-ray, PET, ultrasound, CT 
and MR imaging modalities. We are interested in using MRI because it offers anatomic co-
registration with excellent tissue characterization, lack of ionizing radiation, and in general, 
provides high quality images at clinically relevant imaging depths. In addition, the 
instrumentation and technical support for preclinical MR imaging is readily available to our 
lab. We are particularly interested in using gadolinium-based contrast agents (GBCAs) because 
these are by far the most commonly used MRI contrast agents.2 There are examples of clinically 
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approved manganese and iron-oxide contrast agents for MRI, but we decided to investigate 
derivatives of the macrocyclic ligands for gadolinium contrast agents due to the relative ease 
of synthesis. 
In the decades since the first GBCA was developed and clinically approved 
(Magnevist, 1980’s) many researchers have investigated strategies for improving the efficacy 
of contrast agents.2 This includes improving the relaxivity of the agent, or improving targeting 
to a site of interest, if applicable.2–4 As detailed in Chapter 1 and summarized here, increasing 
the relaxivity can be achieved by: 1) decreasing the molecular tumbling rate, 2) increasing the 
water exchange rate, or 3) increasing the q-value. When the tumbling rate is slowed, for 
example by coupling to a high molecular weight species (eg macromolecule or protein), further 
increases in relaxivity are limited by the water exchange rate.2 To increase water exchange rates 
or q-value, the molecular structure of the chelate must be modified. A cartoon depiction of 
strategies to improve relaxivity of GBCA using macromolecular architectures is shown in Fig. 
3.1, adopted from Caravan’s Review highlighting such strategies, with the GBCA represented 
as a green circle.4 In panel a), the contrast agent is incorporated in macromolecular or polymeric 
form. In panel b), the contrast agent is appended to a nanoparticle, here represented on the 
surface of the particle; a similar architecture is envisioned for a dendritic structure containing 
a GBCA. In panel c), the contrast agent is fixed at the barycenter of a macromolecule. In all 
three scenarios, per-gadolinium relaxivity is increased due to the slower tumbling of the 
species. In a and b, if the contrast agent is not restricted, the agent may still spin on its axis, and 
thus the correlation is not fully matched to the macromolecule. In c, the contrast agent is 
somewhat restricted; relaxivity increases would then be limited by water exchange rates.  
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Figure 3.1 Scheme of macromolecular effects of GBCA. Adopted from Ref. 4. Appending a 
contrast agent to a macromolecule or nanoparticle slows the tumbling rate (represented by the 
large arrows), increasing relaxivity. Increases in relaxivity are then limited by local rotational 
correlation effects (represented by the small arrows), or slow water exchange rates 
In this chapter, polymeric nanoparticle platforms incorporating a gadolinium-based 
contrast agent for magnetic resonance imaging are described. In this approach, the 
nanoparticles are expected to demonstrate increased relaxivity based on the coupling to a 
slower tumbling nanoparticle species (as in Fig. 3.1b). Towards this aim, we prepared 
amphiphilic block copolymers for the formation of micellar NPs, in which the hydrophilic 
block consists entirely of a Gd-based contrast agent for MRI. In developing this type of 
material, we sought a synthetic route through which the Gd3+ functionalized monomers are 
introduced directly into the polymer via a living polymerization approach, obviating the need 
for post-polymerization conjugation strategies, or ligand metalation processes.5–9 We then 
studied these materials as MRI contrast agents using in vitro techniques (nuclear magnetic 
resonance dispersion, NMRD) as well as in vivo, live animal imaging in mice.  
First, the chemical tools for direct incorporation of a GBCA into the ROMP scheme 
are described. This is important in maintaining precise control of functionality and site-specific 
incorporation during synthesis of materials. Described here are the first examples of a directly 
polymerized norbornene-derived GBCA monomer and chain transfer agent (CTA) using 
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ROMP (Fig. 3.2). Having both tools at one’s disposable allows for synthesis of highly tailorable 
materials, with a range of options for modulation of polymer architecture.  
 
Figure 3.2 ROMP scheme for incorporation of a gadolinium-containing monomer or chain 
transfer agent. This scheme was followed for all polymers in the chapter. Depending on the 
ratio of the blocks, the polymer amphiphiles assemble in to different nanoparticle structure. 
With these chemical tools in hand, polymers were synthesized and formulated into 
nanoparticles. These NPs were then evaluated in biologically relevant systems using MRI. 
While current FDA approved clinical agents are mostly small molecules, it is well known that 
macromolecular contrast agents could provide a better platform for diagnostic type materials: 
macromolecule GBCA have higher relaxivities, longer blood circulation times, and favorable 
properties that researchers have explored extensively. Serendipitously, two differently shaped 
NPs were formulated: spheres and fibers. These materials allowed us to probe the following 
questions in subsequent studies: 1) how is the relaxivity of a material affected when GBCA is 
incorporated into polymeric NPs as a discrete block, and 2) how does shape affect the 
relaxivity? The materials were then evaluated in vivo for their contrast ability. Further, with the 
two different shapes, would there be detectable differences in the biodistribution of the 
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materials correlated to their shapes? Another application of direct incorporation of GBCA is 
presented as a CTA; this approach was evaluated and utility demonstrated with a stimuli-
responsive peptide-polymer-based platform. 
The impact of this work lies in the ability to tailor soft materials to a particular imaging 
application. Ultimately, our goal for this work was to establish strategies to incorporate 
clinically translatable imaging agents suitable for in vivo imaging of targeted polymeric 
nanoparticle systems developed in the Gianneschi Lab. With the monomer and CTA in hand, 
along with well-defined methods for characterization of these polymers, materials can be 
formulated for diagnostic purposes. To date, there are no clinically approved, targeted contrast 
agents despite the rich literature investigating targeting of nanoparticle diagnostics. Using a 
targeted NP with a reporter like gadolinium in conjunction with cancer therapy may allow for 
sensitive detection of non-resected tumor, or metatheses, and is a long-term work of this 
research.  
3.10 Graft-Through Polymerization of a Gd-DOTA Moiety 
In this section, graft-through polymerizations of a Gd-DOTA-monoamide monomer 
are described (DOTA = -1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid). The 
polymers are subsequently formulated as nanoparticles, and in vitro studies are described. To 
our knowledge, this represents the first demonstration of a Gd3+-labeled polymer prepared 
entirely by direct polymerization. Examples of Gd3+-labeled polymers and soft NPs to date 
have employed post-polymerization metal chelation, requiring subsequent purification steps 
and removal of excess Gd3+.10 In work from the Kiessling group, one arm of a 
hydroxypyridinone (HOPO)-Gd3+ chelate was directly polymerized using ROMP, followed by 
reaction with the other ligands to form the complete chelate, and subsequent metalation. This 
polymeric GBCA demonstrated higher relaxivities compared to other clinically approved 
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contrast agents, but no enhancement over the small molecule HOPO ligands originally 
developed by Raymond.11,12 In our work, direct, graft-through polymerization of a metalated, 
monomer derivative of a GBCA offers a strategy that circumvents post-polymerization 
modifications and metalations. 
3.10.1 Synthesis of Gd-DOTA Norbornyl Monomers 
Monomer 2 (Figs. 3.2 and 3.18) is a novel compound, synthesized specifically for 
direct incorporation of a modified Gd-DOTA moiety via living, ring-opening metathesis 
polymerization (ROMP).13,14 The norbornenyl-Gd-DOTA monoamide enables visualization 
with standard T1-weighted MRI. Importantly, 2 is complexed to Gd3+ prior to its incorporation 
into synthetic polymers. 
Briefly, a NB-amine was reacted with a mono-NHS activated DOTA. The reaction was 
capped with acetic anhydride, then neutralized before metalation with Gd(OAC)3. The product 
was purified using semi-preparative HPLC. The four reactive acids on DOTA proved 
problematic in the synthesis, with respect to the yield. While the N-hydroxysuccinimide 
(NHS)-DOTA was selected initially as the reactive reagent, the NHS was prone to hydrolysis 
before introducing the material in to the reaction vessel, and therefore did not enhance 
selectivity. The DOTA-derived monomer could also be synthesized using differently protected 
ligands. The tris-tBu monoacid ligand is readily available commercially, and is now more 
commonly used in our lab. A key feature of the monomer is that gadolinium is pre-chelated 
with the organic ligand, obviating the need for most polymerization metalation and 
purifications. Subsequently, the pure monomer was used in further polymerization studies. 
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3.10.2 Preparation and Characterization of Polymers with Gd-DOTA as Hydrophilic 
Entity 
We prepared amphiphilic block copolymers from hydrophobic monomer 1 (-phenyl, 
Ph) and hydrophilic monomer 2 (Gd). Gratifyingly, we could avoid post-polymerization 
modifications, given that 2 was consumed during ROMP reactions (Figs. 3.22 and 3.23). 
Because gadolinium is paramagnetic, peak broadening in the 1H-NMR prevents the monitoring 
of polymerization progression, and therefore HPLC provides a method to monitor reaction 
progress. Polymers were characterized using SEC-MALS, (Figs. 3.22 and 3.23), and 
summarized in Table 3.1. 
Table 3.1 Polymer Characterization. 
Polymer Composition Material Name DP m a DP n a Mn b Ð c Used to make NP: 
P1 1210-b-24 Ph210-b-Gd4 210 4 55,740 1.004 
SMN 
P2 142-b-22 Ph42-b-Gd2 42 2 11,910 1.024 
FMN 
a The degree of polymerization (DP) m and n, are determined using SEC-MALS. b  The number average molecular weight.
  c The 
dispersity of copolymer (Mw/Mn). 
3.10.3 Nanoparticle Formulation and Characterization 
Following synthesis, polymers were self-assembled using a solvent switch method. 
Solutions of P1 and P2 were subjected to slow transition from DMSO to water via dialysis, 
inducing the assembly of micellar NPs. NP structure was determined by transmission electron 
microscopy (TEM) and scanning TEM (STEM). For P1, negative stain TEM revealed spherical 
micellar nanoparticles with low dispersity (with average diameter of 25 nm and standard 
deviation of 2.9 nm, and are hereafter referred to as SMN, Fig. 3.3b and 3.4).   
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Figure 3.3 Particle characterization by electron microscopy of spherical micellar nanoparticles 
(SMNs) and fibril-shaped micellar nanoparticles (FMNs). (b) Negative stained TEM of SMN. 
(c) Unstained BF-STEM of SMN. (d) Unstained HAADF-STEM of SMN. (e) Negative stained 
TEM of FMN. (f) Unstained BF- STEM of FMN. (g) Unstained HAADF-STEM of FMN 
Unstained, bright field STEM (BF-STEM) demonstrated close packing of NPs with 
dark rings around the coronas, as would be expected for a NP bearing a heavy element (i.e. 
Gd3+) in the corona (Fig. 3.3c). This is supported by unstained, high-angle annular dark field 
(HAADF) STEM coupled with energy-dispersive X-ray spectroscopy (EDS), which confirmed 
the presence of Gd3+ in the shell of the particle indicated by bright halos (Z-contrast) around 
the outer edges and characteristic X-ray edges of Gd3+ (Figs. 3.3d and 3.27).  
Similar microscopy characterization was performed on NPs derived from P2. Negative 
stain TEM, unstained BF-STEM, and unstained HAADF-STEM analysis revealed a 
predominantly fibrillar morphology, with Gd3+ present within the shell (Fig. 3.3e-g). STEM-
EDS also confirms Gd3+ on the shell of the particles (Fig. 3.28). We refer to these predominantly 
fibril-shaped NPs as fibrillar micellar nanoparticles (FMN), but note that the FMN formulation 
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was not an entirely homogeneous phase, containing a minor component of spherical NPs. 
Indeed, mixed phases are common for cylindrical micelles.15 However, FMN represents 
approximately 95% of the sample, as determined by TEM image analysis (Fig. 3.5 and Table 
3.2).  
 
Figure 3.4 SMN phase analysis. TEM image analyzed for sphere diameter uniformity (scale 
bar = 100 nm). Diameters of particles were measured in ImageJ. 604 particles were counted, 
and found to have an average diameter of 24.7 nm, with a standard deviation of 2.9 nm. 
 
Figure 3.5 FMN phase analysis. Three TEM images were analyzed for %volume fibrillar phase 
(scale bar = 250nm). Lengths of fibrillar particles were measured in ImageJ, as indicated by 
the yellow lines above in representative TEM images (1)-(3), above. Diameter of the fibers was 
assumed to be the same as the spheres, and volume was calculated using the average sphere 
radius. Volume of the spheres was calculated accordingly, and summation of volume of 
tabulated spheres and fibers was used to determine respective ratios, as listed in Table 3.2. 
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Table 3.2 Measured volumes of spheres and non-spheres in FMN.  
Image # Total measured volume (nm3) Fraction non-sphere % non-sphere 
1 0.013 
0.941 94.2 
2 0.021 
0.963 96.3 
3 0.011 
0.948 94.8 
  
Average %volume non-sphere 95.1 
 
Importantly, the two NP formulations are stable as SMN or FMN for periods in excess 
of 14 months in aqueous media (Figs. 3.25 and 3.26). Moreover, cryo-TEM revealed that NPs 
remain identifiable following incubation in blood serum at 37 ° C for one week (Figs. 3.6 and 
3.7). 
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Figure 3.6 Stability of Nanomaterials in biological milieu: Cryo-TEM of SMN in Water and 
Blood Serum for 1 week. a) and b) Cryo-TEM of SMN in water. c) - f) Cryo-TEM of SMN in 
blood serum after 1 week. 10 uL of SMNs in water was added to 10 uL of blood serum. Sample 
volume was reduced to 10 uL by evaporation under reduced pressure and stored at 37 ºC for 1 
week prior to imaging. Yellow arrows in d, e and f indicate SMN, while white arrows indicate 
examples of ice artifacts stemming from cryo sample preparation. 
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Figure 3.7 Stability of Nanomaterials in biological milieu: Cryo-TEM of FMN in Water and 
Blood Serum. a) and b) Cryo-TEM of FMN in water. c) and d) Cryo-TEM of FMN in blood 
serum. 10 uL of FMNs in water was added to 10 uL of blood serum. The sample volume was 
reduced to 10 uL by evaporation under reduced pressure and stored at 37 ºC for 1 week prior 
to imaging. 
3.10.4 In Vitro Relaxivity 
SMN and FMN were further characterized by nuclear magnetic resonance dispersion 
(NMRD) analysis to investigate the basic magnetic properties as related to their utility as MRI 
contrast agents. At 37 °C and neutral pH, the NMRD profile of both NPs show the characteristic 
line-shape of macro-/supramolecular structures due to a reduction in rotational tumbling rate 
(Fig. 3.8);3,16 this is markedly distinct from the NMRD line-shape of Gd-DOTA. Notable 
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features in the NMRD profile of the NPs include a region of constant relaxivity at low field 
strengths (~0.01 MHz – 0.5 MHz, 0.0002 – 0.01 T) for SMN and FMN, with FMN displaying 
an elevated per Gd3+ relaxivity over SMN at all field strengths. Both NPs have a maximum 
relaxivity at ~20 MHz (0.5 T); SMN has a maximum per Gd3+ r1p of 15.6 mM-1sec-1, while 
FMN demonstrates a favorably elevated r1p of 18.5 mM-1sec-1 (Table 3.3; for detailed 
description of NMRD fit parameters, see Fig. 3.29). We note that the higher per Gd3+ 
relaxivities of SMN and FMN as compared to the mononuclear Gd-DOTA at 20 MHz (Table 
3.3) are competitive (i.e. within the same order of magnitude) with other nanoparticle and 
polymer-based systems.17,18 Further, although all three of these systems converge to similar 
relaxivities at high frequencies, r1 enhancement for SMN and FMN over Gd-DOTA is still 
pronounced both at 3 T (FMN: +210%; SMN: +169%). Such enhancement is largely due to the 
improved rotational dynamics for the two paramagnetic NPs combined with an exchange rate 
of coordinated water sufficiently fast as not to strongly limit the relaxivity. 
 
Figure 3.8 1H NMRD profiles for Gd-DOTA, SMN, and FMN. 
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Table 3.3 Relaxation parameters obtained from the analysis of NMRD profiles reported in Fig. 
3.8.a 
 
20r1p 
(mM-1 s-1) 
Δ2 
(1019 s–2) 
τV 
(ps) 
τRL 
(ns) 
τRG 
(ns) 
S2 
τM 
(ns)b 
SMN 15.6 0.9 52 0.19 5.9 0.20 
560 
FMN 18.5 0.7 53 0.15 2.8 0.25 
350 
Gd-DOTA 3.5 1.0 7 / 0.04 / 
122 
a The fitting parameters a, 310D, q and r were fixed to the values of 4.0 Å, 3.10x10-5cm2 s-1, 1 and 3.0 Å, respectively; b let to vary 
between 100 and 900 ns. 
3.11 In Vivo Analysis of Gadolinium-Containing SMN and FMN 
Next, we performed an in vivo pilot study to determine if the Gd3+-labeled NPs would 
provide sufficient contrast in live mice imaged via MRI. Intraperitoneal (IP) injections were 
chosen based on the lab’s interest in direct injection of therapeutic nanoparticles to the 
peritoneal cavity to localize delivery to areas affected by malignancies such as ovarian cancer. 
There are limited examples in the literature that study the IP delivery of nanoparticles as a 
means of systemic introduction.19–23 By using IP injections, we hoped to understand how 
materials distribute in the IP space and reach systemic circulation, critical information in the 
investigation of nanoparticle treatment strategies.  
In these studies, C57/BL6 mice were first anesthetized and imaged by MRI prior to 
injection. For all formulations of contrast agent studied (Gd-DOTA, SMN, and FMN, n = 3 for 
each material), T1-weighted images obtained immediately after injection demonstrate 
significant IP signal due to the Gd3+ reporter displayed on all injected samples (Fig. 3.9). Each 
animal was then imaged up to several hours post-injection to track retention in the peritoneal 
cavity. At two hours following IP injection, no enhanced signal was observed in the IP space 
of animals following injection of Gd-DOTA (Fig. 3.10). However, measurable signal was 
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clearly observed in the IP spaces of animals injected with either SMN or FMN (Figs. 3.10 and 
3.30). This enhancement demonstrates that the NP formulations are retained in the IP space 
longer than Gd-DOTA. In addition, MRI of the urinary bladder of animals following injection 
of Gd-DOTA demonstrated rapid accumulation of Gd-DOTA, indicating clearance through 
renal excretion, as expected (Fig. 3.11). This was markedly delayed and less intense in the case 
of SMN or FMN. When looking at the liver (Fig. 3.12) there appears to be some signal 
enhancement  in the organ, though the MRI scans nor corresponding quantitative T1 analysis 
indicate definitive acuumuation in the liver tissue. The apparent signal could be an image or 
motion artifact.  
While accumulation in the bladder for Gd-DOTA is quite clear, and follows the known 
clearance of small molecule contrast agents, detection of the NPs over the time points imaged 
was difficult. This could be for several reasons, including slow clearance of NP formulations 
from the IP space. Low concentrations of the Gd reporter are distributed throughout the body, 
and may be below the threshold of detection for MRI. Imaging 1, 2 or 7 days after injection of 
material also did not show contrast enhancement via MRI, and ex vivo organ analysis at 1 week 
indicates more than 99% of material is eliminated (Fig. 3.33). Because we were interested in 
how shape might affect short term biodistribution, we next designed an experiment for more 
sensitive quantification of gadolinium using ICP-MS methods, with the aim of determining 
biodistribution at shorter time points.  
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Figure 3.9 Anatomical MRI post-injection of contrast agent demonstrating successful 
introduction of materials IP. Red arrows indicate contrast surrounding the bowl loops. a) 
Anatomical image of mice 1 – 3, 10 – 30 minutes post-IP injection of Gd-DOTA. b) Anatomical 
image of mice 4 – 6, 5 – 10 minutes post-IP injection of SMN. c) Anatomical image of mice 7 
– 9, 10 minutes post-IP injection of FMN. 
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Figure 3.10 Axial T1-weighted images of the abdomen approximately 2 hours following IP 
injection of a) Gd-DOTA, b) SMN, and c) FMN. See Fig. 3.28 for additional images of IP 
space at 2 hours. Phantoms, containing dilutions of the same material, were placed underneath 
the animal during scanning and used to correct for inter-scan variability. See methods section 
for further description of analysis. 
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Figure 3.11 Time progression of signal enhancement, quantified as T1, and corresponding axial 
T1-weighted images of the bladder after IP-injection of a) Gd-DOTA, b) SMN, and c) FMN. 
For mice 1-9, multiple regions of interest were sampled, normalized by comparing the 
relaxivity of phantoms for each scan to the pre-injection phantom relaxivity, averaged over the 
organ in the scan, then converted to T1. For sampled time points of each material, T1 times were 
averaged, and standard error generated for n = 3 mice. Red arrows indicate the urinary bladder. 
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Figure 3.12 Time progression of contrast enhancement, reported as T1, and corresponding 
anatomical scans of the liver after IP-injection of a) Gd-DOTA, b) SMN, and c) FMN. Any 
contrast enhancement in the stomach is due to food, not injected material. Red arrows indicate 
the stomach, white arrows indicate a vessel, and blue arrows indicate part of the liver. 
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3.11.1 Ex Vivo Analysis 
We next performed an ex vivo biodistribution analysis to gain insight as to where NPs 
localized in vivo following IP injection. As whole body MRI demonstrated possible signal 
enhancement in the liver following injection of NPs (Fig. 3.12), we designed a quantitative 
analysis of Gd3+ in the liver, spleen, and bowel accumulation of NPs following IP injection. At 
2, 12 or 24 hours post-IP injection, animals (n = 3 for each group) were sacrificed and the 
spleen, liver, gut (includes intestines and stomach), kidney, heart and bladder were harvested. 
The tissues were homogenized in acid then analyzed by ICP-MS or ICP-OES for gadolinium 
content. The only tissues displaying significant signal were the spleen, liver and gut and 
therefore only these organs are included in this summary. The results are summarized in Figs. 
3.13, 3.31 and 3.32 for individual animal profiles. Notably, the observation of hepatic uptake 
and non-detectable accumulation in the kidney via ex vivo analysis, is consistent with that of 
others who have observed NP accumulation in the liver following IP injection.24,25 
In these initial in vivo analyses of the materials, there was no clear conclusion to be 
made from the small sample size, but the following trends were observed. SMN appeared to 
accumulate in the spleen and liver (n = 3) at higher concentrations than the bowel at 2 and 24 
hours (Fig. 3.13). FMN showed less accumulation in the spleen or liver as compared to SMN 
at 2 hours post-injection (n = 3). The slightly higher concentration of material in the spleen and 
liver at 12 hours indicates sustained RES clearance throughout the first 24 hours post-injection. 
Interestingly, at 1 week post-injection (Fig 3.33), the total % of injected dose is slightly higher 
for FMN compared to SMN (0.03% versus 0.01%), though both materials are mostly cleared 
from the body by this point. These data suggest that both NPs are cleared relatively slowly 
from the IP space, and while no statistically significant data was generated from the small 
sample size, there appears to be differences in accumulation and clearance for the spherical 
particles compared to the fibrillar particles.  
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Figure 3.13 Accumulation of SMN and FMN in the spleen a), liver b), and bowel c), at 2, 12 
or 24 hours following IP injections as detected by the presence of Gd by ICP-MS and ICP-
OES. For each time point n = 3, except where indicated with *, where n = 2. Error bars represent 
standard deviations. 
3.12 Incorporation of Gd-DOTA as a Chain Transfer Agent 
In some cases, a functional unit may be incorporated into a polymer as a chain transfer 
agent rather than as a monomer. In the Gianneschi Lab we have developed a suite of functional 
chain transfer reagents for end-labeling polymers using ROMP.8 By using a symmetric 
functional olefin, polymerization reactions can be terminated such that the functional agent is 
incorporated on the end. This gives us a handle for synthesizing more complex polymer 
architectures, with control over the incorporation of exactly one functional unit on the polymer 
backbone. Functional termination agents to incorporate functional units have been described, 
but none, to our knowledge, incorporating a Gd-based imaging agent. 
One exploratory aim for using the termination agent was to evaluate location of a 
contrast agent in a polymer or polymeric nanoparticle architecture and how that might affect 
the relaxivity properties of a material. For example, we envisioned a polymer scheme in which 
the contrast agent could be localized on the corona of a NP or buried inside the hydrophobic 
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core (Fig. 3.14, top and bottom, respectively). Based on more detailed discussions in Chapter 
2, we know that phenyl-based hydrophobic blocks of polymer amphiphiles result in high Tg, 
crystalline cores. In labeling a polymer at the terminus of a hydrophobic block, we hypothesize 
that the gadolinium center would be buried in the core versus localized on the corona. A 
gadolinium-based contrast agent must be accessible to water to affect the local water relaxation 
times. If the gadolinium center is buried in the crystalline-like core where water is excluded, 
this will theoretically result in an OFF signal. Other examples in the literature describe situation 
in which gadolinium centers are constricted at the barycenter of a macromolecule; the result in 
this scenario is a constriction of the metal-center, lower tumbling rates, and increased 
relaxivities (Fig. 3.1c).4 Another scenario might be that the hydrophilic GBCA sits at the core-
shell interface and does interact with water; in this case, rotation of the gadolinium center may 
be constricted and instead lead to an increase in relaxivity, rather than an OFF signal. 
 
 
Figure 3.14 Polymer amphiphiles end-terminated with Gd-DOTA moiety. Upon polymer self-
assembly in aqueous environment, the Gd-label is envisioned to sit either at the corona-water 
interface or buried within the assembly. 
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With these design principles in mind, the Gd termination agent of interest was first 
synthesized and then incorporated into polymers. These materials were subsequently 
formulated into nanoparticles and studied. 
3.12.1 End-labeling of Polymers  
First a Gd-DOTA -containing chain transfer agent (Gd-CTA) was prepared and 
characterized according to the schemes in Figs. 3.19-3.21. Next, a series of test amphiphilic 
polymers were prepared in which a phenyl-based norbornene monomer was polymerized as the 
hydrophobic block, and a PEG-monomer was polymerized as the hydrophilic block (Fig. 3.14). 
If the Gd-CTA was desired to be on the end of the hydrophobic block to form “Gd-core” 
particles, PEG was polymerized first, followed by -Ph then termination with Gd-CTA. 
Conversely, if Gd-CTA was desired to be on the hydrophilic end to form “Gd-shell” particles, 
-Ph was polymerized first, followed by PEG then Gd-CTA. Aliquots of the polymerization 
reaction were removed following polymerization of the first and second blocks for 
characterization by SEC-MALS (Table 3.4, Fig. 3.24). Then, at least 1.2 eq of Gd-CTA were 
added to the reaction mixture.  
Table 3.4 Polymers End-labeled with gadolinium-containing CTA. 
Polymer  Composition Material  DP m a DP n a Mn b Ð c Used to make NP: 
P3 119-b-3107 Ph19-b-PEG107-Gd 19 107 43,930 1.017 NP3 “Gd-shell” 
P4 3112-b-110 PEG112-b-Ph10-Gd 112 10 63,840 1.078 NP3 “Gd-score” 
P5 115-b-37 Ph15-b-PEG7-Gd 15 7 6,370 1.044  NP3 “Gd-shell” 
P6 332-b-14 PEG32-b-Ph4-Gd 32 4 14,180 1.018 NP3 “Gd-core” 
 a The degree of polymerization (DP) m and n, are determined using SEC-MALS. b  The number average molecular weight.
  c The 
dispersity of copolymer (Mw/Mn). 
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The kinetics of termination were not determined, but the consumption of the material 
was tracked over 24 hours. This could not be monitored using traditional methods of 1H-NMR 
because gadolinium is paramagnetic and affects peak broadening in the NMR spectrum.9 After 
the Gd-CTA was added to reaction mixture, small aliquots were removed and analyzed by 
HPLC for the presence of unreacted Gd-CTA. This was compared to a standard curve for Gd-
CTA to determine reaction completion. After a few hours the concentration decreased, 
indicating consumption; an excess of Gd-TA was added to ensure complete incorporation. The 
reaction was quenched with ethyl vinyl ether to deactivate the catalyst, and ensure any living 
polymers in the reaction were quenched. Polymers were then analyzed by SEC-MALS, using 
the same dn/dc as the diblock polymers before functional termination. No significant peak shift 
for polymers with or without the functional unit was observed, though the refractive index of 
the polymers changed upon addition of functional Gd-CTA.  
3.12.2 Nanoparticle Formulation 
Polymers were self -assembled using the solvent-switch method, as described above. 
Polymer was dissolved in organic solvent at a concentration of about 1 mg/mL, then water 
slowly added up to 50/50 v/v%. The solution was then transferred to either dialysis cups or 
snakeskin tubing, depending on the volume/scale of the NP formulation, and dialyzed against 
2L water. The water was refreshed 3 times over 3 days. Solutions were then removed from 
dialysis containers, and analyzed by DLS and TEM to evaluate the quality of NP (shape, size, 
dispersity). The results are described in Fig. 3.15. 
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Figure 3.15 TEM images and DLS of NP3-6 and dynamic light scattering, formulated from 
polymers P3-6, end-labeled with a gadolinium-containing CTA. For DLF of NP3-6, the % 
intensity was plotted for each of the nanoparticle solutions. NP3-4 were unfiltered solutions: 
aggregates are readily apparent at hundreds of nanometers, while the peaks at about 90 and 60 
nm are from the particles. NP5-6 were filtered prior to measurement and display radius of about 
30 and 50 nm, respectively. The discrepancy from the observed diameters by TEM are not 
uncommon in DLS analysis: as is apparent here, these NPs readily aggregate in solution, and 
the TEM samples are readily prone to staining and drying artifacts. 
3.12.3 Application of End Termination of Polymers with Gd-Based Agent 
Next relaxivity of materials was evaluated at 300 MHz using an inversion recovery 
experiment. Control experiments measuring the relaxivity of a standard compound, Gd-DOTA, 
resulted in expected relaxivity determination (~4 mM-1sec-1, see Fig. 3.34). However, there was 
a systematic experimental error in measuring the relaxivity of the gadolinium NPs 3-6. The 
solutions were made in deuterated water, which was believed to be a source of the tremendous 
experimental error. Using 2H, a spin-inactive nucleus, effectively changes the concentration of 
1H protons that were detected during the experiment. The results are depicted in Fig. 3.34 but 
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due to the large experimental error, should not be taken as representative data. Another possible 
source of error may have been the concentration used in determining the per mM relaxivity, 
though this error was circumvented by verifying gadolinium concentration with ICP-MS.   
3.13 Applications of Peptide Polymeric Materials with a MRI 
Contrast Agent 
In the previous sections, application of polymeric nanoparticles containing a GBCA 
were described and studied, wherein the only targeting property of the material was its shape 
(SMN versus FMN). As discussed in Chapter 1, the Gianneschi lab is interested in developing 
peptide polymer materials in which the specific peptide sequence is used as a stimuli-
responsive unit. Here, two example applications of peptide polymer materials containing a 
GBCA are described. 
The Gianneschi group has developed an active accumulation method for nanoparticles 
at tumor targets using enzymes. Peptide polymer amphiphiles (PPAs) contain an optimized 
sequence for matrix metalloproteinases (MMPs), proteins that are upregulated in tumor 
extracellular space. The MMPs recognize NPs and impart a phase change, causing particles to 
both accumulate at, and stick in, the tumor tissue. This EDAPT [enzyme-directed assembly of 
particles in tissue] method has been demonstrated as a proof-of-concept using in vivo 
fluorescence imaging. (A cartoon depiction of EDAPT provided in Chapter 1, Fig. 1.3.) MRI 
of targeted nanoparticle systems is highly desirable, owing to its clinical translatability, with 
other advantages over optical detection, including deep-tissue imaging and mitigation of 
background auto-fluorescence of biologic tissue. 
We were curious if we could make similar PPAs incorporating a GBCA using the 
norbornyl Gd-DOTA monomer. ROMP was used to polymerize amphiphiles that contain: 1) a 
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hydrophobic core block, 2) a peptide-containing block, blended with a carboxylic acid, and 3) 
a gadolinium-based contrast agent, as shown in Fig. 3.16. The peptide sequence selected is the 
same as used in previous studies, and contains the optimized sequence “GPLGLAG” and 
solubilizing residues after that.5,26–28 Based on previous observations, the peptide sequence may 
experience steric crowding in the polymer architecture, and must be blended to decreases 
density to allow enzyme access.29 The gadolinium based contrast agent is polymerized as a 
short block. 
 
Figure 3.16 Polymer scheme for enzyme-responsive, MRI-labeled materials. m = 25, n = 3, o 
= 4, p = 2. 
The polymer was used to prepared micelles using similar methods as described in 
previous sections. The particles were spherical in morphology and about 30 nm in diameter. 
The particles were subjected to enzymatic treatment using a model enzyme, thermolysin. 
Results are described in Fig. 3.17. 
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Figure 3.17 Evaluation of enzyme-responsive polymeric nanoparticles. a) TEM of 
nanoparticles. b) TEM of particles after treatment with enzyme, showing not change in 
morphology. c) DLS of particles before and after treatment. It appears there may be some 
aggregation after treatment (red trace), but the TEM confirms that it is most likely the particles 
sticking together, no changing morphology. d) Example HPLC of control peptide monomer 
treated with thermolysin, showing the various cleavage products expected over time. 3) HPLC 
of the nanoparticle solution over time. No cleavage products were detected by HPLC. 
Despite the polymers give discrete, uniform spherical nanoparticles, under the 
conditions probed, they were not responsive to enzyme treatment. DLS seemed to show 
aggregation post-enzyme treatment, but this is most likely just the particles sticking together in 
solution, a property seen in the TEM of the particles post-treatment. The control treatment of 
peptide monomer only confirmed that the enzyme was active. Therefore, there was most likely 
a problem with the nanoparticle architecture that prohibited the enzyme activity and 
morphology switch. Future work using this type of enzyme-responsive unit should optimize 
the polymer size, degree of polymerization of peptide block, and the spacing of monomers to 
prevent crowding of the peptide sequence from inhibiting the enzyme. Nevertheless, this is a 
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feasible way to prepare polynorbornene materials that incorporate a targeting and imaging 
moiety.  
In another project, enzyme- and heat-responsive elastin peptide-like polymer 
amphiphiles containing a gadolinium contrast agent are studied.30 The polymers were end-
labeled with the gadolinium-containing CTA, and used as a probe to measure effects of phase 
transitions on relaxivity. While no changes in relaxivity were observed, the relaxivities of the 
polymers in solution, ~ 3-4 mM-1sec-1, are consistent with the relaxivity of the small molecule 
chelate, rather than a macromolecular species. This is evidence that free rotation of the chelate, 
as opposed to coupling of rotation time to the polymer, is occurring in this polymer architecture.  
3.14 Conclusions and Outlook 
In this chapter, strategies towards preparing polymeric materials containing a 
gadolinium-based contrast agent are described. First, a new synthetic method for labeling 
polymers and NPs with a Gd3+-based contrast agent through direct polymerization of a 
monomer is described. This procedure ensures that the entire shell of the nanoparticle consists 
of Gd3+-labeled monomers, and can be extended to more complex polymers synthesized 
through ROMP, for example those incorporating a targeting moiety. This route led to the 
preparation of two different phases of NP, one entirely spherical (SMN), the other 
predominantly fibrillar (FMN). Preliminary in vivo MRI and ex vivo elemental analyses suggest 
that these differently shaped NPs derived from chemically identical starting materials show 
promise for imaging following IP injection. We note that the concept of shape dependent in 
vivo behavior of NPs has been observed in the context of intravenous (IV) injection by Discher, 
Caruso, Mitragotri, and others,31–38 but to the best of our knowledge, this report represents the 
first to begin to address the effects of NP shape following the clinically important IP injection 
route. Indeed, direct delivery of small molecule chemotherapeutic agents via intraperitoneal 
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(IP) injection is a well-established therapeutic paradigm in the treatment of human metastatic 
ovarian, pancreatic and gastric malignancies.21,22,39–41 Interestingly, there is research 
investigating the importance of NP size in efficacy of nanoscale formulations for enhanced 
delivery and targeting to peritoneal malignancies when introduced via IP.20 These studies note 
that small NPs easily clear from the peritoneum owing to the larger stomata openings 
(lymphatic duct openings), while larger NPs and micrometer size NPs are retained more easily. 
Additionally, cationic charges on the NPs favors greater retention due to greater interactions 
with macrophages in the cavity.42 The studies presented herein suggest the favorable retention 
of FMNs in the IP cavity compared to small spherical NP. Future studies will build on these 
initial in vivo observations to further explore and exploit NP physicochemical properties for 
greater retention and targeting to tissues in the intraperitoneal space, especially with regards to 
therapies specific for peritoneal malignancies like ovarian cancer.. Using a norbornyl-monomer 
of the GBCA as a hydrophilic block in a block copolymer amphiphile, two differently shaped 
nanoparticles were prepared. These nanoparticles exhibited increased relaxivity, as expected 
for a macromolecular contrast agent, and were used to study the shape effects of nanoparticles 
in vivo. MRI studies of nanoparticles injected via intraperitoneal injection demonstrated 
retention in the IP space compared to a small molecule contrast agent, and the materials 
appeared to exhibit differences in bioaccumulation and RES clearance. The small sample size 
prohibits definitive conclusions. Nevertheless, the imaging strategies performed in this study 
were the first examples of MRI imaging in live animals in our group, one of few studies in the 
literature comparing head-to-head spherical versus cylindrical NPs in vivo, and to the best of 
our knowledge one of the few that evaluates biodistribution qualitatively using MRI. 
Retention of nanoparticles in the IP space represents an important delivery strategy for 
therapeutics treating diseases of the IP cavity. In the future, it would be interesting to sample 
from the IP cavity over time to quantitatively determine the concentration of materials; this 
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could be accomplished using lavage techniques for sampling from the IP space.23 The 
Gianneschi Lab develops therapeutic polymeric nanoparticles designed to treat ovarian cancer 
specifically,43 and on-going work should evaluate the differences in efficacy of NP drug 
delivery using the IP versus IV route of administration. Based on our observations and the 
observations of others, large, high-aspect ratio nanoparticles should be the goal for optimal 
peritoneal cavity retention. 
Ultimately, using an end-label for incorporation of GBCA (via the CTA) is not an 
effective strategy for developing materials for in vivo imaging. Though MRI is very sensitive, 
there does need to be a minimal local concentration to observe contrast enhancement. Due to 
the architecture of polymers that only incorporate one gadolinium atom per polymer chain, and 
the limitations of solubility of polymeric nanoparticles in solution, concentration of contrast 
agent in solution will limit detectability via MRI, unless the relaxivity enhancements from the 
architecture are extremely favorable. From the latter perspective, members of the Gianneschi 
group are pursuing alternative ligand types for gadolinium based contrast agents., in particular, 
the HOPO-class of ligands, with a q-value of two.12 
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3.16 Methods 
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All reagents were purchased from Sigma-Aldrich or Macrocyclics and used without 
further purification. RP-HPLC, semi-preparative RP-HPLC, NMR, mass spectrometry 
analyses, and SEC-MALS were performed using the same equipment and methods as described 
in Chapter 2 (2.7 Methods). 
3.16.1 Monomer Synthesis 
Monomer 1, (N-Benzyl)-5-norbornene-exo-2,3-dicarboximide was prepared as 
previously described. Synthesis of Gd-DOTA-MA monomer 2. See Fig. 3.2 for chemical 
structures. 2-(2-aminoethyl)-3a,4,7,7a-tetrahydro-1H-4,7-methanoisoindole-1,3(2H)-dione 
was prepared as previously described,22 (50 mg, 0.158 mmol) and dissolved with DOTA-
NHS•HPF6•CF3CO2H (100 mg, 0.131 mmol) (purchased from Macrocylcics) in pyridine 
(0.655 mL). The reaction solution was placed on a vortex overnight. Acetic anhydride (0.309 
mL, 3.28 mmol) was added and the reaction mixture was mixed on a vortex mixer for 10 min. 
Gd(OAc)3 (160 mg, 0.393 mmol) was then added to the remaining solution and placed back 
on the vortex overnight. The reaction was concentrated to dryness to give a light brown 
residue. The product was then purified by semi-preparative RP-HPLC over a 50-minute linear 
gradient from 8% to 15% acetonitrile in water with 0.1% TFA (50 mg, 75%) (Fig. 3.18 for 
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HPLC chromatogram and mass spectra). LRMS (ESI) 748.21 [M+H]+, 770.17 [M+Na]+, 
HRMS, expected [M+H]+: 748.1936, found: 748.1932. 
 
Figure 3.18 Monomer 2 characterization following purification by RP-HPLC. a) Analytical 
RP-HPLC chromatogram of purified monomer 2 and b) LR-ESI-MS. 
3.16.2 Symmetric Chain Transfer Agent Synthesis 
The “Gd-CTA” was synthesized as described in Fig. 3.19. Using a symmetric 
diamine44 dissolved in pyridine, a slight excess (2.1) of equivalents of “DOTA-NHS” 
(Macarocyclics) was added and the two reagents were allowed to react at room temperature 
overnight. The reaction was monitored for completion using HPLC, then purified by prep-
HPLC optimized gradient of 15-23% acetonitrile in water with 0.1% TFA. The functional 
termination agent was then metalated by the addition of Gd(OAc)3 and vortexed vigorously 
over two days. The reaction was analyzed by ESI-MS and purified by semipreparative HPLC 
using normal buffer conditions and monitoring at 214 nm. In all cases, % yield was low, 
presumably because of multiple reactive sites on both the macrocyclic ligand and symmetric 
terminating agent precursor. Alternatively, the Gd-CTA could be prepared in a one pot 
synthesis as described in Wang et al,30 in which a DOTA-tris(tert-butyl ester) was stirred with 
an amine functionalized symmetric olefin, acid deprotected then purified by RP-HPLC, 
followed by metalation at pH 6, and re-purification by HPLC. 
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Figure 3.19 Scheme to prepare Gd-CTA. 
 
Figure 3.20 Characterization of Gd-CTA. a) The RP-HPLC chromatogram of purified organic 
ligand precursor i. in blue, and the metalated Gd-TA, compound 4 in green. ESI-MS i. and 
compound 4 are shown in b and c, respectively. b) Expected mass is 1098.56. c) Expected mass 
is 1408.36. 
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Figure 3.21 Alternative preparation of Gd-CTA. Described as in Ref. 42. 
3.16.3 Polymer Synthesis and Characterization 
Polymerizations were performed under a dry dinitrogen atmosphere with anhydrous, 
degassed solvents in a glove box. Initiator (IMesH2)(C5H5N)2(Cl)2Ru=CHPh was prepared as 
described by Sanford et al45 and in Chapter 2. 
Synthesis of P1. A solution of the initiator (2.44 mg, 0.00335 mmol) in anhydrous 7:2 
CH2Cl2:CH3OH (0.129 mL) was added to a stirred solution of 1 (68 mg, 0.268 mmol) in a 
mixture of anhydrous 7:2 CH2Cl2:CH3OH (2.97 mL) in a glove box. The reaction was left to 
stir in a glove box for 20 min, after which an analytical aliquot (approximately 32% by volume) 
was removed and mixed with an excess of ethyl vinyl ether for 30 min, then dried under high 
vacuum to give a homopolymer of 1 as a solid. To the remaining reaction mixture, a solution 
of 2 (25 mg, 0.0335 mmol) in anhydrous 7:2 CH2Cl2:CH3OH (0.08 mL) was added immediately 
following analytical aliquot removal. The reaction was monitored by analytical RP-HPLC 
(using the same conditions described above for compound 2, see Fig. 3.22a) to ensure complete 
consumption of 2. The mixture was left to stir in a glove box for 90 min and then quenched 
with excess ethyl vinyl ether (0.0251 mL) for 20 minutes, which was concentrated to dryness 
to give a greenish solid. This was used without further purification until particle formation. The 
homopolymer and block-copolymer were analyzed by SEC-MALS as shown in Fig. 3.22b. 
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Figure 3.22 Characterization of P1, 1210-b-24. a) Analytical RP-HPLC chromatogram of 
reaction mixture demonstrating consumption of monomer 2. Expected retention time of 
monomer 2 is highlighted with an asterisk.  b) SEC-MALS and RI analyses of homopolymer 1 
and block copolymer 1210-b-24 in CHCl3. 
Synthesis of P2. In a similar manner to the polymerization procedures described above, 
a solution of the initiator (3.9 mg, 0.005 mmol) in anhydrous CH2Cl2 (0.8 mL) was added to a 
stirred solution of monomer 1 (61 mg, 0.24 mmol) in anhydrous CH2Cl2 (1.4 mL) in a glove 
box. After 20 min, an analytical aliquot (approximately 20% by volume) was removed and 
mixed with an excess of ethyl vinyl ether for 30 min, and dried under high vacuum to give a 
homopolymer of 1 as a solid. To the remaining reaction mixture, a solution of monomer 2 (25 
mg, 0.033 mmol), in anhydrous CH3OH (0.625 mL) was added immediately following aliquot 
removal. The reaction was monitored by analytical RP-HPLC (using the same conditions 
described above for compound 2, see Fig. 3.23a) to ensure complete consumption of monomer 
2. After 90 min, the polymerization was quenched with excess ethyl vinyl ether for 30 minutes. 
A small aliquot was removed for subsequent analysis. This material was carried on without 
further purification until particle formation. The homopolymer and block-copolymer were 
analyzed by SEC-MALS, as shown in Fig. 3.23b. 
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Figure 3.23 Characterization of P2 142-b-22. a) Analytical RP-HPLC chromatogram of the 
reaction mixture demonstrating consumption of monomer 2. Expected retention time of 
monomer 2 is highlighted with an asterisk. b) SEC-MALS and RI analyses of homopolymer 1 
and block copolymer 142-b-22 in 0.05 M LiBr in DMF. 
 
Figure 3.24 SEC-MALS traces for P3-6. Polymers end-labeled with Gd-CTA. In each panel, 
i. are the light scattering traces, and ii. are the RI traces. Blue traces are for the homopolymer, 
black is the copolymer end terminated with ethyl vinyl ether (control) and green is for the 
copolymer end-labeled with Gd-CTA. 
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3.16.4 Formulation of Polymeric Nanoparticles 
SMN (P1, 1210-b-24). P1 (75 mg, 1.35 µmol) was dissolved in DMSO (2.5 mL) and the 
solution was sonicated until fully dissolved. A solution of 1:1 DMSO:H2O (2.5 mL) was added 
drop wise. The cloudy polymer mixture was sonicated for 15 minutes, then transferred to a 
3,500 MWCO snakeskin dialysis tubing (Pierce) and dialyzed against a 1:1 DMSO:H2O 
solution (2L). After 24 hours, the milky solution was removed from dialysis and H2O was 
added drop wise (2.5 mL) to the polymer mixture. This mixture was then transferred to a 10,000 
MWCO snakeskin dialysis tubing and dialyzed against 2L of H2O. After 24 hours, H2O (2.5 
mL) was added to the dialysis bag and the dialysate was refreshed with 2L of H2O. Dialysis 
was allowed to continue for 24 hours. The sample was removed from dialysis and the tubing 
was rinsed with H2O (3 x 1mL) into the polymer sample. The sample was further diluted with 
25 mL of H2O, which was then sonicated for 9 hours. The sample was placed in a centrifuge at 
4000 rcf for 6 min. The supernatant was used for all further analysis.  
FMN (derived from P2 142-b-22). Half of the reaction volume from the synthesis of P2 
was diluted to 2 mg/mL with respect to the starting materials with 7:2 CH2Cl2:CH3OH. This 
solution was placed into a 3,500 MWCO snakeskin dialysis tubing and dialyzed against DMSO 
for 4 hours. The sample was then dialyzed against 4:1 DMSO:H2O for 4 hours, followed by 
3:2 DMSO:H2O for 4 hours, followed by 2:3 DMSO:H2O for 4 hours, followed by 1:4 
DMSO:H2O for 4 hours, then 2 x H2O for 4 hours each to yield an opalescent sample, which 
was used as is for all further analysis. 
NPs 3-6 were formulated as above. 
3.16.5 Characterization of Nanomaterials 
Transmission Electron Microscopy. Dry-state TEM was prepared as descried in Chapter 2, 
stained with a 1% uranyl acetate solution. Samples for Cryo-TEM were prepared by depositing 
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3.5 µL of sample to a freshly glow discharged Quantifoil R2/2 TEM grid. The grids were 
blotted with filter paper under high humidity to create thin films and rapidly plunged into liquid 
ethane. The grids were transferred to the microscope under liquid nitrogen and kept at < -175 
ºC while imaging. 
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Figure 3.25 TEM of SMN, imaged 14 months after preparation. A and b are negatively stained 
with 1% uranyl acetate. C-f are not stained. 
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Figure 3.26 TEM of FMN, imaged 14 months after preparation. A and b are negatively stained 
using 1% uranyl acetate/ c and d are not stained. 
For STEM-EDS, images were acquired on a JEOL JEM 2100F TEM equipped with an 
INCA (Oxford) EDS detector at the University of Pittsburgh, PA. Samples were prepared by 
drop-casting 5 µL of sample onto TEM grids (ultrathin 5 nm A-type carbon with 400 mesh 
Copper) followed by slow drying covered on the bench top for at least 3 hours. Samples were 
then dried under vacuum for 24-48 hours to remove contamination that would interfere with 
STEM-EDS. STEM-EDS data was collected for 180 - 600 s at specific points, using the largest 
probe size (1.5 nm electron beam diameter) with a 200 kV accelerating voltage.  Images were 
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collected in bright field (BF) and high-angle annular dark field (HAADF) modes, and grid 
background subtraction taken. 
 
Figure 3.27 STEM-EDS Analysis of SMN. a) STEM-HAADF of SMN with area chosen for 
EDS analysis (annotated as spectrum 2). b) EDS of SMN from the area selected in (a). Iron and 
copper signals are artifacts from the specimen holder and copper grid. 
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Figure 3.28 STEM-EDS Analysis of FMN. a) STEM-HAADF of FMN with area chosen for 
EDS analysis (annotated as spectrum 1). b) EDS of FMN from the area selected. Iron and 
copper signals are artifacts from the specimen holder and copper grid. 
3.16.6 1H NMRD Profiles, Fitting Parameters, and Description 
Proton 1/T1 NMRD profiles were measured on a Fast Field-Cycling Stelar 
SMARTracer NMR Relaxometer (Stelar, Mede (PV), Italy) over a continuum of magnetic field 
strengths from 0.00024 to 0.25 T (corresponding to 0.01-10 MHz proton Larmor frequencies). 
The relaxometer operates under computer control with an absolute uncertainty in 1/T1 of ± 1%. 
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Additional data points in the range 20-70 and 400 MHz were obtained on a Bruker WP80 NMR 
electromagnet adapted to variable-field measurements (15-80 MHz proton Larmor frequency) 
Stelar Relaxometer and Jeol ECP spectrometer (9.39 T), respectively. The 1H T1 relaxation 
times were acquired by the standard inversion recovery method with typical 90° pulse width of 
3.5 μs, 16 experiments of 4 scans. The temperature was controlled with a Stelar VTC-91 airflow 
heater equipped with a calibrated copper–constantan thermocouple (uncertainty of ±0.1 °C). 
The temperature was determined by previous calibration with a Pt resistance temperature 
probe. The nuclear magnetic relaxation dispersion (NMRD) profiles allow a detailed 
characterization of the paramagnetic solutes in terms of a large set of structural and dynamic 
parameters. The experimental profiles were measured in aqueous solution at 310 K and neutral 
pH. The best fit parameters, listed in Table 3.3, were obtained using the standard equations for 
the inner sphere (IS) and outer sphere (OS) relaxation contributions and by fixing the values of 
the following parameters: the hydration number (q = 1), the Gd-Hw distance (r = 3.0 Å), the 
distance of closest approach of the bulk water molecules (a = 4.0 Å) to the metal ion, the relative 
diffusion coefficient (D = 3.1x10-5 cm2s-1).3,16,46  
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Figure 3.29 NMRD Proton relaxivity as a function of temperature for SMN (left) and FMN 
(right) at 20 MHz and pH=7.2 In the case of SMN (left) the relaxivity increases with 
temperature up to about 320 K and then it remains stable at higher temperatures. This behavior 
is associated with a longer value of the residence lifetime, which implies a more pronounced 
limiting effect on relaxivity. In the case of FMN (right panel) the profile is characterized by a 
broad peak centered at about 305-315 K: this implies that around physiological temperatures 
relaxivity reaches a maximum value and it is not limited by the relatively slow exchange of the 
bound water molecule. A good fit of the NMRD data was obtained with 298τM values of 350 
and 560 ns for FMN and SMN, respectively, in full agreement with the temperature-
dependence study. 
In the case of the paramagnetic nanoparticles, the analysis of the NMRD profiles takes 
into account the occurrence of a relatively fast local rotation of the metal complex 
superimposed to the global motion of the nanoparticle (Lipari–Szabo approach).47,48 This model 
allows for the separation of the contribution of the overall global rotation of the paramagnetic 
nanoparticle (τRG = 5.9 and 2.8 ns for SMN and FMN, respectively) from the contribution of a 
faster local motion (τRL = 0.19 and 0.15 ns for SMN and FMN, respectively) associated with 
the rotation of the coordination polyhedron about the linker connecting the complex to the 
nanoparticle. The large difference between the two correlation times indicates that the system 
is rather flexible and its relaxivity limited by the relatively short value of τRL. The correlation 
of the two types of motions is described by the parameter S2 whose value is comprised between 
zero (completely independent motions) and one (totally correlated motions). The parameters 
for electronic relaxation (Δ2, τV) were used as empirical fitting parameters and do not have a 
precise physical meaning for these macromolecular systems.49,50 The temperature dependence 
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of proton relaxivity was also measured at 0.5 T in order to obtain an independent evaluation of 
the residence lifetime τM of the coordinated water molecule (Fig. 3.29).  
3.16.7 In Vitro and In Vivo MRI  
MR images were acquired on a Bruker 7.0 T magnet with Avance II hardware equipped 
with a 72 mm quadrature transmit/receive coil. Axial MR images were acquired using a 
standard T1-weighted sequence with a repetition time of 3249.2 ms, time to echo of 7.6 ms, 
with fat suppression, a matrix of 256 x 256, field of view (FOV) of 4.00 x 3.00 cm, resolution 
of 156 x 117 microns, slice thickness of 1.00 mm, inter-slice distance of 1.00 mm, 80 slices. 
T1 shortening was determined by selecting regions of interest (ROI) using Software ParaVision 
Version 5.1 from T1-T2 map with the following parameters: Times to echo of 11, 33, 55, 77, 
and 99 ms and 6 repetition times of 5000, 3000, 2500, 2000, 1500, and 1200 ms, and a flip 
angle of 180º. 
All animal procedures were approved by University of California, San Diego’s 
institutional animal care and use committee, protocol S10145. Female mice (C57Bl/6) 
weighing 18 grams were purchased from Harlan Sprague Dawley, and were anesthetized with 
3% isofluorane in O2 and subjected to baseline MRI imaging before injection. A total of nine 
mice (three sets of three) were injected with 550 µL of an aqueous 0.4 mM Gd-DOTA, SMN, 
or FMN intraperitoneally and imaged continuously under anesthesia for two hours and then 
again at selected time points of approximately 3h, 4h, 5h, 6h, 7h, 8h, 24h, 48h, and 1 week 
(each measurement made under anesthesia). Images of successful IP injections can be found in 
Fig. 3.9.  
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Figure 3.30 Anatomical MRI of IP space at two hours post-injection demonstrating no signal 
enhancement (for Gd-DOTA) or signal enhancement (for SMN and FMN): NP formulations 
are retained in the IP space longer than Gd-DOTA. (a) Anatomical image of mice 1 – 3, two 
hours post-IP injection of Gd-DOTA. (b) Anatomical image of mice 4 – 6, two hours post-IP 
injection of SMN. (c) Anatomical image of mice 7 – 9, two hours post-IP injection of FMN. 
3.16.8 Analysis of T1 Data  
To correct for minor scan-to-scan variations due to noise, T1 was normalized to pre-
injection phantom relaxivities. Phantoms of Gd-DOTA, SMN or FMN, were included in each 
scan corresponding to the material injected. Concentrations selected were 0.41, 0.12, 0.033, 
0.0095, and 0.0027 mM with respect to Gd3+ in H2O. Pre-injection relaxivities were generated 
for each mouse by averaging 1/T1 (r1) values (sec-1) for each phantom concentration over 
selected slices of the mouse. (The selected slices were those in which the organs of interest 
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were visible.) For each scanning time point after injection, an average 1/T1 for 5 phantoms were 
calculated and compared to the pre-injection relaxivity value to generate an adjustment factor 
for the scan of interest. Relaxivity values generated from phantoms for each scan were within 
(+/-) 1 - 20% of the pre-injection phantom relaxivity. After organ ROI T1 was converted to 
1/T1, each were multiplied by the adjustment factor. 1/T1 was averaged over each organ and 
then converted back to T1 (msec). Normalized T1 were averaged over three mice for each time 
point sampled and each material. Error for urinary bladder and liver are standard errors, over 
three mice for each material, using normalized T1 for each specific time point sampled.  
3.16.9 Ex vivo ICP-MS Analysis of Organs 
Mice were sacrificed using a lethal overdose of >5% isofluorane and selected organs 
harvested. The liver, bowel and spleen were dissected, placed in separate tubes and their masses 
were recorded individually. Mass of the entire liver, bowel and spleen was recorded, added to 
concentrated nitric acid (900 µL), and placed on a shaker overnight, vented. The following 
morning, concentrated H2O2 (50 µL) was added to each of the organ solutions and placed back 
on the shaker, vented, for approximately 30 min. An aliquot (200 µL) of the digested organs 
was added to distilled DI water (800 µL) and submitted to Exova for ICP-MS analysis to 
determine Gd3+ concentration. The final concentration of Gd3+ in each organ normalized to 
organ mass. Individual animal profiles at 2, 12 and 24 hours and average gadolinium 
concentration detection at 1 week are described in Figs. 3.31-3.33. 
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Figure 3.31 Average and three individual mice for SMN at 2, 12 and 24 hrs. Graphs a, e and i 
are the average of three mice. Graphs b-d, are individual mice sacrificed at 2 hours post 
injection. Graphs f - h are individual mice sacrificed at 12 hrs, Graphs j-k are individual mice 
sacrificed at 24 hrs. Error bars are for n= 3 mice except where annotated with *, where n = 2. 
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Figure 3.32 Average and three individual mice for FMN at 2, 12 and 24 hrs. Graphs a, e and i 
are the average of three mice. Graphs b- d, are individual mice sacrificed at 2 hours post 
injection. Graphs f- h are individual mice sacrificed at 12 hrs. Graphs f- h are individual mice 
sacrificed at 24 hrs. Error bars are for n= 3 mice except where annotated with *, where n = 2. 
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Figure 3.33 Detection of gadolinium in mice 1 week post injection.  %ID/g tissue in spleen, 
liver and gut for SMN and FMN. Total % of injected dose (spleen, liver and gut) at 1 week 
3.16.10 Concentration Determination of Gadolinium in Aqueous Nanoparticles 
Standard Curve for Gd3+ Concentration Determination. A 0.1 M stock solution of 
GdCl3 in H2O was prepared. From this stock, concentrations of 3.0, 1.0, 0.5, and 0.01 mM of 
Gd3+ in 2:3:5 HNO3:H2O:D2O were made. T1 relaxations were determined for each 
concentration of Gd3+ using inversion recovery experiments on a 300 MHz Varian NMR 
instrument. 1/T1 were averaged for three separate samples at the same concentration, then 
plotted to give a relaxivity of free Gd3+ of 13.8 mM-1sec-1 ± 0.830 with an R2 value of 0.9992. 
General Procedure to Determine Concentration of Gd3+ for SMN and FMN. In order 
to determine Gd3+ concentration, the metal was first stripped from the chelate using 
concentrated nitric acid. 80% HNO3 in water (115 µL) was added to an aliquot of each sample 
(115 µL). Each mixture was then heated at 65 ºC for approximately 12 hours. The sample was 
diluted with 230 µL of D2O and T1 was determined using an inversion recovery experiment on 
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a 300 MHz Varian NMR. Based the standard curve created above, the concentration of Gd3+ in 
stock solutions of SMN and FMN were determined to be 0.408mM and 0.444mM, respectively. 
3.16.11 Relaxivity Measurements for CTA Polymer Nanoparticles 
The T1 times of serial dilutions of Gd-DOTA, NP3 or NP4 were determined on a 300 
MHz Varian NMR using an inversion recovery experiment, as described above. The results are 
depicted as plots of concentration of gadolinium in mM versus 1/T1 in seconds. The results are 
inconclusive. 
 
Figure 3.34 Relativity measurements using inversion recovery experiments at 300 MHz, with 
R-squared of the linear best fit inset. a) relaxivity plot for Gd-DOTA, the control compound. 
Relaxivity was measured as 4 mM-1sec-1. b) One example plot for NP3, “Gd-shell” particles. 
A relaxivity measurement of 28 mM-1sec-1is based on estimated concentration. A second 
measurement of this particle also generated a relaxivity of about 28 (not pictured). When 
concentration was adjusted based on measured concentration (ICP-MS) the relaxivity was in 
turn adjusted to 227 mM-1sec-1. c) One example plot for NP4, “Gd-core” particles. A relaxivity 
measurement of 52 mM-1sec-1is based on estimated concentration. When concentration was 
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adjusted based on measured concentration (ICP-MS) the relaxivity was in turn adjusted to 1450 
mM-1sec-1. The linear regression fit for data sets a and b were satisfactory, but not good for plot 
c. No conclusions can be made from these experiments. 
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Chapter 4  
Fatty Acid Conjugates for Hitchhiking on 
Albumin: Diagnostic and Therapeutic 
Applications  
4.18 Introduction 
Synthetic nanoparticles are widely explored for nanomedicine applications, yet 
efficient tissue targeting in vivo remains a challenge. As an alternative to polymeric 
nanomaterials, a protein drug carrier is proposed. Harnessing human serum albumin’s 
endogenous and naturally evolved role as a hydrophobic molecule carrier, we designed 
conjugates of warheads with diagnostic or therapeutic application to hitchhike on the protein. 
The designed gadolinium-based contrast agents and paclitaxel based warheads are covalently 
attached to a long chain fatty acid. Through specific conjugate design, these “protein 
nanoparticles” experience prolonged circulation and accumulation profiles compared to small 
molecule counterparts. 
Preliminary exploratory work of the proposed fatty acid (FA) platform technology 
examined a paclitaxel (PTX) pro-drug conjugate (PTX-FA) of octadecandioic acid (ODDA, 
C18) formulated with albumin in treatments of tumor-burdened mice. While detailed in vivo 
experiments are out of the scope of this thesis, representative data provides evidence of the 
efficacy of the novel platform in xenograft models (Fig. 4.1). With evidence that a therapeutic 
drug formulated with albumin could target and suppress tumor growth with safer administration 
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compared to a clinical standard, Abraxane (ABX), we turned to investigating the scope of this 
platform.  
 
Figure 4.1 PTX-FA + HSA was tested head-to-head against Abraxane in a xenograft HT-1080 
tumor model. Tumor-burdened animals were dosed with respect to mg of paclitaxel per kg 
body weight (mg/kg) 3 times total, every 4 days (q4dx3). Panel (a) shows a Kaplan-Meyer 
survival plot. The tumor growth plots in panel (b) show efficacy in suppressing tumor growth 
at various dosings. On-going in vivo studies are investigating optimal therapeutic dosings in 
the HT-1080 model, as well as other tumor models of interest.   
 A gadolinium-based contrast agent conjugate of ODDA was envisioned for use as a 
blood pool contrast agent and a targeting imaging agent. Described herein is a Gd-DOTA 
moiety modified with ODDA, its characterization in vitro with regards to enhancement of 
relaxivity, and its utility in in vivo imaging, with subsequent blood circulation and 
bioaccumulation profiles generated. We hypothesized that utilizing this platform for an 
imaging agent would provide key information regarding utility of the diacid-albumin 
interaction for favorable in vivo properties: hijacking the albumin for prolonged circulation 
time of the gadolinium based contrast agent (GBCA) will provide a longer window of 
opportunity for imaging and favorable biodistribution, circumventing problems with existing 
small molecule clinical contrast agents. Furthermore, when the small molecule fatty acid 
conjugate binds with HSA, the rotational correlation time of the species will slow down, as it 
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is coupled to a macromolecular species; this will cause an increase in relaxivity. We compare 
a fatty acid Gd-DOTA conjugate (FA-Gd) head-to-head to MultiHance and Gd-DOTA to 
understand behavior in blood circulation time and bioaccumulation, especially targeting tumor 
tissue. 
In the second part of this chapter we sought to establish a screening tool to evaluate 
the toxicity of novel fatty acid-conjugates, and examine effects of modifications of the 
conjugate with respect to toxicity. Comprehensive in vitro toxicity for several fatty acid- 
derivatives was performed. Initial mechanistic studies using a surrogate fatty acid-fluorescein 
probe provided preliminary information regarding cancer cell uptake of fatty acid conjugates 
under the investigated conditions.  
4.19 Fatty Acid Conjugates as Diagnostic Agents 
Of interest in the drug delivery field are methods to prolong the circulation time of 
small molecule diagnostic agents, and to enhance their targeting at the region of interest. The 
FA platform presents a means to address both of these challenges, and designing MRI 
 contrast agents to bind with HSA is a strategy employed by other clinical and academic 
examples.1 
A fatty acid conjugate of a modified Gd-DOTA chelate was prepared and examined 
for its relaxivity properties. The FA-Gd was formulation with HSA then evaluated in vivo for 
imaging capabilities, blood circulation time enhancement, and well as targeting to a tumor. A 
cartoon overview of this FA-Gd platform is depicted in Fig. 4.2. 
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Figure 4.2 A cartoon of FA-Gd conjugates of a diagnostic warhead, designed to selectively 
interact with HSA. a) represents the ODDA hydrophobic tail (green) and Gd-DOTA moiety 
(purple dot). The small molecule conjugate is amphiphilic and may aggregate, as in panel (b). 
Panel c) represents 5 molecules of ODDA-conjugate binding to HSA; equilibrium arrows are 
used because it is a reversible process. 
4.19.1 Synthesis and Formulation Strategy  
The fatty-acid-chelate for gadolinium was prepared in a similar strategy to previously 
prepared fatty-acid conjugates.2 The mono-methyl ester ODDA was activated as the 
pentafluorophenol (-PFP) ester to give a good leaving group, then reacted with a commercially 
available, mono ethylamide, tris-t-butyl DOTA derivative (Fig. 4.3). Subsequent exposure to 
acidic then basic conditions removed the t-butyl and methyl-ester protecting groups. The free 
fatty-acid-DOTA ligand was then metalated with gadolinium at neutral pH and purified using 
RP-HPLC to give the FA-Gd-DOTA compound (FA-Gd) (Fig. 4.19). 
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Figure 4.3 The synthetic strategy for preparing FA-Gd-DOTA. Detailed methods included in 
method section. 
 Before use in further experiments, free Gd3+ was removed from the aqueous solution 
of FA-Gd using a basic precipitation method. The purified solution was confirmed to have no 
free metal using the Arsenazo assay.3  
The FA-Gd compound contains a hydrophobic fatty acid chain and a hydrophilic 
DOTA moiety. The compound is amphiphilic in nature, and found to be fully soluble in 
aqueous conditions. To probe whether the compound aggregates in solution as a small molecule 
surfactant, a pyrene critical micelle concentration (CMC) assay was performed.4 Under 
physiological conditions (DPBS, pH ~7.5), FA-Gd was found to have a CMC of about ~ 1mM 
(Fig. 4.21). A CMC concentration is important to keep in mind while measuring other 
physicochemical parameters of the compound, especially relaxivity, where macromolecular 
species have drastically different properties than small-molecule constituents. 
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4.19.2 Relaxivity Measurements 
To evaluate the efficacy of FA-Gd as a potential contrast agent, the relaxivity was 
compared to clinically relevant contrast agents. Relaxivity was measured at 1.4 T using a 
Bruker minispec over a range of concentrations. FA-Gd was measured either on its own or in 
the presence of HSA, and compared to MultiHance, gadobenate dimeglumine (inset Fig. 4.3, 
MH), and Gd-DOTA with HSA. Measurements were repeated with different stock solutions. 
The results are described in Fig 4.4 and Table 4.3. FA-Gd has a relaxivity of 3.9 mM-1sec-1, but 
when formulated in the presence of excess HSA to form FA-Gd + HSA, the relaxivity increases 
to 13.5 mM-1sec-1. FA-Gd + HSA demonstrates higher relaxivity than MultiHance formulated 
with HSA, which had a measured relaxivity of 5.8 mM-1sec-1. FA-Gd + HSA also demonstrated 
higher relaxivity than Gd-DOTA (Dotarem™, gadoterate meglumine) in the presence of HSA, 
which had a relaxivity of 6.0 mM-1sec-1. These experiments confirm the advantage of 
formulating the FA-Gd with HSA: as a small molecule, and below the CMC (fully solvated), 
FA-Gd has a relaxivity in the regime of other small molecules. For samples at concentrations 
at or above the CMC, relaxivity enhancement was greater, presumably from effects of 
macromolecular aggregates of FA-Gd (data not reported, but omitted from analysis). When 
formulated with HSA, the FA-Gd molecule binds strongly with HSA, which imparts a 
relaxivity enhancement from coupling the tumbling time of the Gd chelate to that of the slower 
tumbling protein. This interaction was expected, and similarly demonstrated for other protein-
binding small molecule Gd chelates.5,6 We tested our formulation with MH head-to-head, 
showing that our formulation had higher relaxivity compared to clinical MH. The favorable 
relaxivity of our complex could be attributed to the more selective and strong binding affinity 
for a fatty-acid-type molecule compared to the non-specific hydrophobic binding moiety in 
MH.  
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Figure 4.4 Representative relaxivity plots comparing FA-Gd, MultiHance (MH) formulated 
with HSA and FA-Gd formulated with HSA. 
An experiment was performed in which FA-Gd was formulated at different ratios to 
HSA. In fact, because the interaction between FA-Gd and HSA is non-covalent, despite the 
predicted strong binding constant, the molecule exists in equilibrium between a bound and un-
bound state with HSA (Fig. 4.2. equilibrium between species a and c). The previously discussed 
experiments were done with excess protein to favor a FA-Gd + HSA bound complex. 
Formulation of FA-Gd in the presence of varying ratios of HSA sought to tease out any effects 
of relaxivity from a mixture of protein- bound and unbound FA-Gd. Under the conditions 
probed, there seemed to be little to no effect of the ratio of FA-Gd to HSA (Table 4.4). 
4.19.3 In Vivo Evaluation 
To evaluate contrast enhancement, differentiation in circulation time, and 
bioaccumulation in vivo, the FA-Gd was formulated and introduced in a xenograft model 
bearing an HT-1080 tumor. FA-Gd was formulated with HSA at a 5:1 molar ratio with respect 
to Gd; this formulation emulates the on-going in vivo efficacy work with PTX-FA. Three types 
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of in vivo experiments were performed: blood half-life, imaging and biodistribution. Three 
materials were tested: FA-Gd, MH and Gd-DOTA formulated with HSA at low and high doses, 
in either healthy or tumor-burdened animals.   
First, preliminary studies investigated the feasibility of using our novel materials for 
MRI imaging in healthy animals. Imaging using a 4.7 T preclinical MRI scanner, imaging was 
performed in conjunction with blood half-life studies. Theses preliminary results indicated that 
both FA-Gd and MH circulate in the bloodstream of healthy mice hours post tail-vein injection 
(Figs. 4.22 and 4.27). FA-Gd had slightly higher serum concentration compared to MH at the 
same time point, indicating an enhancement of circulation time with our formulation strategy 
(Fig. 4.27). MRI scans revealed contrast enhancement at the gall bladder, clearance via the 
hepatobiliary system (Fig. 4.22). At the same timepoint, MH did not have a significant contrast 
enhancement in the gall bladder. With these results in hand, we pursued investigation of our 
materials in a tumor-burdened animal. 
In the next study, FA-Gd and MH were introduced via tail-vein injection in tumor-
burdened mice. A conservative dosing of Gd-material was used (“low dose” for FA-Gd  = 100 
nmol, for MH = 50 nmol). MRI imaging immediately post-injection, and at 2 hours and 4 hours 
post-injection show contrast enhancement at the gall bladder out to 4 hours post-injection (Figs. 
4.23 and 4.24). The contrast is apparent despite the low plasma concentration of gadolinium, 
confirmed with blood draws and analysis via ICP-MS (Fig. 4.28), indicating clearance from 
the blood via hepatobiliary system and accumulation at this organ. Inspection of the tumor-
region did not show obvious contrast enhancement expected from either formulation. At 24 
hours, animals were imaged, and no contrast was visible. The animals were then scarified, 
perfused with saline, then organs harvested and digested for biodistribution analysis. The 
experimental procedures are described in more detail in the methods section, along with the 
biodistribution results (Figs. 4.30 and 4.31). In summary, while gadolinium was detected in the 
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heart, liver, kidney, spleen, lung and tumor, there were no significant trends across the small 
sample size (n = 3). Additionally, total percent recovery of injected dose was low in all animals 
(< 0.3%), and in some organs the concentration detected was below the limit of quantification 
using ICP-MS.  
The third round of studies in tumor-burdened animals used a significantly higher 
dosing regimen, dosing at 1 μmol Gd per animal, using 200 μL tail-vein injections of a 5 mM 
solution. In this study, FA-Gd, MH and Gd-DOTA were compared head-to-head to determine 
the blood circulation half-life and imaging capabilities. The animal receiving FA-Gd and MH 
showed contrast enhancement at the gall bladder out to six hours post-injection (Fig. 4.5 and 
4.25). Gd-DOTA did not provide contrast enhancement at any of the multiple-hour time points. 
For all mice receiving contrast agents, no significant change in signal was detected at the tumor 
site. 
Analysis of blood serum corroborated the prolonged blood circulation time of the 
gadolinium-based contrast agent formulations. Before injection, then immediately post-
injection, and 1, 4, 7 and 24 hours post-injection, blood samples were drawn and serum 
separated and analyzed for gadolinium content. For each material, 3 animals were evaluated, 
and the average gadolinium concentrations are reported in Fig. 4.6, with individual animal 
profiles in Fig. 4.29. Minutes after injection, the dose is distributed in the blood volume of the 
mouse, giving the max concentration in the blood: the concentration of gadolinium for all 
samples is comparable in this first time-point post-injection. At 1 hour, there is already a 
significant drop-off in gadolinium concentration for all samples, though the FA-Gd has a 
distinctly higher concentration compared to MH or Gd-DOTA. Our determination of the half-
life of MH is consistent with the reported elimination half-life of 1.17-2 hours.7 This was 
shorter than that for FA-Gd, indicating a prolonged and favorable blood circulation time of the 
reporter agent containing a fatty-acid moiety. At the 7 hour blood analysis point, the average 
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concentration of gadolinium in the blood is 270 ppb, compared to 4 ppb for both MH and Gd-
DOTA. Despite the clearance of most of the material from the blood around this time point, 
and formulation of a GBCA with the FA, e.g. FA-Gd serves as a strategy for extending the 
circulation time and thus imaging window for experiments utilizing a GBCA. In addition, we 
confirmed hepatobiliary clearance of MH, and observed our FA-Gd material clearing via this 
mechanism (Fig. 4.5). This is a significant result because it represents an alternative 
formulation strategy for a GBCA that may be more suitable for patients experiencing decreased 
renal function. The MR experiments performed in this chapter were not-optimized; on-going 
and future work will need to evaluate targeting effects to the tumor, which was not observable 
via MR imaging under the conditions employed here. 
 
Figure 4.5 Representative MRI scans for tumor-burdened mice receiving high dose of FA-Gd, 
MH or Gd-DOTA. Yellow circle highlights the signal intensity in the gall bladder; the blue 
arrow indicates the tumor, when present in the slice shown. 
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Figure 4.6 Blood Half-life. FA-Gd, MultiHance (MH), and Gd-DOTA, formulated with HSA, 
and injected via tail vein in a tumor-burdened animal (HT-1080 xenograft).  
4.20 Fatty Acid-Taxol Conjugates for Therapeutic Applications 
Preliminary investigation of C18 conjugates involved derivatives of paclitaxel, with the 
aim to compare efficacy head-to-head with Abraxane. The taxol-conjugate (PTX-FA, Fig. 
4.10) was formulated with HSA to yield, then evaluated for efficacy in vivo. Different 
formulations yielded PTX-FA + HSA (1:1), PTX-FA + HSA (2:1) and PTX-FA + HSA (5:1), 
where the number describes equivalents of PTX-FA to albumin protein. On-going in vivo 
studies focus on the PTX-FA + HSA (5:1) formulation because of the higher loading of taxol 
per protein. Based on promising results, this technology has been further evaluated for mode 
of action and pharmacokinetic/pharmacodynamic studies: those results are out of the scope of 
this dissertation, but relevant experimental data is provided for context.  
4.20.1 Stability of PTX-FA 
PTX-FA was prepared under standard amide coupling conditions, per published 
procedures.2 The stability of the PTX-FA compound was evaluated using HPLC to confirm 
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that hydrolysis of the prodrug could be achieved. Briefly, PTX-FA was dissolved in organic 
solvent with either acidic, neutral or basic water added at a low enough concentration such that 
the small molecule did not precipitate. The control solution in organic solvent did not contain 
water. The solutions were incubated for 24 hours, then analyzed by HPLC to detect degradation 
of the parent compound. Before incubation, pure PTX-FA had a retention time of about five 
minutes. The control solution showed no change after 24 hours, while the PTX-FA subject to 
acidic conditions yielded partial degradation, with the PTX cleavage product appearing at two 
minutes. Under basic conditions, all PTX-FA was cleaved. This assay demonstrates that PTX-
FA is a labile prodrug of PTX, and that liberation of the active PTX occurs readily under basic 
conditions, but not as readily under acidic conditions. This is important when looking towards 
the toxicity of PTX-FA or formulations thereof in vitro and in vivo.  
 
Figure 4.7 HPLC traces of PTX-FA under various experimental conditions. 
4.20.2 Formulation of PTX-FA with Albumin  
To formulate PTX-FA with its carrier protein HSA, the two components were 
combined in a mixed-solvent solution, lyophilized, then resuspended in DBPS prior to use in 
further experiments. HSA was dissolved in MilliQ water at 1X, while PTX-FA was dissolved 
in t-butanol at 10X. The two were combined, mixed, flash frozen in liquid nitrogen, then 
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lyophilized to give a white powder. Details on concentrations used in formulation are described 
in the methods section. PTX-FA and HSA could be combined at increasing ratios of PTX-FA 
to protein. HSA has at least five strong binding sites for long-chain fatty acids, and formulations 
of 1:1 molar ratio PTX-FA to HSA, 2:1 and 5:1 were explored. Using the higher-loading (5:1), 
higher dosing of taxol is achieved.  
4.20.3 In Vitro Toxicity 
With the PTX-FA in hand, and a strategy for formulating with HSA, the toxicity of the 
small molecule and its formulated counterpart were evaluated in vitro. First, the toxicity was 
tested against HeLa cells, a human cervical cancer line. After comparing toxicity of the 
commercially available paclitaxel compound to PTX-FA and PTX-FA + HSA, toxicity was 
tested against a range of cancer cell lines, including: HT-1080 (human fibrosarcoma), H522 
(human lung), HT-29 (human colon), PANC-1 (human pancreas/duct cancer), and HepG2 
(human liver carcinoma/hepatocellular carcinoma). All toxicity studies described herein were 
performed in the same manner so that results may be directly compared, though the 
experiments are not optimized for each treatment condition. The initial in vivo efficacy, 
described in a later section, was evaluated for an HT-1080 xenograft model, so establishing an 
in vitro assay for comparison of the HT-1080 line to other cancer lines was critical. HT-29, 
PANC-1 and H522 were also tested in xenograft models. HepG2 is of particular interest 
because of its known interactions with HSA- and we envisioned this as a cancer model wherein 
strong HSA interactions would provide even more favorable results with respect to specificity 
and efficacy. Ongoing experiments are evaluating the genes for specific cell receptors 
responsible for HSA targeting to HepG2 cells specifically.  
Viability experiments with HeLa cells reveals that PTX-FA is not as toxic as the parent 
PTX compounds (Fig. 4.8a). This could be attributed to the fact that PTX-FA is a prodrug, and 
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over the time of the experiment, not all PTX is liberated. Additionally, PTX-FA might be seen 
differently by the cells: the long chain fatty-acid may provide an alternate pathway for the 
molecule to be taken into the cell. The conditions used in vitro also appear to affect toxicity. 
For example, treatment with serum-free media (Opti-MEM, OM) decreases the toxicity of 
PTX, but not drastically in PTX-FA. Cell culture media with serum proteins may associate with 
the small molecule drug, affecting its mode of action, or interaction with the cell. Preliminary 
mechanistic studies evaluating the effects of formulation and treatment conditions on cell 
uptake were performed and provide some insight in to this problem (see section 4.5).  
Formulations with HSA were shown to be toxic to cells: the 1:1 and 2:1 molar ratio 
(PTX-FA: HSA) had comparable toxicities to PTX-FA, while the 5:1 ratio had lower IC50 
values, but did not impart full cell death on HeLa cells (Fig. 4.8b). A comparison of different 
formulations of PTX-FA in the presence and absence of serum proteins in media is presented 
in Fig. 4.2c. Across the board, treatments in serum-free media are more toxic than treatments 
of the same compounds in serum-containing media. This could be attributed to serum proteins 
of FBS interacting with PTX-FA, sequestering them and hindering hydrolysis of PTX or 
preventing cell-membrane interactions. PTX was significantly more toxic than PTX-FA or 
when formulated with HSA: this is not surprising as the formulation with HSA must undergo 
more steps before reaching its target in the cell nucleus. While toxicity is still on a similar order 
of magnitude as free PTX, the novel prodrug compounds present a strategy towards higher 
dosing with diminished toxicity, as is evident by in vitro cell culture studies.  
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Figure 4.8 Representative IC50 curves for conjugates of PTX, and formulations thereof. a) 
PTX, PTX-FA in normal media (in black), or serum-depleted media (in red). The dashed lines 
are commercially available PTX; the solid lines are the synthetic small molecule PTX-FA.  b) 
Formulations with HSA. 1:1 ratio (black solid), 2:1 ratio (blue), or 5:1 ratio (red). c) A 
comparison of all compounds and treatment conditions. More representative IC50 curves and a 
summary of all trials are in Figs. 4.32 and 4.33 and Table 4.5. 
A comparison of the toxicity of fatty acid conjugates across different cell lines shows 
that PTX-FA and formulation with HSA are comparable in toxicity in HeLa, HT-1080, HT-29 
and HepG2 (Fig. 4.9). While the compounds are not as toxic in PANC-1 or H522 cell lines, 
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there is still evidence of cytotoxicity. This corroborates unpublished data that shows efficacy 
of PTX-FA suppressing tumor growth in PANC-1 and H522 xenograft tumor models (not 
shown). A table summarizing toxicity of various compounds in the cell lines is provided in 
Table 4.1, with representative IC50 curves in Figs. 4.34-4.38 and Tables 4.6-4.10 
 
Figure 4.9 IC50 plots of PTX-FA and formulation with HSA across 6 cell lines. The values 
shown here are toxicity in complete media. Tables summarizing all experiments on the various 
cell lines are included in Tables 4.6 through 10. 
 
Table 4.1 IC50 values PTX-FA and PTX-FA + HSA (1), (2), and (5) in various cell lines. 
 
 
 
 
 
 
 
 
 
 
 
Cell line PTX-FA 
PTX-FA 
+ HSA (1) 
PTX-FA 
+ HSA (2) 
PTX-FA 
+ HSA (5) 
HeLa 57.05 59.00 278.25 25.375 
HT-1080 1.11 9.27 47.6 12 
HT-29 36.1 16.3 9.24 8.62 
PANC-1 1381 283 N/A 9.09 
H522 65.8 182 N/A N/A 
HepG2 1.89   34.6 
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4.20.4 In Vivo Efficacy 
The PTX-FA formulations with HSA were tested head-to-head against Abraxane in a 
xenograft HT-1080 tumor model. Tumor-burdened animals were dosed with respect to mg of 
paclitaxel per kg body weight (mg/kg) 3 times total, every 4 days (q4dx3). Select results are 
shown in Fig. 4.1. Panel (a) shows a Kaplan-Meyer survival plot. Favorable survival plots were 
seen for animals receiving 30 or 50 mg/kg ABX and 5 or 300 mg/kg PTX-FA + HSA. Animal 
death before the last dose was attributed to toxicity of the therapeutic, whereas animal death 
past 12 days from the start of the therapy (e.g. saline) was attributed to tumor overgrowth and 
morbidity. ABX at medium (30 mg/kg) and high dosing (50 mg/kg) showed some drug toxicity, 
however if the animals survived the initial dosing of taxanes, it had a good chance of efficacy 
against the tumor. The lowest dose of ABX (5 mg/kg) was ineffective, showing similar results 
to the saline control. PTX-FA was tolerated well by the animals, and prolonged animal survival, 
compared to saline. Of note is that the animals could tolerate the PTX-FA 300 dose, providing 
evidence of a safer formulation strategy, which in turn allows for higher dosing of therapeutic, 
and greater efficacy. The tumor growth plots in panel (b) show efficacy in halting tumor growth 
at various dosings. ABX at 30 mg/kg and PTX-FA at 300 mg/kg are comparable with regards 
to suppressing tumor growth. ABX and PTX-FA at the same dose (5 mg/kg) show comparable 
ability to suppress tumor growth, which is not as effective as the higher doses, but better than 
the saline control. On-going in vivo studies are investigating optimal therapeutic dosings in the 
HT-1080 model, as well as other tumor models of interest.  
4.21 Exploring the Scope of the Fatty Acid Platform 
We next explored the scope of the fatty acid platform by testing a variety of taxol-
derivatives wherein the carbon chain length and attachment was varied. The compounds were 
evaluated in vitro using the established cytotoxicity assays as described in the previous 
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sections. Just as several agents  have been formulated with albumin in a method similar to the 
Abraxane formulation with paclitaxel,8 we demonstrate that our approach could also be tailored 
to make other conjugates of warheads of interest. Methotrexate, camptothecin, and peptide 
conjugates are briefly described and evaluated for their therapeutic nature. Methotrexate 
(MTX) is used a folate antagonist, used to treat solid tumors and rheumatoid arthritis, among 
other diseases.9,10 Camptothecin (CPT)  is a quinoline alkaloid class of cytotoxins, approved 
for treatment of several types of cancers, including colorectal, ovarian, cervical and small-cell 
lung cancer.11 A KLA peptide (KLAKLAKKLAKLAK, or KLAKLAK2) was chosen for 
evaluation because of its known characterizations and utility, and because of its mode of action: 
the in-tact peptide must be in the cytosol where it inserts in to and disrupts the membrane of 
mitochondria, causing cell apoptosis.12  
4.21.1 Other Paclitaxel-Derivatives 
The importance of the 18-carbon fatty acid chain for utility in HSA-binding was 
evaluated by synthesizing fatty-acid -paclitaxel conjugates with modified carbon chains and 
linkers.2 Specifically, the length of the chain, saturation and the role of any additional linker 
was evaluated. Four new PTX-prodrugs were prepared in a similar manner to PTX-FA (see 
Fig. 4.10 for structures). This is not an exhaustive exploration of compounds of interest. 
Examples are specifically chosen to support the claim that this is a generalizable platform 
technology. Future studies might investigate different fatty acid derivatives to tune properties 
such as binding kinetics and equilibria. The hexadecanedioic acid (C16-PTX) and eicosanedioic 
acid (C20-PTX) conjugates simply vary the fatty acid chain length, while maintaining the 
terminal free acid and ester linkage to paclitaxel. The octadec-9-enedioic acid (C18unsat-PTX) 
conjugate has 9-10 trans-unsaturation, and maintains the ester link to paclitaxel; the 
unsaturation may provide a kink in the fatty acid chain, affecting its binding with HSA. A final 
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derivative contained a mono-methyl-ester protected acid, with a 6-amino-hexanoic acid linker 
to ester-attached paclitaxel; this compound is labeled “C6linked-PTX” here forth, referring to the 
extended linker carbon length.  
 
Figure 4.10 Various fatty acid-PTX conjugates evaluating key features of the fatty acid 
compounds.  
As described in the introduction, HSA has specific binding for various fatty acid 
derivatives, and we have seen that clinical drugs modified with a myristic (C14) acid exhibit 
favorable interactions with the protein (reference fatty acid binding differences and Levemir). 
We were curious how extending or shortening the length of our ODDA probe might affect the 
function of the prodrug. The aim was to use the cytotoxicity assay as a surrogate screen for 
fatty acid conjugate activity, alleviating the need for resource-intensive in vivo studies to screen 
for efficacy. Cytotoxicity experiments in HeLa cells revealed that the C18unsat- and C20-PTX 
compounds had similar toxicity to PTX-FA, whereas C16-PTX was less toxic, and the C6linked-
PTX was significantly less toxic (Fig. 4.11 and Table 4.2). It is interesting that two less carbons 
had such an impact on toxicity, and may be attributed to slightly decreased hydrophobicity of 
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the chain affecting interactions with serum proteins or the cell membrane. The decrease in 
toxicity of the C6linked-PTX was less surprising: the methyl-protected ester may have impacted 
the solubility of the complex or led to differing interactions with the serum proteins present. 
Alternatively, the 7 extra atoms in the chain may have proved too many, affecting how it was 
“seen” by serum-proteins or the cell. The free acid was not present on C6linked-PTX conjugate 
(methyl-ester protecting group maintained), and represents the only example in this study 
where the ionic interaction with the pit of the binding pocket was altered (a positive residue 
sits inside key binding pockets of HSA, allowing for strong interactions with negatively 
charged carboxylates). There are countless iterations of long-chain fatty acid with linkers to 
find an optimal binding moiety with HSA optimized for the warhead. Other avenues of 
exploration include further optimizing chain and linker length, altering the non-functional 
terminus of the fatty acid to have a noncharged moiety (e.g. stearic acid derivative) or tuning 
the cleavable linker using functional groups such as carbonates, carbamates, or other labile 
linkers.13,14 
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Figure 4.11 Cytotoxicity of taxane-type conjugates in HeLa cells. These are representative IC50 
plots. For Repeat experiments, see Fig. 4.39 and Table 4.11. 
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Table 4.2 IC50 values PTX-FA, C16-PTX, C18unsat-PTX, C20-PTX and C6link-PTX in HeLa cells. 
Compound 
PTX-FA 
C16-PTX C18unsat-PTX C20-PTX C6link-PTX 
IC50 (nM) 57.04 195.6 40.0 27.8 2329 
4.21.2 Other Categories of Therapeutic Agents 
To demonstrate the broad applicability of this platform technology, two other small 
molecule cytotoxic drugs were prepared and evaluated with an initial screen for toxicity in 
vitro: camptothecin and methotrexate. Both FA-CPT and FA-MTX were only prepared as 
ester-linked C18 fatty acid conjugates. FA-MTX required an amino-linker between the 
carboxylic acids of the MTX and the dicarboxylic acid, and the product was a mixture of 
isomers, both of which are described in Fig. 4.12.  
 
Figure 4.12 FA-CPT and FA-MTX: cytotoxic drugs modified with a ODDA. 
With FA-CPT and FA-MTX in hand, the compounds were tested for activity against 
HeLa cells using the same protocol as for the paclitaxel conjugates, and compared to their 
parent compounds (Fig. 4.40 and Tables 4.12 and 4.13). CPT and MTX were found to have 
IC50 values of 49.8 nM and 6.0 nM. The conjugates had non-optimal IC50 curves, with a 
response of about 50% viability up to 50 μM for FA-MTX and FA-CPT. The drastic difference 
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in toxicity from the respective parent compounds was unexpected. This may be to poor 
solubility of the conjugates, or steric hindrance of the fatty acid and the labile ester bond of the 
pro-drug form. Experiments at higher concentrations will need to be performed along with 
optimization of the cytotoxicity assay for these compounds. CPT- and MTX-derivatives have 
been found to be cytotoxic for a number of cell lines,10,11 so subsequent testing to evaluate 
cytotoxicity of our fatty-acid conjugates should be done in other cell lines.  
4.21.3 Peptide Conjugates 
The fatty acid platform is amendable to therapeutic compounds other than small 
molecule cytotoxins, specifically peptides. The “KLA” peptide was of interest for its 
therapeutic function in cells.12 The FA-KLA conjugate was prepared by first synthesizing the 
KLA peptide using standard solid phase peptide synthesis. After the last lysine residue was 
coupled to the peptide, an excess of mono TIPS-protected ODDA was washed over the resin 
to couple the fatty acid to the peptide. The FA-peptide conjugate (FA-KLA, Fig. 4.13) was then 
cleaved from the resin using acidic conditions, which also served to deprotect the TIPS 
protected acid group. The compound was purified under dilute conditions using preparatory 
RP-HPLC. A formulation with HSA proved straightforward because the FA-KLA was fully 
soluble in aqueous solution. FA-KLA and HSA were prepared at 2X concentration in DPBS 
then added in 1:1 volume to get a 1X concentration of FA-KLA + HSA, where the FA-KLA 
and albumin are at a 1:1 mol ratio. 
 
Figure 4.13 A “KLA peptide” conjugate, FA-KLA. 
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With FA-KLA in hand, preliminary cytotoxicity experiments were performed. In HeLa 
cells, FA-KLA had an IC50 of about 38 μM in media, or 17 μM in serum-free media, while 
when formulated with HSA, cell viability had a minimal response with treatments up to 1mM 
(restricted by solubility of HSA at high concentrations) (Fig. 4.41 and Table 4.14). The lack of 
toxicity of FA-KLA when formulated with HSA was apparent in both competent and serum-
free media. This was an interesting result since the KLA peptide must be in the cytosol to 
impart function (e.g. cell death), and it was hypothesized that HSA would be critical for 
chaperoning the FA-conjugate in to the cell. However, without formulation with HSA, and 
even without serum proteins in the treatment media, the FA-KLA could impart cell death, and 
was thus inside the cell. Two hypotheses could relate to how FA-KLA was able to get in the 
cell. In one instance the amphiphilic-type molecule (hydrophilic peptide, hydrophobic fatty 
acid residue) might aggregate in aqueous conditions, and the cell might “see” the compound as 
a nanoscaled aggregate, allowing internalization via an endocytotic pathway. A crude DLS 
experiment looking at aggregation at increasing concentration predicted that an approximate 
critical aggregation concentration was around mM. Below that (e.g. the concentrations used in 
viability experiments), the FA-KLA should be fully solvated and aggregated at higher 
concentrations. This may explain why treatments at 1mM of FA-KLA began to show a 
response in viability: the cell was seeing and internalizing a macromolecular aggregate, rather 
than a solvated peptide-conjugate. Minimal differences between treatments in media with or 
without serum proteins suggests that protein association is not part of the mechanism for getting 
in to cells. Alternatively, the FA-KLA maybe be invoking a fatty-acid transport mechanism for 
cell uptake, though no further studies support that idea at this time. When sequestered upon 
formulation with HSA, the KLA activity is greatly diminished, suggesting that formulation 
with a protein carrier may be shielding the material from accessing the cell cytosol or 
mitochondria. Further optimization of this system and assay is necessary, though it is promising 
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that FA-KLA shows toxicity in cells. This is on the same order of toxicity compared to what 
was seen previously in our group, where a multivalent (polymeric) version of the KLA peptide 
is toxic around 10 μM, while free peptide is not toxic up to 100 μM.15  
4.22 Cellular Internalization of Fatty Acid Conjugates 
Toxicity of compounds was preliminary evaluated using in vitro viability assays for 
FA-conjugates and their formulations with HSA. The deviation in toxicity across compounds, 
and especially toxicity of free FA-KLA, prompted initial investigation of mechanism of 
internalization of materials in vitro. Importantly, the toxic paclitaxel-, camptothecin-, and 
methotrexate-derived materials were ester-linked prodrugs of the parent compounds. The free 
compounds must be inside the cell to prove toxic, based on their targets and mechanism of 
action. The FA-conjugates may enter the cell in-tact, then hydrolyze to release the toxic 
compound, or alternatively, may undergo hydrolysis outside the cell, followed by diffusion of 
active compounds in to the cytosol and subsequent cell death. The KLA compound must be 
inside the cell in order to have activity: its target is the mitochondria. The FA-KLA conjugate, 
however, is amide-linked and thus in order to be toxic, the conjugate must be inside the cell. A 
few scenarios might explain how the conjugate on its own may be internalized: passive 
diffusion in the cell, hydrophobic interactions with the hydrophobic cell membrane, 
internalization via a fatty-acid uptake pathway, or aggregation in solution such that the cell 
“sees” the material as an aggregate rather than a dispersed small molecule leading to 
endocytosis, as described in the previous section.  
To get a basic understanding of internalization pathway, cell uptake studies were 
performed using a fluorescein labeled FA-conjugate surrogate. The FA-Fluor was prepared in 
a similar manner as the other ODDA-conjugates (Fig. 4.14). A fluorescein-labeled FA-KLA 
conjugate was also prepared using biorthogonal protecting groups during SPPS. These 
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materials could then be formulated with (or without) HSA and introduced in cells to evaluate 
differences in cell uptake using standard flow cytometry methods.  
 
Figure 4.14 Fluorescein conjugates formulated with HSA to evaluate cell uptake pathway. 
4.22.1 Cell Uptake Evaluated by Flow Cytometry 
Concentration dependence of uptake of FA-fl was evaluated for effects of the treatment 
media, e.g. serum proteins. As shown in Fig. 4.15, cell-associated fluorescence signal increased 
with treatment concentration, with the greatest increases in signal for treatments of FA-fl (a) in 
serum-free media. Interestingly, FA-fl + HSA (b) in media had modest increases in 
fluorescence compared to DPBS control, with treatments in serum-free conditions, 
demonstrating slightly higher increases in fluorescence. The differences in signal increase from 
FA-fl compared to formulation with HSA is counter to the hypothesis that HSA chaperones 
cargo in to all cells: if this hypothesis were true, cells treated with FA-fl + HSA would be 
expected to show higher fluorescence increases compared to FA-fl. Experiments using DMEM 
without FBS supplementation yielded similar results as the serum-free OptiMEM media 
(results not pictured): OptiMEM was used as the “serum-free media” for all experiments in this 
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section. This may demonstrate effects of serum-protein opsonization of FA-fl or FA-fl + HSA 
and so was evaluated along-side regular, serum-containing media. 
 
Figure 4.15 Concentration dependent uptake of (a) FA-fl and (b) FA-fl + HSA in complete 
media or serum-free media in HeLa cells. Formulation with HSA was made at 1:1 conjugate: 
albumin ratio. Representative cell scattering dot-plots and histograms showing clear population 
shifts, are also described in the methods section (Fig 4.42-4.44) These data are gated healthy 
populations, and the treatment solution did not seem to affect the viability of the cells. 
The observed preferential cell uptake of FA-fl under serum-free conditions is also 
observed in other select cell lines (Fig. 4.16). Similar to HeLa cells, HT-1080, HT-29 and 
HepG2 cells treated with FA-fl in serum-free media demonstrated the highest increase in 
fluorescence signal. FA-fl + HSA also demonstrated increases in fluorescence, with not as 
drastic increases in fluorescence for treatments in serum-free media compared to the 
unformulated conjugate. The surprising result of higher fluorescence signal for the FA-fl in 
serum-free media prompted preliminary mechanistic studies of cell uptake. 
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Figure 4.16 Internalization of FA-fl in other cell lines. All treatments at 4.6 μM fluorescein 
Representative cell scattering dot-plots and histograms showing clear population shifts, are also 
described in the methods section. Treatments did not significantly affect cell viability. 
Representative dot plots and histograms showing population shifts in Fig. 4.27-4.32. 
In addition to FA-fl and formulation with HSA, a fluorescein-labeled FA-KLA 
conjugate was prepared and is depicted in Fig 4.14. FA-KLA(fluor) and FA-KLA(fluor) + HSA 
were used to treat HT-1080, HT-29 and HepG2 cells (Fig 4.17). In HT-1080 cells a large 
increase in fluorescence for both formulations was observed, both in complete and serum-free 
media; this represents greater increases in signal compared to that from FA-fl or FA-fl + HSA 
treatments. In HT-29 cells increases in signal were observed for both materials. Interestingly, 
there appeared to be little advantage for formulating the peptide conjugate with HSA or 
treatment in serum-free media, which is on contrast to the results observed with FA-fl in 
serum0free conditions. HepG2 cells demonstrated the greatest relative increases in 
fluorescence, with FA-KLA(fluor) generating a marginally higher fluorescence signal than 
when formulated with HSA. 
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Figure 4.17 Internalization of fluorophore labeled peptides (FA-KLA(fluor)) in different cell 
lines. HeLa was not evaluated. All treatments were at 4.6 uM with respect to fluorophore, and 
formulation with HSA were at a 1:1 mol ratio of peptide to albumin. Dot plots and histograms 
are in Figs. 4.45-4.50. 
4.22.2 Evaluation of Mechanism of Action 
 To elucidate possible mechanisms leading to differences in uptake between FA-fl and 
HSA formulations therefore, experiments were performed to probe active versus passive 
mechanism, and using a metabolic inhibitor, MβCD. This inhibitor depletes cholesterol-rich 
membranes associated in the lipid-rafts involved in the clathrin-independent/caveolae-
mediated endocytosis pathway, which is the mechanism cited for HSA transcytosis across the 
endothelial emmbrane.16,17 The FA-fl or FA-fl + HSA were prepared in media or serum-free 
media, then used to treat HeLa cells for 1 hour at 37˚C or 4˚C. Incubation at 4˚C would shut-
off any active internalization pathway: a relative decrease in signal would indicate that an 
energy-dependent pathway was responsible for cell uptake. If a caveolae-mediated endocytotic 
pathway played a role in cell uptake, treatment with the metabolic inhibitor would disrupt this 
pathway, and again, a relative decease in signal would occur. 
For FA-fl, regardless of media composition, fluorescence signal was maintained for 
incubation at 4˚C versus 37˚C (Fig.4.18a). This suggests that the process of FA-fl entering cells 
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is non-energy dependent. This might occur if the small molecule passively diffused through 
the membrane as other small molecules are known to do, or the hydrophobic tail passively 
inserts in to, or associates with, the cell membrane. For the latter, a thorough wash of the cells 
and a heparin wash should remove material not inside the cell or its membrane, and although 
the heparin wash was not included for the cell uptake experiments, the preliminary cell uptake 
experiments found that the heparin wash had no effect on the cell fluorescence. Co-incubation 
with MβCD did not affect cell uptake of FA-fl compared to controls or treatment of FA-fl 
without inhibitor at 37˚C, indicating that a caveolae mediated-pathway may not be responsible 
for FA-fl uptake. For FA-fl + HSA (Fig.4.10b), signal increase was higher upon incubation at 
4C, again suggesting a non-metabolic dependent pathway for uptake of the complex; MβCD 
did not negatively affect uptake. An alternative explanation for the effects seen for FA-fl + 
HSA formulations is that the FA-fl may be in its unbound form under these conditions and thus 
interacting with the cell [passively] as a small molecule. 
153 
 
 
Figure 4.18 FA-fl (a) or FA-fl + HSA (b) treatment of HeLa cells under various conditions, all 
at 4.6 μM with respect to fluorescein. All data normalized to vehicle, which is 1. Representative 
dot plots and histograms in Fig. 4.51-4.53. 
These experiments demonstrate that fatty-acid conjugates may be passively diffusing 
in to cells due to their small molecular weights. To elucidate differences in uptake of free fatty-
acid conjugate compared to complexation with albumin, HSA should be labeled with another 
fluorophore, complementary to fluorescein. Further experiments are on-going in the lab and 
focused on investigating both HSA-receptor proteins and fatty-acid transport proteins (FATPs). 
Regardless of the mode of internalization, the cytotoxic FA-conjugates were able to 
demonstrate toxicity across cell lines, either through passive or active mechanisms in to the 
cell, with availability of ester bond cleavage revealing the active form of the drug. 
4.23 Conclusions and Outlook 
Taking advantage of endogenous protein-small molecule interactions for improved 
pharmacokinetics via prolonged blood circulation times is an exciting opportunity for enhanced 
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drug delivery of many classes of drugs. Human serum albumin represents an ideal platform for 
hitchhiking a small molecule drug to enhance circulation time and targeting to some tissue, 
such as cancerous and inflamed tissue. Clinical success stories such as Abraxane and Levemir 
indicate utility and promise of designing molecules for more efficient drug delivery. Inspired 
by naturally occurring interactions of long-chain fatty acids with HSA, a platform technology 
utilizing ODDA-modified with various warheads was developed and tested to show efficacy in 
therapeutic and diagnostic applications. Therapeutic efficacy of PTX-FA demonstrates that our 
novel formulation is safer than the comparable ABX, allowing for higher dosing and a greater 
therapeutic window. Ongoing pharmacokinetic and pharmacodynamic studies are investigating 
detailed absorption, distribution, and metabolism of PTX-FA, and dose-dependence thereof. 
Other in vitro experiments discussed herein and preliminary in vivo studies (not included here) 
indicate that PTX-FA is efficacious against various cell lines. In the diagnostic realm, a 
gadolinium-based fatty-acid derivative demonstrated favorable relaxivity properties in vitro, 
and utility as a blood-pool imaging agent.  
Based on interest in understanding the mechanism leading to successful targeting of 
HSA and HSA-bound molecules to tumor targets, in vitro cell experiments preliminarily 
investigated a FA-fluorescein molecule for mechanism of action getting in to a cell. Other have 
attributed ABX success to EPR effects, gp60-mediated transcytosis, and SPARC recognition 
for localization at the tumor cell, though mechanisms investigating cell uptake of warhead 
remain elusive. It is suggested that albumin mediates internalization of warheads in to cancer 
cells where payload is delivered, though detailed studies have not been done, and are out of the 
scope of this work. Ongoing collaborative studies are working to identify genes for cancer cell 
receptors for PTX-FA formulations of paclitaxel. Using CRISPR-Cas9 technologies, a range 
of endocytotic and fatty-acid receptors are being probed for their role in PTX-FA uptake. 
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Identifying the mode and species internalized by cancer cells will allow researchers to even 
more specifically target cancer tissue and cells. 
Also of note in the albumin-mediated world is how formulation of HSA with a 
chemically-modified fatty acid might affect how the protein is seen in the body, specifically 
albumin-specific receptors like gp60, gp18 and gp30. It was discussed that gp60 is specific for 
native albumin, while gp18 and gp30 specific for modified albumin. Not investigated here is 
how a natural carrier molecule (ODDA) chemically modified with a bulky hydrophobic or 
hydrophilic small molecule (paclitaxel or gd-DOTA) affects its binding with albumin. This 
could be done with computational modeling, and experimental cell work investigating 
efficiency of transcytosis of modified fatty-acids in endothelial cells or specificity towards 
albumin receptors. (reference for experimental transcytosis exps).  
The results from cell toxicity and uptake studies highlight effects that experimental 
conditions may have on the results of the experiment. For example, differences in toxicity of 
PTX-FA and PTX-FA + HSA are evident, and are also dependent on serum-containing media 
used in the experiments. Cell uptake studies reveal that FA-fluorescein more readily associates 
with cells compared to when formulated with albumin. The latter uptake experiment suggests 
that a fatty-acid conjugate with a non-labile linker (e.g. FA-fl) may internalize in to cells via a 
fatty-acid uptake mechanism. More detailed experiment are necessary to conclude this as the 
mechanism for cell association, but this idea is important when considering the efficacy of the 
PTX-FA molecule.  
PTX-FA is a prodrug of the active moiety PTX, which is linked via an ester moiety, 
allowing for hydrolysis and release of free taxol, which inside the nucleus binds microtubules, 
halting cell reproduction. Thus, it is imperative that taxol is both releases from the fatty-acid 
carrier and is in the cell. There is an interplay of PTX-FA and protein binding equilibrium and 
kinetics, as well as PTX-FA hydrolysis kinetics. We know that hydrolyzed PTX is in cancer 
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cells based on reduction in tumor volume in in vivo models, but it is unknown in which form 
(e.g. PTX-FA, PTX-FA + HSA, or PTX it is internalized in the cell. More detailed equilibrium 
experiments looking at the binding equilibrium of PTX-FA with albumin under physiologic 
conditions may reveal information about how tightly bound the modified FA-molecules are 
with the protein. Isothermal calorimetry (ITC) experiments were attempted using PTX-FA, but 
due to the many possible binding sites of PTX-FA with HSA, the experiments did not yield 
reliable binding coefficients. Future investigation of PTX, PTX-FA and PTX-FA + HSA 
should look at interplay between binding kinetics, hydrolysis kinetics, and how these 
compounds are recognized by the cancer cell, including investigation of albumin-mediated 
internalization mechanisms, as described above. Investigation of the role and specificity of the 
fatty acid chain was investigated with regards to taxol conjugates. C16, C18, C20 and C6link, 
conjugates of taxol were prepared and tested for toxicity. All compounds were shown to have 
similar toxicities in HeLa cells, even when compared to PTX-FA, though no information about 
binding equilibriums or hydrolysis kinetics was obtained. While literature indicates binding 
constant of C18 is strongest compared to (other chain lengths),18 depending on the application 
and interaction with albumin, the exact synthetic structure of the FA-conjugate can easily be 
modulated.  
The results from the in vivo evaluation of the diagnostic agent were promising. We 
achieved desired enhancement of blood serum circulation time using our strategy of 
formulation with HSA, and a change in profile compared to clinical small molecule standards, 
including one (MH) designed to interact with HSA for enhanced circulation and a second (Gd-
DOTA) not specific for blood pool imaging. While contrast enhancement was observed using 
a preclinical 4.7 T MRI, we were unable to determine using MRI if the material was 
accumulating at the tumor target. It is important to point out that blood circulation or clearance 
time does not necessarily equate to elimination half-lives. Materials are subject to metabolism 
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and deposition or accumulation in various organs, in addition to elimination. While metabolic 
experiments were not performed for these materials, the accumulation at the tumor-target site 
and off-target organs was evaluated ex vivo at 24 hours, but no significant trends in 
accumulation were detected. Future work will need to work out the proper dosing and imaging 
parameters for using this novel diagnostic agent. 
The platform technology described here is widely amendable to various therapeutic 
treatments. Ongoing projects in the Gianneschi lab are investigating fatty acid conjugates of: 
RNA, other peptides, other therapeutic small molecules (include methotrexate, docetaxel, 
camptothecin), other metal based therapeutic molecules (platinum or gold-based), other 
imaging agents (cyanine dyes) and combinatorial therapies. This formulation strategy is only 
limited by synthetic accessibility of the fatty-acid conjugate.  
4.24 Acknowledgments 
Chapter 4, in part, was published as a patent: “Modified Cytotoxins and Their 
Therapeutic Use.” Callmann, Cassandra; Thompson, Matthew P.; LeGuyader, Clare L. M.; 
Bertin, Paul A. and Gianneschi Nathan C. 2016. The dissertation author was a contributing 
author on this reference.  
Chapter 4, in part, was also published as a patent entitled “Modified MRI Contrast 
Agents and Uses Thereof.” LeGuyader, Clare L. M.; Thompson, Matthew P.; Callmann, 
Cassandra; Ditri, Treffly; Bertin, Paul A.; Gianneschi, Nathan C. 2017. The dissertation author 
is the primary investigator of this material.  
Chapter 4 also contains material that is currently being prepared for submission for 
publication: Callmann, C.; Thompson, Matthew P.; Barback, Christopher; LeGuyader, Clare 
L. M.; Hennis, Robert; Henriksen, Niel; Jaremko, Matthew; Momper, Jeremiah; Burkart, 
158 
 
Michael; Bertin, Paul A. and Gianneschi, Nathan C. The dissertation author is a contributing 
author of this pending manuscript. 
Sha He and the Almutairi Group at UCSD are acknowledged for the use of their bench-
top relaxometer, used to measure relaxivity of all samples in this chapter. 
This work was supported in part by resources in the Environmental and Complex 
Analysis Laboratory located at the University of California, San Diego. 
4.25 Methods 
4.25.1 General Synthetic Methods 
General synthetic and analytical methods were performed in a similar manner to that 
described in previous chapters. Paclitaxel, camptothecin and other reagents were obtained from 
Fischer. ODDA was provided by Elevance Renewable Sciences.  
Synthetic methods of key intermediates and compounds are detailed in Ref. 2 (Mono-TIPS-
FA, PTX-FA, FA-MTX, C16-PTX, C20-PTX, C18unsat-PTX and C6linked-PTX). The FA-CPT and 
FA-Gd-DOTA compounds are described here because they are novel compounds prepared by 
this dissertation author. 
Synthesis of FA-Gd-DOTA (FA-Gd). (Fig. 4.3) The first intermediate, compound 1, was 
prepared per Ref. 2. i. Compound 1 (0.284 mmol) was dissolved in chloroform and compound 
2 (0.188 mmol, purchased from Macrocyclics) was predissolved in chloroform then added to 
reaction flask. The reaction mixture was stirred under N2 for 2 days, or until all of 2 was 
consumed. The product compound 3 was purified by flash chromatography using a 10% 
methanol in DCM mobile phase.  
ii. Pure compound 3 was dissolved in chloroform. TFA was added and reaction stirred 
overnight, or until full t-butyl deprotection. After deprotection confirmed, the organic solution 
was concentrated and the product precipitated with ether three times. 
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iii. Next, the resulting precipitate was dissolved in a 1:1 methanol:water solution. Excess NaOH 
was added and the reaction mixture stirred vigorously at room temperature. After deprotection 
was confirmed by MS and HPLC, metalation was performed: 
iv. Fully deprotected ligand was dissolved in water and 1.2 equivalents of GdCl3 were added. 
Adjust pH to neutral using HCl. Gently heat in oil bath at 60˚C. Purify via semi-prep HPLC, 
75% MeOH/water+0.1%TFA. Lyophilize to give white powder.  Expected mass: 897.38. 
 
Figure 4.19 Semi-preparative RP-HPLC purification of FA-Gd-DOTA, and ESI-MS, positive 
ion mode, low resolution. 
Synthesis of FA-CPT. ODDA was stirred in DMF solution along with EDC, DMAP and 
Camptothecin. After reaction was complete, reaction solution was concentrated, brought up in 
DCM, then washed 2x 1M HCl and 1x H2O. The organic layer was dried over MgSO4, filtered 
and concentrated. Crude FA-CPT was purified first by flash chromatography using a gradient 
elution (100% DCM 10% methanol in DCM); then purified by prep RP-HPLC using a 70-
90% acetonitrile in water + 0.1% TFA gradient, monitoring at 260 nm. The purified product 
was lyophilized to remove the HPLC solvents, leaving a yellow-tinted powder. 1H-NMR 
(CDCl3), 400 MHz. Chemical shifts: δ (ppm): 8.41 (s, 1H), 8.23 (d, 1H, J = 8.4 Hz), 
7.95 (d, 1H, J = 8.1 Hz), 7.84 (t, 1H, J = 8.5 Hz), 7.68 (t, 1H, 7.1 Hz), 7.26 (s, 1H), 5.68 
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(d, 1H, J = 17.2 Hz), 5.42 (d, 1H, J = 17.2 Hz), 5.31 (s, 2H), 2.49 (m, 2H), 2.35 (t, 2H, 
J = 8.0 Hz), 2.29 (m, 1H), 2.17 (m, 1H ), 1.70-1.59 (m, 4H), 1.39-1.11 (m, 24H), 0.98 
(t, 3H, 7.4 HZ). 
 
Figure 4.20 HPLC trace after prep-HPLC purification of FA-CPT. ESI-MS, low resolution. 
4.25.2 Critical Micelle Concentration Determination 
The fluorescence spectrum of pyrene is sensitive to small changes in solvent 
environment, specifically the vibrational bands I and III (λem = 373 and 384 nm). To determine 
critical micelle concentration, the concentration of surfactant versus ratio of II to IIII was plotted. 
The change in slope of this relationship indicates CMC. Stock pyrene solution was prepared at 
2 μM in spectral grade methanol. Solutions containing increasing concentration of FA-Gd and 
constant concentration of pyrene were prepared. Fluorescence was measured using a Photon 
Technology International fluorescence detector, with excitation at 334 nm, and emission slit 
widths of 8 nm and 2 nm for λem = 373 and 384 nm, respectively. 
Concurrently, DLS was measured on the same solutions. As concentration increased, 
changes intensity count were expected as the surfactant aggregates. Because DLS is not as 
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sensitive as fluorescence of pyrene vibrational bands, the distinction of CMC value was not as 
clear, though appears around the same concentration as determined in the pyrene assay. 
 
Figure 4.21 Critical micelle concentration using pyrene assay and DLS. For the DLS 
experiment, concentration was plotted on a log scale to more clearly see a transition in intensity 
counts. 
4.25.3 Relaxivity Measurements  
Relaxivity measurements were performed using a Bruker minispec mq60 relaxometer 
(60 MHz, 1.41 T, 37˚C). Samples were prepared the day of measurement as a 2X concentrated 
stock solution of the small molecule Gd-containing compound, either FA-Gd or Multihance. 
For the FA-Gd only, serial dilutions were made to obtain the experimental solutions. For the 
formulations in the presence of HSA, a 2x HSA solution was prepared (using defatted HSA, 
Sigma) in DPBS such that the experimental solution would have an excess of protein. Equal 
volumes of the 2X FA-Gd and HSA solutions were mixed together and serial dilutions were 
made from this solution.  
The aqueous sample was loaded in to an NMR tube, and T1 times measured using the 
following parameters: Pulse separations from 10ms to 10,000 ms, with 10 data points. Delay 
sampling window = 0.05 ms, sampling window = 0.02 ms, time for saturation curve display = 
3s. The inverse of T1 time was plotted versus mM concentration of Gd, which was determined 
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from ICP-MS. Correlation coefficients (R2 values) were found to be at least 0.99 in almost all 
data sets, indicating good linear correlation Experiments were repeated and the relaxivities 
averaged. Relaxivity with varying ratios of FA-Gd to HSA are reported in Table 4.4. 
Experiments with FA-Gd at concentrations above the CMC were omitted due to poor fit with 
the rest of the dilution series: this is presumably from a macromolecular effect of FA-Gd 
aggregates versus unimer FA-Gd. A student t-test confirmed that FA-Gd in the presence of 
HSA had a significantly higher relaxivity than FA-Gd (p < .03) and significantly higher 
relaxivity than MH + HSA (p < .06).  
Table 4.3 Relaxivity Data. 
formulation 
Relaxivity 
(mM-1sec-1) R2 fit 
FA-Gd 2.45 0.999 
 6.51 0.999 
 4.19 0.99999 
 2.42 0.991 
FA-Gd + HSA 8.48 0.999 
 20.87 0.9898 
 12.87 0.997 
 11.86 0.9793 
MH + HSA 6.64 0.9997 
 4.97 0.999 
Gd-DOTA + HSA 5.98 0.92 
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Table 4.4 Relaxivity measurements FA-Gd, varying ratios with HSA. 
Mol FA-Gd Mol HSA 
Relaxivity 
(mM-1sec-1) R2 
1 5 8.48 0.999 
1 1 8.92 0.9999 
5 1 8.07 0.9999 
10 1 8.53 0.999 
4.25.4 General In Vivo Imaging Methods 
All animal studies and procedures were performed in accordance with IACUC, 
protocol S10145. Xenograft nu/nu mice, female, 4-6 weeks old, were inoculated with 10^6 HT-
1080 cells as a bolus injection, subcutaneously (as previously described19). After ~10 days, 
tumors had grown to an average volume of ~400 mm3, as measured with calipers, using the 
formula: W2 *(L/2) and ready for experimenting. Animals were injected via tail vein with 100 
μL of stock solution of Gd-containing compound. Animals were anesthetized with 3% 
isofluorane in oxygen, at a flow rate of 2 mL/minute. 
MR images were taken using an MR solutions table top preclinical scanner 
(MRSolutions 4000MRS MR), with integrated anesthesia and animal monitoring systems, 
using pre-programmed scan sequences (scout, 4.7 T FSE T1w coronal; 4.7 T FSE T1w axial). 
Images were acquired at strategic timepoints to monitor for increased contrast and/or 
accumulation in the tumor. Slices highlighting the tumor and whole body are pictured in Figs. 
4.22-4.25 For the preliminary imaging and half-life studies, animals received 45.7 nmol of 
gadolinium for FA-Gd + HSA, and 755.9 nmol of gadolinium for MultiHance (low dose).  
Healthy animals received 1 μmol gadolinium, as did the follow-up studies in tumor-burdened 
mice comparing FA-Gd, MH and Gd-DOTA head-to-head. 
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Figure 4.22 MRI scans of healthy animals receiving 1 μmol FA-Gd or MH. For FA-Gd, 
contrast enhancement is clearly visible in the gall bladder out to 7 hours, and recovers to 
baseline at 24 hours, indicating clearance from the animal. The animal receiving MH did not 
show distinct enhancement at the same 7 hour timepoint; this material is cleared faster from 
the blood. 
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Figure 4.23 Representative MRI scans of tumor-burdened mouse receiving FA-Gd at low dose. 
Contrast is clearly visible out to 4 hours post-injection in the gall bladder, indicated with a 
yellow circle. The tumor is indicated with the blue arrow. 
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Figure 4.24 Representative MRI scans of tumor-burdened mouse receiving MH at low dose. 
Contrast is visible out to 4 hours post-injection in the gall bladder, indicated with a yellow 
circle. The tumor is indicated with the blue arrow. 
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Figure 4.25 Representative MRI scans for tumor-burdened mice receiving high doses of FA-
Gd, MH or Gd-DOTA. Contrast is visible for FA-Gd and MH, but not for Gd-DOTA. 
 
Figure 4.26 MRI scans of tumor-burdened animals receiving FA-Gd. All three animals imaged 
demonstrate contrast enhancement out to 6 hours post-injection in the gall bladder. (Animal 2 
is identical image to that in Fig. 4.5). 
4.25.5 Blood Half -Life Studies and Protocols 
Blood half-life of FA-Gd, MultiHance and Gd-DOTA were evaluated head to head by 
analyzing for gadolinium concentration in blood plasma. Blood samples were collected via 
retro-orbital blood draw pre-injection (0 point) then 1, 2, 4, 7 and 24 hours post injection in to 
heparanizied borosilicate glass pipettes. Whole blood aliquots were immediately spun down at 
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1500 rpm for ten minutes to separate plasma from red blood cells. 25 μL of plasma was isolated, 
and stored at -80˚C until acid digested, after which the sample was diluted for analysis by ICP-
MS. 
 
 
Figure 4.27 Blood half-life healthy animals. High dose (1 μmol Gd). 3 animals receiving FA-
Gd, 1 animal for MultiHance. 
 
                    
 
Figure 4.28 Pilot study, blood half-life tumor-burdened animal, average of n=3. Low dose.           
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Figure 4.29 Blood Half Life, tumor-burdened animal. 3 animals each, FA-Gd, MH and Gd-
DOTA. Inset highlights changes in serum concentration in the first 5 hours post-injection. 
4.25.6 General Ex Vivo Analysis Methods 
At time points of interest (e.g. 24 hours), mice were sacrificed using a CO2 overdose. 
If the animals were perfused, a butterfly needle was used, and ~20 mL of saline was flushed 
through over ~20 minutes. The heart, kidney, liver, spleen, lung, tumor mass, were collected, 
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weighed then digested in concentrated HNO3 (900 μL, or 500 μL for the liver).  For the non-
perfused animals, after CO2 overdose was administered, cervical dislocation was performed 
prior to beginning dissection and organ harvest. Organs were digested as above. After the 
tissues were homogenized, aliquots were diluted to a final volume of 5 mL at a final acid 
concentration of 5% for ICP-MS analysis.  
For ICP: for all experiments in this chapter, ICP analysis was done at the UCSD ECAL 
facility, using a Thermo Scientific iCAP RQ ICP-MS. Calibration standards ranged from .01 
to 10,000 ppb in 5% nitric acid. Biodistribution data in Fig. 4.30 is represented as %ID/g 
tissue, a standard way to normalize amount of material in tissues of different masses. Plots 
comparing total amounts of material detected at 24 hours both as total ng Gd detected and % 
of injected dose are reported for each material and each animal. 
 
Figure 4.30 Biodistribution in tumor-burdened animals, Low Dose. Individual animal profiles 
looking at normalized accumulation in organs of interest: heart, liver, kidney, tumor, spleen 
and lung. These animals were perfused prior to organ harvest. 3 animals received FA-Gd, at a 
dose of 100 nmol gadolinium (15,725 ng) and 3 animals received MH at a dose of 50 nmol 
(7,862.5 ng).  * denotes no detection by ICP-MS.    
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Figure 4.31 Plots describing total ng of Gd detected in the animal (sum organs) and %injected 
dose are described; these plots correspond to the animals in Fig. 4.30, which were perfused 
prior to organ harvest. 
4.25.7 General Cell Culture Methods 
All cell lines were obtained from an in-house sub-culture originally purchased from 
ATCC. Cells were incubated at 37˚C at 5% CO2 using Dulbecco’s modified eagle medium, 
DMEM (high glucose, no glutamine, Life Technologies/Gibco, Cat 11960044) supplemented 
with 10% FBS (heat inactivated, Omega Scientific, Cat FB-02), and 1x of sodium pyruvate 
(100x = 100mM, Life Technologies, Cat 11360070), non-essential amino acids (Life 
Technologies, Cat 11140050), GlutaMAX (Life technologies Cat 35050061) and antibiotics 
(Penicillin-Streptomycin, Life Technologies Cat 15140122). Opti-MEM reduced serum 
medium (Life Technologies, Cat 31985070) was used as is, and DMEM without phenol red 
(Life Technologies, Cat 31053028) was supplemented as in other DMEM. Cell cultures were 
maintained by sub-culturing in flasks every 4-7 days when cells became confluent using 
trypsin-EDTA, 0.25% (Life Technologies, Cat 25200114). 
4.25.8 Cytotoxicity 
Cytotoxicity of compounds was evaluated using the CellTiter Blue (CTB) assay 
(Promega, cat G8081). Treatments of fatty acid-conjugates were prepared as 1000x serial stock 
dilutions in DMSO, then diluted into media for 1X, 0.1% DMSO treatment solutions. PTX-FA 
+ HSA formulations and FA-KLA were prepared as concentrated solutions in DPBS, then 
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diluted in media for treatment solutions. Cells were plated in 96-well plates, 1 day before 
treatment, at the following densities: HeLa at 3,000 cells/well, HT-1080 at 4,500 cells/well, 
HT-29 at 7,500 cells/well, PANC-1 at 10,000 cells/well, H522 at 10,000 cells/well, and HepG2 
at 4,500 cells/well. After 24 hours, plating media was removed, then treatments of 100 μL were 
added to the wells. After 3 days, the media was removed and replaced with 100 μL complete 
DMEM without phenol red. Then 20 μL of CTB reagent was added, and the cells incubated for 
two hours at 37˚C. Fluorescence was measured at 590 nm with excitation at 560 nm using a 
Perkin Elmer EnSpire plate reader. Average background fluorescence of CTB reagent in media 
without cells was subtracted from average fluorescence readings of the experimental wells 
(three wells per treatment concentration). Viability was calculated as the average background-
subtracted signal in a well compared to that of a negative control well (cells treated with 
vehicle, either 0.1% DMSO/media or media). Viabilities were fit in GraphPad Prism using a 
non-linear, dose-dependent inhibition curve. The IC50 numbers given in the table reflect the 
concentration at which the cell death is 50% of the maximum response. The log (IC50) and error 
in logIC50 are reported, and reflects the standard error in the fit. Where applicable, average 
viabilities are reported; these averages reflect experiment-to-experiment variability. Of note is 
the high variability from experiment-to-experiment. This could come from error in 
concentration determination of the compound of interest, or a treatment solution in which the 
organic compound precipitates. Future studies should include a validation of concentration of 
treatment and freshly prepared treatment solutions.  
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Figure 4.32 Representative IC50 curves for PTX-FA conjugates compared to parent PTX 
compound in complete versus serum-free media, with 0.1%DMSO to solubilize the organic 
compounds, in HeLa cells. In both cases, the conjugates are not as toxic as the parent 
compound. There is also not much different in toxicity between treatments in complete media 
(a) versus serum-free media (b). Three repeats for the PTX-FA compound are shown here, with 
IC50 values for each trial reported in Table 4.5. 
 
 
Figure 4.33 Representative IC50 curves for PTX-FA formulations with HSA in HeLa cells. The 
concentrations are given with respect to taxol concentration. Additionally, there is no great 
difference in toxicity in the serum-free media (dotted plots in panels a) and b)). Panel c) shows 
examples of cytotoxicity experiments where the treatment concentration was not high enough 
to generate a complete IC50 curve and these results were excluded from overall analyses. In 
panel d), it is interesting that even at very high concentrations (~10uM), full cell death does not 
occur, whereas at comparable concentrations for the other formulations, viability is very low. 
IC50 values for each trial reported in Table 4.5. 
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Table 4.5 Toxicity of PTX, PTX-FA, and formulations with HSA in HeLa cells. Evaluation in 
complete media and serum-free media (OM) are reported. 
Compound 
Media 
conditions 
 
Log 
IC50 
std error 
log (IC50) 
IC50 nM avg stdev 
  
PTX DMEM 
trial 1 -7.917 0.1045 12.1   
trial 2 -8.143 0.1991 7.2 6.73 5.6 
trial 3 -9.049 0.1057 0.893   
PTX OM 
trial 1 -8.334 0.373 4.64 4.54 0.1 
trial 2 -8.353 0.0649 4.43   
PTX-FA DMEM 
trial 1 -7.504 0.3078 31.37   
trial 2 -7.365 0.326 43.18 57.05 34.8 
trial 3 -7.015 0.1773 96.6   
PTX-FA OM 
trial 1 -7.32 0.149 47.9 47.35 0.8 
trial 2 -7.33 0.4995 46.8   
  trial 1 -7.522 0.2551 30.1   
  trial 2 -7.056 0.3937 87.9 59.00 
40.9 
PTX-FA + 
HSA (1) DMEM 
trial 3* 
-6.582 0.2206 261.7   
  trial 4* -6.948 0.1132 112.7   
  trial 5* -7.267 0.1015 54.1   
PTX-FA + 
HSA (1) OM 
trial 1 
-7.359 0.1397 43.8 48.80 7.1 
  trial 2 -7.27 0.08076 53.8   
PTX-FA + 
HSA (2) DMEM 
trial 1 
-6.886 0.3259 129.9 278.25 209.8 
  trial 2 -6.37 0.4964 426.6   
PTX-FA + 
HSA (2) OM 
trial 1 
-7.316 0.1333 48.4 66.40 25.5 
  trial 2 -7.074 0.2687 84.4   
PTX-FA + 
HSA (5) DMEM 
trial 1 
-8.084 0.2529 8.25 25.38 24.2 
  trial 2 -7.372 0.3616 42.5   
*omitted from average. 
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Figure 4.34 Representative IC50 curves for PTX-FA and formulations with HSA in HT-1080 
cells. All experiments were done in using complete media. IC50 values for each trial reported 
in Table 4.6.  
  
Table 4.6 Toxicity of PTX, PTX-FA, and formulations with HSA in HT-1080 cells. Evaluation 
in complete media are reported. 
Compound log IC50 
std error 
log (IC50) 
IC50 nM 
PTX -8.738 0.2055 1.83 
PTX-FA -8.953 0.4755 1.11 
PTX-FA + HSA (1) -8.033 0.8264 9.27 
PTX-FA + HSA (2) -8.323 0.2649 47.6 
PTX-FA + HSA (5) -7.922 0.1245 12 
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Figure 4.35 Representative IC50 curves for PTX-FA and formulations with HSA in HT-29 
cells. Evaluation of toxicity in complete media is reported. IC50 values for each trial reported 
in Table 4.7.  
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Table 4.7 Toxicity of PTX, PTX-FA, and formulations with HSA in HT-29 cells. Evaluation 
in complete media are reported. 
Compound log IC50 
stdev log 
IC50 
IC50 nM avg  
std dev 
PTX -8.409 0.2406 3.9    
PTX-FA -9.129 1.278 0.743    
PTX-FA -6.989 0.2349 102.5 36.1 57.5 
PTX-FA -8.294 0.1672 5.08  
 
PTX-FA + HSA (1)* -6.675 0.2506 211.6  
 
PTX-FA + HSA (1)* -6.318 0.3546 481.3  
 
PTX-FA + HSA (1) -7.88 0.201 13.2 16.2 4.31 
PTX-FA + HSA (1) -7.715 0.167 19.3  
 
PTX-FA + HSA (2) -8.183 0.2993 6.57 
9.235 
 
3.768879 
PTX-FA + HSA (2) -7.925 0.262 11.9 
PTX-FA + HSA (5) -8.064 0.1336 8.62    
*omitted from average. 
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Figure 4.36 Representative IC50 curves for PTX-FA and formulations with HSA in H522 cells. 
Evaluation of toxicity in complete media is reported. IC50 values for each trial reported in Table 
4.8.  
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Table 4.8 Toxicity of PTX-FA and formulations with HSA in H522 cells. Evaluation in 
complete media are reported. 
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Figure 4.37 Representative IC50 curves for PTX-FA and formulations with HSA in PANC-1 
cells. Evaluation of toxicity in complete media is reported. IC50 values for each trial reported 
in Table 4.9.  
 
Table 4.9 Toxicity of PTX-FA and formulations with HSA in PANC-1 cells. Evaluation in 
complete media are reported. 
Compound log IC50 
stdev log 
IC50 
IC50 nM avg  
 
stdev 
PTX-FA -5.86 0.3674 1381  
 
PTX-FA + HSA (1) -6.325 0.5044 473.1 
283.4 
 
 
169.6 PTX-FA + HSA (1) -6.835 0.2824 146.2 
PTX-FA + HSA (1) -6.636 0.3553 231 
PTX-FA + HSA (5) -8.606 0.3241 2.48 9.09 9.3 
PTX-FA + HSA (5) -7.805 0.1381 15.7  
 
Compound log IC50 
stdev log 
IC50 
IC50 nM avg  
 
stdev 
PTX-FA -7.807 0.1417 15.6 65.8 70.9 
PTX-FA -6.936 0.1413 115.9    
PTX-FA + HSA (1) -6.818 0.1312 152 182.3 42.9 
PTX-FA + HSA (1) -6.672 0.1685 212.6    
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Figure 4.38 Representative IC50 curves for PTX-FA and PTX-FA + HSA (5:1) formulations in 
HepG2 cells. Evaluation of toxicity in complete media is reported. IC50 values for each trial 
reported in Table 4.10.  
 
Table 4.10 Toxicity of PTX-FA and formulations with HSA in HepG2 cells. Evaluation in 
complete media are reported. 
Compound log IC50 
stdev 
log IC50 
IC50 
nM 
avg  
 
stdev 
PTX-FA -8.738 0.9402 1.89  
 
PTX-FA + HSA (5) -8.025 0.1348 9.44   
PTX-FA + HSA (5) -7.906 0.4158 12.4 34.6 41.1 
PTX-FA + HSA (5) -7.086 0.3833 82.1    
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Figure 4.39 Representative IC50 curves for C16-PTX, C18unsat-PTX, C20-PTX and Me-C18-
C6link-PTX in HeLa cells. Evaluation of toxicity in complete media is reported. IC50 values for 
each trial reported in Table 4.11. 
 
Table 4.11 Toxicity of C16-PTX, C18unsat-PTX, C20-PTX and Me-C18-C6link-PTX in HeLa cells. 
Evaluation in complete media are reported. 
Compound 
  Log IC50 Std.Error 
Log IC50 
IC50 nM avg  stdev 
    
C16-PTX 
trial 1 -6.681 0.1044 208.3   
trial 2 -6.775 0.1576 167.8 195.6 24.1 
trial 3 -6.677 0.184 210.6     
C20-PTX 
trial 1 -7.754 0.1528 17.6   
trial 2 -7.293 0.2017 50.9 27.8 20.1 
trial 3 -7.827 0.0822 14.9     
C18unsat-
PTX 
trial 1 -7.237 0.1087 57.9   
trial 2 -7.565 0.1923 27.2 40.03 16 
trial 3 -7.456 0.1669 35     
Me-C18-
C6-link-
PTX 
trial 1 
-5.633 
0.0792 2329 N/A N/A 
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Figure 4.40 Cytotoxicity of MTX, FA-MTX and CPT, FA-CPT in HeLa. 
 
Table 4.12 Toxicity of control (parent) compounds CPT and MTX. 
Compound log IC50 
std error 
log IC50 
IC50 nM avg  std dev 
  CPT -7.036 0.2723 92     
CPT -7.453 0.1864 35.2 49.8 37.1 
CPT -7.652 0.1356 22.3     
MTX -8.111 0.3208 7.75   
MTX -8.069 0.05742 8.54 6.01 3.72 
MTX -8.759 0.09587 1.74     
 
Table 4.13 Toxicity of FA-CPT and FA-MTX in HeLa cells. 
Compound 
  
highest 
dosing viability 
FA-CPT trial 1 10 uM 77% 
FA-CPT trial 2 10 uM 47% 
FA-CPT trial 3 10 uM 60% 
FA-MTX trial 1 10 uM 95% 
FA-MTX trial 2 50 uM 60% 
FA-MTX trial 3 50 uM 51% 
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Figure 4.41 Representative IC50 curves for FA-KLA and FA-KLA + HSA in HeLa cells. 
Evaluation of toxicity in complete media is reported and serum-free media is reported. IC50 
values for each trial reported in Table 4.14. 
 
Table 4.14 Toxicity of FA-KLA and FA-KLA + HSA in HeLa cells. Evaluation in complete 
media as and serum-free media (OM) is reported. 
Compound condition 
  
log  IC50 
std error 
log  IC50 
IC50 uM avg  
stdev 
    
FA-KLA DMEM 
trial 1 -4.458 0.2741 34.9   
trial 2 -3.01 0.6444 978 38.7 5.4 
trial 3 -4.371 0.2609 42.5     
FA-KLA 
  
OM 
  
trial 1 -5.348 0.3241 4.49 
17.6 16.4 trial 2 -4.444 0.3295 36 
trail 3 -4.912 0.2561 12.3 
FA-KLA + HSA   trial 1     - - - 
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4.25.9 Cell Uptake Experiments 
Flow cytometry was used to elucidate the association of a fluorescein-fatty acid 
compound or FA-KLA with fluorescein tag with a cell. Flow cytometry analysis gives an idea 
of cell-associated fluorescence coming from the treatment solutions, over that of background 
cell fluorescence (control cells). 24 hours prior to treatment, 100,000-120,000 cells were plated 
in each well of a 24-well plate. After one day, media was removed, then treatment solution of 
fluorescein-containing treatment solution was added (500 μL of treatment solution prepared as 
in the cytotoxicity experiments: 0.1%DMSO/media for FA-fl, treatments, media only for all 
other compounds and formulations). The cells were incubated for 1 hour at 37 ˚C. Control cells 
were treated with the vehicle (media) for a background fluorescence signal. After incubation, 
treatment solution was removed, then cells washed with DPBS 3 times. A heparin wash 
(0.5mg/mL solution) was performed with 5 minute incubations. [This step would remove 
negative components of a treatment solution from the cell surface. It was found that omitting 
the heparin wash did not significantly affect results from flow cytometry analysis (results not 
shown).] Next, cells were lifted from the wells by incubating with 250 μL 0.25%trypsin/EDTA 
solution for 10 minutes. The trypsinization solution was quenched with 500 μL complete 
media, and cells mixed well, before transferring to an eppendorf with 750 μL DPBS. 
Eppendorfs were centrifuged for 5 min at 300 g, to pellet out cells; supernatant was aspirated, 
then cell pellet suspended in 70 μL cold DPBs. Cells were stored as is in eppendorfs on ice 
until analysis.  
4.25.10 Cell Uptake Mechanistic Experiments 
In the experiments examining mechanism of uptake of materials, the following 
considerations were taken: cells were incubated with material for 1 hour in a fridge at 4˚C. This 
would inhibit any active uptake mechanism. For the MβCD inhibitor (Fischer, cat C4555), prior 
183 
 
to treatments, 37 μL of a 128 mM MβCD solution in DPBS was added to the wells containing 
500 μL DMEM for a final concentration of 9.5 mM. The cells were incubated at 37˚C or 4˚C. 
Then, for experiments in complete media, the treatment solutions were added directly to the 
wells: for FA-fl, 5 μL of a 460 μM solution in DMSO was added to give a final concentration 
of 4.6 μM. For FA-Fl + HSA, 33 μL of a 70 μM solution in DPBS was added to give a final 
concentration of 4.6 μM. For experiments in serum-free media, after the 30 minute incubation 
with MβCD, all media and MβCD was aspirated, then treatment solutions of 4.6 μM FA-fl in 
0.1%DMSO/OM with 9.5 mM MBCD or 4.6 μM FA-fl + HSA in OM with 9.5 mM MβCD 
were added. The cells were incubated for 1 hour at either 37˚C or 4˚C. Then the same procedure 
as above was used to harvest the cells.  
4.25.11 Flow Cytometry Analysis  
A BD-Accuri C6 Plus flow cytometer was used for all analyses. Immediately before 
analysis, cells were gently vortexed, and visually confirmed to be distinct cells in suspension 
using light microscopy. Each analysis was performed for 10,000 events using slow fluidics 
mode (14 μL/min). All samples were gated to a healthy cell population, with the gate generated 
from the analysis of the vehicle control cells. Fluorescein channel (FL1-A) was analyzed, and 
fluorescence intensity count normalized to the fluorescence count for control cells. 
Representative scattering plots for different cell types (HeLa, HT-1080, HT-29, HepG2) are 
shown for treatments with media or serum-free media (Opti-MEM). In most cases, there was 
no significant change in population with the serum-free media or with the various treatment 
solutions. The exception is when performing mechanistic uptake studies with the MβCD 
inhibitor. Extended incubation time (multiple hours) with MβCD is known to negatively affect 
cell viability; the resulting scattering plots (Figs. 4.51, 4.52) shows a large decrease in healthy 
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cell gated population. The scatter plots and histograms below are representative of data 
presented in Figs. 4.15-4.17.  
 
Figure 4.42 Dot plots showing forward scattering (FSC, x axes) versus side scattering (SSC, y 
axes) for representative experiment of HeLa cells treated with FA-fl or FA-fl + HSA, and gating 
used for healthy cell populations. Points close to origin are from cellular or other debris. A) is 
cells treated with complete media, vehicle control (gate = 44.4%). B) cells treated with 4.6 μM 
FA-fl in complete media (gate = 53.4%); c) FA-fl + HSA formulation, 4.6 μM in complete 
media (gate = 63.2%); d) serum-free media, vehicle control (gate = 54.5%); e) 4.6 μM FA-fl in 
serum-free media (gate = 54.9%); f) FA-fl + HSA formulation, 4.6 μM in serum-free media 
(gate = 54.1%).  Select histograms showing population shifts in fluorescence intensity is shown 
in Figs 4.43 and 4.44. 
 
185 
 
 
Figure 4.43 Representative histograms for cell uptake, showing concentration dependent 
uptake of FA-fl using a) complete media or b) serum-free media for HeLa cells. For a treatment 
of 9.2 μM FA-fl there is a ~2-fold increase in fluorescence, whereas treatment in serum-free 
media yields a much larger increase in signal, about 75-fold increase. The drastic difference in 
fluorescence increase for serum-free media indicates that the bovine serum proteins may be 
altering the uptake mechanism of the material. This was evaluated in mechanistic uptake 
studies.  
 
Figure 4.44 Representative histogram for cell uptake, showing concentration dependent uptake 
of formulations with HSA using a) complete media or b) serum-free media. For a treatment of 
9.2 μM with respect to fluorescein, a ~3-fold increase in fluorescence is observed, while 
treatment in serum-free media shows ~6-fold increase in fluorescence signal. The modest 
increases in fluorescence signal compared to FA-fl in serum-free media again alludes to the 
role of HSA and/or serum proteins in cell uptake. 
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Figure 4.45 Dot plots showing forward scattering versus side scattering for representative 
experiments investigating mechanism of uptake of FA-fl, FA-fl + HSA, FA-KLA or FA-KLA 
+ HSA materials in HT-1080 cells, and gating used for healthy cell populations. All 
experiments are done in complete media.  Conditions for treatment are included in an inset in 
each plot and gated populations represent 47-57% of cell populations analyzed, indicating 
minimal effect of the treatment material on the cell morphology. 
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Figure 4.46 Representative histograms for cell uptake of FA-fl, FA-fl + HSA, FA-KLA or FA-
KLA + HSA in HT-1080 cells. Treatments in complete and serum-free media were performed. 
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Figure 4.47 Dot plots showing forward scattering versus side scattering for representative 
experiments investigating mechanism of uptake of FA-fl, FA-fl + HSA, FA-KLA or FA-KLA 
+ HSA materials in HT-29 cells, and gating used for healthy cell populations. All experiments 
are done in complete media.  Conditions for treatment are included in an inset in each plot and 
gated populations represent 27-45% of cell populations analyzed.  
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Figure 4.48 Representative histograms for cell uptake of FA-fl, FA-fl + HSA, FA-KLA or FA-
KLA + HSA in HT-29 cells. Treatments in complete and serum-free media were performed. 
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Figure 4.49 Dot plots showing forward scattering versus side scattering for representative 
experiments investigating mechanism of uptake of FA-fl, FA-fl + HSA, FA-KLA or FA-KLA 
+ HSA materials in HepG2 cells, and gating used for healthy cell populations. All experiments 
are done in complete media. Conditions for treatment are included in an inset in each plot and 
gated populations represent 22-27% of cell populations analyzed. 
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Figure 4.50 Representative histograms for cell uptake of FA-fl, FA-fl + HSA, FA-KLA or FA-
KLA + HSA in HepG2 cells. Treatments in complete and serum-free media were performed. 
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Figure 4.51 HeLa cells treated with FA-fl formulations in complete media. Dot plots showing 
forward scattering versus side scattering for representative experiments investigating 
mechanism of uptake of FA-fl or FA-fl + HSA materials in HeLa cells, and gating used for 
healthy cell populations, using complete media. Conditions for treatment are included in an 
inset in each plot. There appeared to be no change in populations of healthy cells when 
incubated at 37˚C (a) or 4˚C (d). gating from vehicle controls to experimental samples included 
45-67% of population analyzed; a decrease in gated population was observed for treatment with 
MβCD at 37˚C (c and h), with ~38% of population included in fluorescence analysis. This 
decrease in healthy cells is attributed to MβCD disturbing the cell membrane. Select histograms 
showing population shifts in fluorescence intensity is shown in Fig. 4.52. 
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Figure 4.52 HeLa cells treated with FA-fl formulations in serum-free media. Dot plots showing 
forward scattering versus side scattering for representative experiments investigating 
mechanism of uptake, and gating used for healthy cell populations, using serum-free media. 
Again, there appeared to be no major change in populations of healthy cells when incubated at 
37˚C (a) or 4˚C (d). Gating from vehicle controls to experimental samples included 43-65% of 
population analyzed; a decrease in gated population was observed for treatment with MβCD at 
37˚C (c and h), with ~23 or 10% of cell population included in fluorescence analysis. This 
decrease in healthy cells is attributed to MβCD disturbing the cell membrane. Incubation of 
FA-fl + HSA at 4˚C also showed a decrease in gated cell population (plot i), 29% of 
population). Select histograms showing population shifts in fluorescence intensity is shown in 
Fig. 4.53. 
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Figure 4.53 Representative histograms for mechanistic cell uptake studies on HeLa cells for 
FA-fl (a and c) and FA-fl + HSA (b and d) formulations under various conditions. The top two 
panels are treatments in complete media (a and b), while lighter colors (c and d) are treatments 
in serum-free media. 
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Chapter 5   
Conclusions and Perspectives 
5.27 Conclusions on Polymeric Nanoparticle and Bioconjugate 
MRI Contrast Agents for In Vivo Imaging 
In this dissertation, two strategies were studied towards the goal of using 
macromolecular scaffolds as carriers of conventional small molecule MRI contrast agents. 
Using a graft-through approach to polymerize a novel gadolinium-based contrast agent 
monomer, polymer amphiphiles were synthesized, then formulated in to nanoparticles. These 
nanoassemblies were either spherical or fibrillar in phase. Using these MR-active materials, the 
biodistribution patterns were investigated using intraperitoneal injections followed by in vivo 
imaging and ex vivo elemental analysis. Our results demonstrated the importance of 
nanoparticle shape in enhancing retention of materials in the peritoneal space, and suggested 
differential clearance via the RES system. As an alternative to polymeric nanomaterials, we 
explored a second strategy employing human serum albumin-specific ligands conjugated to the 
gadolinium based contrast agent. By high-jacking albumin blood proteins we sought to enhance 
the circulation time of a small molecule contrast agent, and take advantage of the affiliation of 
albumin with different disease states.   
The studies performed herein demonstrate proof-of-concept of strategies to enhance 
the circulation and distribution profiles of small molecule MRI contrast agents. Further, in vivo 
imaging experiments proved that these materials are useful in non-invasive imaging 
applications.  
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5.28 On-Going and Future Work 
Despite the progress made in understanding polymer self-assembly towards interesting 
morphologies and developing nanomaterials towards in vivo imaging, the optimal nanoparticle 
system for all drug delivery applications has not been identified for any nanoparticle systems. 
Studies over the years in the Gianneschi group have capitalized on the MMP-responsive 
targeted nanoparticle systems, but sensitive imaging of clinically relevant disease models 
remains to be articulated.  
 The nanoparticle systems discussed in this thesis, particularly the gadolinium-
containing spherical and fibrillar nanoparticles, represent crucial preliminary studies 
motivating on-going work in the lab. As described, intra-peritoneal injections were used in 
these studies, and represents an important treatment paradigm for malignancies of the 
peritoneal cavity. On-going work in the lab consist of formulating nanoparticles loaded with 
platinum-based drugs to specifically target ovarian cancer. Designing materials with high-
aspect ratios and introducing them via the peritoneum are key design principles being 
developed in these projects.  
Often times, the nanoparticles formulated with ROMP polymers results in spherical 
structures. A hallmark project pursued in the lab is working to understand how to formulate 
nanoparticles with diverse structures predictably, either through polymer design or 
micellization strategy. Colleagues are evaluating kinetic and thermodynamic effects of 
polynorbornene and other polymer architectures towards answering questions regarding the 
energetics of polymeric nanoparticle formation. The findings in this thesis, particularly that 
non-aromatic hydrophobic blocks are useful to formulating cylindrical nanoparticles, have 
been used in publication from the lab, and are considered in this project.1 
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The albumin drug carrier project described in Chapter 4 has revealed fascinating 
fundamental science and applied clinical questions. A main contribution from this author is in 
designing and evaluating MRI contrast agents using this fatty acid platform technology. The 
initial results demonstrating enhanced blood circulation, especially compared to other clinical 
agents, is a good start in evaluating another class of blood-pool imaging agents. We know that 
albumin loaded with a therapeutic agent are effective at suppressing tumor growth, so on-going 
work in this project is identifying how and why the diagnostic agents accumulate (or not) in 
the intended tumor target. By taking advantage of the body’s natural small molecule carrying 
system, e.g. abundant blood proteins like albumin, we hope to avoid any unintended immune 
response. 
The amenability of the fatty acid conjugates means that any number of warheads may 
be attached. In Chapter 4, other cytotoxins and peptides were evaluated, and on-going 
collaborations extend to nucleic acid and gadolinium-free agents as fatty-acid conjugates. 
Fundamental science questions that may be addressed with this technology include evaluation 
of the targeting mechanism of the HSA-formulations. On-going collaborative work in this 
project is investigating cell receptors and endocytotic pathways responsible for internalization 
of fatty acid conjugates or albumin-carried conjugates. Using a CRISPR-Cas9 gene screen, key 
cell uptake pathways involving fatty acid transport and albumin specific uptake will be 
evaluated.  
5.29 Perspective: The Future of Translatable Nanoparticle Drug 
Delivery Systems 
The ultimate goals of the field of nanomedicine is to be able to more efficiently delivery 
cargo to a target, with minimal off-target or toxicity effects. The research and development 
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divisions at pharmaceutical industrial companies invest billions of dollars towards capturing 
the most effective new drug for market, yet the industry still suffers from low output, as well 
as challenges for more efficient and sustainable research programs. Early pipeline screens for 
efficacy and toxicity have been identified as a key area for improvement towards clinical 
approval.2 As the field of polymeric nanoparticle drug delivery continues to expand and 
diversify, if clinical applicability is sought, focus needs to switch towards designing more 
robust materials, coupled with early pipeline identification of potentially successful drug 
candidates. As outlined in a meta-review by Chan et. al., despite the vast resources contributed 
towards nanomedicine in the recent decades, there is still a disconnect between materials 
developed in the lab, and clinical approval.3 Furthermore, researchers continue to overstate the 
importance of the enhanced permeability and retention effect in human translatable 
nanosystems.4 Rather than developing highly complex and intricate nanoparticle systems, 
researchers should focus on more robust nanoparticle design and preparation, and better 
methods for pre-clinical evaluation.  
With respect to nanoassembly design, the physicochemical parameters of size, shape 
and charge are the principal properties to consider and evaluate. It is challenging to examine 
all physicochemical properties in one study, and size, shape and charge of a material do not 
stand on isolated pedestals as the key contributing factors to nanoparticle success or failure. 
Topics not explored in this work, but of interest to the field include the force modulus, or 
stiffness of material, and how the material behaves in flow and under sheer forces.5,6  
 With respect to laboratory evaluation of efficacy, 3D assays, co-culturing and 
organotypic tissue slicing may be more informative than monolayer in vitro experiments with 
regards to high through-put assays.7 Recent advances in organ-on-a-chip technologies present 
opportunities for informative, high-throughput studies.8 As discussed in the introduction, the 
translatability from animal model to humans is severely lacking. While organ-on-a-chip 
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technology is not yet capable of providing the same pharmacokinetic and pharmacodynamic 
information that a murine model might provide, we must critically think about the best way to 
evaluate materials for effectiveness and toxicity profiles. In our own work, we employ 
xenograft tumor models: immune-suppressed mice burdened with a human tumor mass. This 
is the standard for evaluation for drug delivery materials such as those studied in this 
dissertation, though the most obvious body system, the immune system, is absent. Evaluation 
of materials in healthy animals as well as humanized mice containing hallmarks of the human 
immune system alongside immunosuppressed xenograft models may aid in understanding off-
target effects and toxicities of nanoparticle delivery systems.9 With the age of personalized 
medicine, decades of research in nanomedicine, and a pivot in focus towards better methods to 
evaluate potential efficacy of a drug early in development, the field stands ready for major 
advancements in disease treatment in the coming years. 
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